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Abstract  
Introduction: The South African public sector antiretroviral therapy (ART) roll-out has been 
associated with emergence of HIV drug resistance (HIVDR) in therapy-naïve and treated patients. 
These drug-resistant viral strains are archived in viral reservoirs and may persist as minority 
variants when outgrown by fitter wild-type strains, in the absence of sufficient drug pressure. 
Although minority drug resistant variants may predict failure, they are not readily detectable with 
PCR and Sanger sequencing when constituting less than 20% of the viral population.  
Next generation sequencing (NGS) allows the detection of minor drug resistant variants and 
investigation of linkage of HIVDR mutations when sufficient read-length is obtained. Various NGS 
platforms, available in South Africa, offer per-sample cost reductions when sufficient numbers of 
samples are pooled. However, targeted resequencing on NGS platforms requires template 
enrichment by PCR that can result in PCR-induced error and template re-sampling error. 
Resampling error is a result of random error or a primer selection bias and is more pronounced 
when using long fusion primers for NGS amplicon sequencing.   
Methods: As data were limited on minor HIVDR variants in infants who became infected despite 
the Western Cape Prevention of Mother-to-Child HIV Transmission (PMTCT) regimen and in adults 
with virological failure without major protease inhibitor (PI)-resistance mutations on a PI-based 
regimen, we performed NGS in these populations.  
In the first cross-sectional study we sample minority variants from seven adults who failed PI-
based therapy due to poor adherence. Samples were enriched for NGS with a nested fusion primer 
PCR and minor variants were identified on the 454 Life Sciences, FLX Titanium platform 
(Connecticut, USA). 
In the second cross-sectional study we sampled viral species from 15 PMTCT-failed infants. 
Nested PCR amplicons were size-fragmented and ligated to platform-specific sequencing 
adaptors. The sequence library was sequenced in parallel on the Ion Torrent Personal Genome 
Machine (PGM) (Life Technologies, California, USA) and the Illumina MiSeq (California, USA) and 
was validated by clonal sequencing. 
In study three, we attempted to characterise resampling error when using fusion primers and 
correct it by partitioning PCR reactions in emulsion. We compared the 454 NGS sequence yields 
when using “open” or emulsified PCR for template enrichment and investigated the effect of 
varying degrees of primer-template mismatches when the sampled population consisted of 
mixtures of plasmids. 
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Findings: In the first study, NGS improved the drug resistance mutation detection in five of the 
seven patients although no majority variants with PI-resistance were identified. We concluded that 
limited or intermittent drug pressure resulted in insufficient selection for major drug-resistant 
variants to emerge. In study two, NGS conducted on the PGM and MiSeq improved the drug 
resistance detection in 15 PMTCT-failed infants. Although amplicon sequencing using fusion 
primers allows the most efficient use of NGS coverage, it is prone to PCR resampling error 
depending on the degree of template-to-primer mismatches. In study three, emulsion PCR was 
able to reduce but not correct this resampling error.  
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Opsomming 
Inleiding: Die Suid Afrikaanse publieke sektor antiretrovirale terapie (ART) uitrol gaan gepaard met 
die tevoorskyning van MIV middelweerstandigheid (MIVMW) in terapie-naïewe en behandelde 
pasiënte. Hierdie middel-weerstandige virusstamme word in die virus reservoir opgeneem en kan 
voortbestaan as minderheid-variante wanneer dit oorgroei word deur wilde tipe variante, in die 
afwesigheid van voldoende geneesmiddel-druk. Alhoewel minderheid-middelweerstandige variante 
terapie faling mag voorspel, kan dit nie geredelik met PKR en Sanger 
nukleinsuurbasispaaropeenvolgingbepaling (NSOB) aangetoon word wanneer dit minder as 20% 
van die viruspopulasie uitmaak nie.  
Nuwe generasie NSOB (NGB) laat die aantoning van minderheid middel weerstandige variante toe 
en die ondersoek van gepaartgaande MIVMW mutasies wanneer die lees-lengte voldoende is.  
Verskillende NGB platforms, beskikbaar in Suid Afrika, bied kostebesparing per monster wanneer 
daar voldoende monsters saamgepoel word. Nietemin vereis geteikende NGB die verryking van 
die templaat deur PKR wat kan lei tot PKR-geïnduseerde ewekansige foute of inleier-seleksie-
sydigheid en is meer uitgeproke wanneer lang fusie-inleiers gebruik word vir NGB amplikon 
analise.  
Metodes: Aangesien data beperk is oor minderheids-MIVMW variante in babas wat geïnfekteer is, 
ten spyte van die Wes-Kaap Voorkoming  van Moeder-na-Kind MIV Oordrag (VMNKO) 
behandelingsplan en in volwassenes met virologiese faling sonder major protease inhibitor (PI)-
weerstandigheid mutasies, op ‘n PI-gebaseerde middelkombinasie,  het ons NGB in hierdie 
populasies uitgevoer.  
In die eerste deursnit studie het ons monsters geneem van minderheidsvariante van sewe 
volwassenes wat faling van PI-gebaseerde terapie gehad het weens swak 
behandelingsgetrouheid.  Monsters is verryk vir NGB met ‘n geneste fusie-inleier PKR en 
minderheidsvariante is geïdentifiseer op die 454 Life Sciences, FLX Titanium platform 
(Connecticut, VSA).  
In die tweede deursnitstudie het ons monsters van virus variante van 15 VMNKO –gefaalde babas 
geneem.  Geneste PKR amplikons is grootte-gefragmenteer en ligeer aan platform-spesifieke 
NGB-aanpassers. Die NGB biblioteek is in parallel op die Ion Torren Personal Genome Machine 
(PGM) (Life Technologies, California, USA) en die Illumina MiSeq (California, VSA) getoets en 
bevestig deur klonale NSOB.  
In die derde studie, het ons gepoog om die herproefneming fout wat voorkom wanneer fusie-
inleiers gebruik word the karakteriseer en te korrigeer deur PKR reaksies “af te sper” in emulsie. 
Ons het die 454 NGB opbrengs vergelyk tussen “oop” PKR en geëmulsifiseerde PKR reaksies vir 
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templaat verryking en vir die effek van variërende inleier templaat mispassings wanneer die 
populasie-steekproef opgemaak word deur plasmiedmengsels.  
Bevindings: In die eerste studie het NGB die aantoning van MIVMW mutasies in vyf van sewe 
pasiënte verbeter, alhoewel geen meerderheid-variante met PI-weerstandigheid geïdentifiseer is 
nie. Ons het tot die gevolgtrekking gekom dat beperkte of afwisselende middel-druk gelei het tot 
onvoldoende seleksie om meerderheid middel-weerstandheid variante te laat verskyn. In die 
tweede studie het NGB, uitgevoer op die PGM en MiSeq, middel weerstandigheid-aantoning in 15 
VMNKO –gefaalde babas, verbeter. Alhoewel amplikon NSOB met fusie-inleiers die effektiefste 
gebruik van NGB dekking bewerkstellig, is dit geneig tot PKR herproefneming foute, afhangend 
van die graad van templaat-inleier mispassing. In studie drie, was emulsie PKR instaat om hierdie 
fout te verminder maar nie te korrigeer nie.  
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1 Introduction   
1.1 HIV in South Africa  
There are currently 25.8 million people estimated to be infected with human immunodeficiency 
virus (HIV) in sub-Saharan Africa (World Health Organisation 2015), 6.19 million of which are 
estimated to be living in South Africa (Statistics South Africa 2014). The Human Sciences 
Research Council estimates that approximately 5.5% of the population that resides in the Western 
Cape Province is HIV positive (Shisana et al. 2014). As antiretroviral therapy (ART) is the most 
effective way to improve patient health by suppressing viral replication and allowing immune 
recovery, the national government supplies antiretrovirals (ARVs) through a public sector therapy 
roll-out. Combination antiretroviral therapy has been shown to drastically limit or completely halt 
viral evolution in patients who are adherent to therapy (Kearney et al. 2014), with the incident risk 
of therapy failure decreasing with increased duration of therapy (Rosenblum et al. 2009). However, 
patients who are infected with a viral strain that already harbours HIV drug resistance mutations 
(transmitted drug resistance) are at a high risk of therapy failure (Cambiano et al. 2013) and in 
patients with inadequate therapy adherence or pre-existing drug resistance from prior regimen 
failure, drug resistance could emerge and evolve if therapy continues in the presence of drug 
resistance (Nachega et al. 2011). 
1.2 Anti-retroviral therapy (ART) 
ART began with zidovudine (AZT), which was approved by the USA Food and Drug Administration  
(FDA) in 1987 (Brook 1987; Ezzell 1987). When administered to HIV-infected individuals, clinicians 
observed a decrease in their blood-HIV load (at that stage measured by a p24 antigenaemia 
assay) for a limited period before their viral load increased again (Hirsch 1988). These patients 
then progressed to therapy failure, acquired immunodeficiency syndrome (AIDS) and eventually 
death (Molina et al. 1994). In the years that followed the FDA approved additional ARVs which 
were sequentially administered as ART, however, this mono-therapeutic approach did not prevent 
the onset of AIDS. 
ARVs are divided into five broad categories based on the stage of viral replication in which they are 
active:  
 Attachment and fusion inhibitors (FIs) – Either prevent the virus from binding to the target 
host cell (attachment inhibitors e.g. Maraviroc) or prevent the virus from fusing with the host 
cell membrane (e.g. Enfuvirtide) (Lalezari et al. 2003). 
 Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) – Nucleoside reverse 
transcriptase inhibitors are not phosphorylated and require triphosphorylation, whereas 
nucleotide reverse transcriptase inhibitors are monophosphorylated and require only two 
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phosphorylation steps. This class of ARVs prevents the reverse transcription of viral RNA 
into cDNA by the drug triphosphate competing with the native nucleotide triphosphate and 
resulting in chain termination (since they lack 3’ OH groups). Common examples of NRTIs 
include zidovudine (AZT), abacavir (ABC), lamivudine (3TC), emtricitabine (FTC), and 
tenofovir (TDF) (De Clercq 2004). 
 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) – NNRTIs inhibit reverse 
transcription by binding to a pocket next to the active site, thereby changing the 
conformation  of the viral reverse transcriptase enzyme and preventing nucleotide 
incorporation into the viral cDNA strand. Examples of this class of inhibitor include 
nevirapine, Efavirenz (EFV), etravirine and rilpivirine (De Clercq 2009). 
 Protease inhibitors (PIs) – These inhibitors prevent the viral aspartyl protease enzyme from 
by binding to the enzyme’s active site and competing with the natural substrate. Typical PIs 
are lopinavir (LPV), ritonavir, indinavir, darunavir and atazanavir (De Clercq 2009). 
 Integrase nuclear strand transfer inhibitors (INSTIs) – This class of inhibitors prevent the 
viral integrase enzyme from incorporating the viral DNA into the host genome. This class 
includes raltegravir, elvitegravir (EVG) and dolutegravir (De Clercq 2012). 
In 1997, two research groups publicised improved therapy outcomes seen when combining two 
NRTIs with a PI (Hammer et al. 1997; Gulick et al. 1997), while other studies observed similar 
benefit when two NRTIs were combined with one NNRTI (Williams & De Cock 1996; D’Aquila et al. 
1996). This combination antiretroviral therapy (cART) marked the birth of highly active antiretroviral 
therapy (HAART) which was capable of durable viral suppression (Gulick et al. 1997). cART was 
quickly implemented clinically and has been used for treatment-naïve (first-line regimens) and 
treatment-experienced patients (second-line, third-line or salvage regimens).  
1.2.1 First-line cART 
First-line cART has developed from the initial combinations consisting of two NRTIs and one PI 
(Gulick et al. 1997) or two NRTIs and one NNRTI (D’Aquila et al. 1996; Montaner et al. 1998). In 
resource-rich settings, fist-line cART now consists of two NRTIs with either a boosted PI, NNRTI or 
an INSTI (European AIDS Clinical Society 2014) while two NRTIs combined with one NNRTI are 
used as first-line therapy in resource-limited settings (World Health Organisation 2013). To improve 
therapy adherence fixed-dose combination tablets are now available and reduce the pill burden, 
that is the number of pills taken per day: these include the combination of EFV, TDF and FTC 
(Nachega et al. 2014) or FTC, TDF, EVG and cobicistat (marketed as STRIBILD) (Manzardo & 
Gatell 2014). TDF, FTC and EFV is the most widely used first-line regimen in developing countries 
and this and other NNRTI-based first-line regimens have low genetic-barriers requiring a the few 
drug resistance mutations for loss of activity.  
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1.2.2 Second-line cART 
Second-line cART, in resource-limited settings, consists of a ritonavir-boosted PI, in combination 
with two NRTIs (World Health Organisation 2013). The addition of the low dose ritonavir (notated 
“/r”) increases the trough drug level by inhibiting drug metabolism, reducing the risk of failure and 
drug resistance. As ritonavir-boosted PIs require multiple drug resistance mutations to lose 
efficacy, the second-line regimen has a high genetic barrier compared to the first-line regimens. 
Initially, this regimen was poorly tolerated since both lopinavir and didanosine (ARVs commonly 
used for second-line therapy) had gastrointestinal side effects. The WHO has subsequently 
recommended the use of AZT and 3TC or TDF and FTC/3TC combined with LPV/r for second-line, 
due to lower toxicity and better tolerability (World Health Organisation 2013).   
1.2.3 The prevention of mother-to-child transmission (PMTCT) in South Africa 
Apart from using ARVs for therapy, they can also be used to prevent vertical HIV transmission from 
mother-to-child since mothers who are virologically suppressed have the lowest risk of vertical 
transmission (European collective study 2005). AZT given from 14 weeks of gestation, during 
labour and after birth was shown to reduce transmission by about 70% (Connor et al. 1994). 
However, this regimen was difficult to implement in developing countries. Also, simplified regimens, 
based on nevirapine monotherapy showed efficacy (Guay et al. 1999; Dabis et al. 2005). 
Moreover, early initiation of cART in mothers not only maximally reduces HIV transmission but also 
provides maternal health benefits and may prevent transmission in subsequent pregnancies should 
the mothers remain adherent. Therefore in 2013, South Africa adopted the WHO Option B plus 
treatment plan as the national PMTCT plan (Ton & Frenkel 2013). Option B plus consists of cART 
initiation in pregnancy in all pregnant HIV-infected women who are not yet receiving cART, 
irrespective of disease stage or CD4 count, and which is continued uninterrupted thereafter.      
1.2.4 Therapy failure  
The WHO defines virologic failure as a persisting VL >1000 copies/ml (World Health Organisation 
2013). A large proportion of patients failing first-line cART are expected to have HIV drug 
resistance (Marconi et al. 2008; Wallis et al. 2014; World Health Organisation 2012) due to the low 
genetic barrier of the regimen. In contrast, few patients failing a second-line ritonavir-boosted PI 
regimen have any PI resistance mutations (van Zyl et al. 2011; Wallis et al. 2011). 
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1.2.5 Accumulation of drug resistance mutations 
Drug-resistant variants would replace sensitive variants under drug pressure to become the most 
dominant circulating population. The emergence of multi-drug-resistant viral strains requires a 
number of interrelated evolutionary mechanisms including a relatively high mutation rate (due to 
reverse transcriptase lacking proofreading), enrichment of resistant variants through selection 
pressure (exerted by therapy) and viral recombination events of variants harboring different 
mutations (zur Wiesch et al. 2011). Different drug-resistant variants could recombine when 
infecting the same cell, as HIV reverse transcriptase often switches templates. Subsequently, viral 
strains that accumulate DRMs to a range of ARVs emerge. A typical example of this scenario is 
when a multi-drug-resistant variant develops and replicates effectively under first-line NNRTI-
based cART.  
In some cases, the cost of replicating in the presence of a particular drug is reduced replication 
fitness (Kulkarni et al. 2012). Relative fitness is dependent on the replication environment: Viruses 
harbouring drug resistance mutations usually replicate less efficiently than the wild-type variant in 
the absence of drug pressure since they encode enzymes that often have reduced processivity 
compared to wild-type, but which enable them to replicate better than the wild-type in the presence 
of ARVs. These drug-resistant strains retain dominance until the selection pressure is removed 
and dominance is restored to the fitter wild-type strain. However, these resistant variants are 
‘archived’ as proviruses in quiescent CD4 cells, acting as viral reservoirs, and may rapidly replace 
wild-type when the same or similar drugs are recycled (Siliciano & Siliciano 2004). In this way, 
treatment-experienced patients who have failed multiple regimens accumulate various DRMs 
which eventually limit their therapy options. In addition, transmission of drug-resistant viral strains 
limits the therapeutic options for the newly infected individual. These variants decrease the 
baseline susceptibility (before therapy initiation) in the general population, as observed by various 
studies investigating ARV resistance in treatment-naïve populations (Hamers et al. 2011; Gupta et 
al. 2012). 
1.3 Challenges in clinical drug resistance testing  
In light of the observed DRMs in ARV-naïve population, drug resistance testing (DRT) would 
become valuable for baseline testing in settings with high levels of transmitted drug resistance, 
which is associated with high therapy coverage (especially when not accompanied by viral load 
monitoring) (van Zyl et al. 2014; Phillips et al. 2011). While the costs and reduced accessibility of 
DRT in resource-limited countries have prevented the WHO from recommending its widespread 
implementation, DRT in itself has a list of obstacles that reduce its practicability. 
 
Stellenbosch University  https://scholar.sun.ac.za
5 
 
1.3.1 Intra-host diversity  
As HIV reverse transcriptase lacks proofreading, viral replication is prone to base substitutions at 
an estimated rate of roughly once per five viral genomes (Hu & Hughes 2012). This, together with 
a high rate of viral replication, results in a myriad of diverse viral species produced daily. The vast 
diversity of HIV makes viral genotyping challenging because Sanger sequencing relies on reaction 
priming with genome-specific primers. Using degenerate primers increases the selection tolerance 
to include multiple variants, although, too many degenerate bases causes non-specific priming and 
failed sequencing reactions.    
1.3.2 Sensitivity - Subtype B tests and Subtype C prevalence 
Commercially available DRT kits are readily available but require appropriately skilled lab 
technicians and access to diagnostic facilities with sufficient infrastructure to perform and process 
DNA sequencing. In addition, interpreting the sequencing results to detect HIV drug resistance 
often requires online drug resistance database access. In resource-limited settings such as sub-
Saharan Africa, access to technology to perform drug resistance assays and interpret sequences 
is limited. Moreover, most commercial DRT assays target are designed for subtype B viral strains 
(e.g.: Applied Biosystems’ ViroSeq® (California, USA) and Visible Genetics’ TRUGENE® (Ontario, 
Canada)) and have reduced sensitivity to subtype C variants that are prevalent in sub-Saharan 
Africa (Aghokeng et al. 2011). However, if sufficient technical infrastructure is available, published 
in-house DRT methods could be adapted and implemented, enabling a ~50% reduction in DRT 
costs ($ 112 as opposed to the commercial $ 300) (Chaturbhuj et al., 2014). These methods could 
also achieve a high rate of sequencing success through improved primer selection for conserved 
targets and to match local circulating strains. 
1.3.3 Sample turnaround time  
Despite reduced costs, in-house resistance genotyping is time consuming and necessitates 
various “hands-on” and computational analysis steps: nucleic acid extraction, cDNA synthesis, 
PCR enrichment, gel electrophoresis (to confirm PCR amplification), PCR clean-up, sequencing 
reactions, automated Sanger DNA sequencing, sequence alignment, contig assembly and 
bioinformatic drug resistance interpretation. While an automated drug resistance sequence 
analysis pipeline such as “RECall” could shorten sequence processing (Woods et al. 2012), few 
interventions are capable of reducing the laboratory processing time requirements without cost 
implications. Because peripheral clinical care facilities lack the necessary infrastructure to process 
DRT samples, they are compelled to ship samples to core laboratories where in-house DRT can 
be performed and could increase turnaround time.    
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1.3.4 In-house DRT 
In-house DRT (or bulk sequencing) methods are more affordable than commercial alternatives, 
however, unlike commercial assays, there is a lot of inter-laboratory variation in in-house assay 
design and performance (Parkin et al. 2012; World Health Organisation 2013). These methods 
require the processes mentioned above (section 1.3.3) and rely heavily on template enrichment 
through multiple rounds of pre- and nested PCR. In most cases, the primers used in these 
reactions are designed to amplify the most common strains identified in the region where testing is 
conducted. Primers are designed by downloading an alignment of many geographically-relevant 
viral sequences from an online HIV database (such as 
http://www.hiv.lanl.gov/components/sequence/HIV/search/search.html), investigating nucleotide 
conservation surrounding the DRT relevant regions, and selecting feasible pre- and nested PCR 
primers.  
 
The alternative approach is to order and use primers designed by other researchers, which are 
proven to amplify the required genomic regions. When either approach is successful, the nested 
PCR products are sequenced using internally-binding sequencing primers and the Sanger 
dideoxynucleotide sequencing method. Since the above methodology relies heavily on gene-
specific primers, these reactions are greatly biased and primer-mismatched or minor variants are 
underrepresented (Rowley et al. 2010). Nevertheless, in-house DRT by PCR and Sanger 
sequencing can be used to detect baseline resistance or transmitted resistance in recently infected 
patients, and acquired drug resistance in patients failing therapy. However, these methods have 
limited sensitivity as they cannot reliably detect minority, drug-resistant variants below a threshold 
of 20% (Palmer et al. 2005).  
1.3.4.1 Minority, drug-resistant populations  
When therapy-naïve individuals are infected with drug-resistant HIV, the transmitted viral 
population is possibly monophyletic, not containing wild-type variants (Little et al. 2008; Gandhi et 
al. 2003). Reversion to the more fit, wild-type viral strain is estimated to take between four to ten 
years during which the resistant population wanes, becoming a minor variant (Little et al. 2008). 
While these variants are indefinitely archived in viral reservoirs, they may persist undetected by 
conventional DRT since Sanger genotyping methods. Nevertheless, these variants are clinically 
important since their presence has been shown to predict therapy failure (Metzner et al. 2009; 
Jourdain et al. 2010; Paredes et al. 2010; Li et al. 2012; Li et al. 2013). 
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1.3.4.2 Minor variant detection solutions  
The solutions presented below are practical alternatives to conventional PCR and Sanger DRT, 
aimed at detection drug-resistant, minor variants.   
1.3.4.2.1 Allele-specific PCR (AS-PCR) 
During a standard PCR, the polymerase encounters a primed genomic region and proceeds to 
complement the single-stranded genomic region that follows (Kleppe et al. 1971). However, if the 
3’ end of the primer is unbound to the single-stranded template, primer extension would be 
inefficient. As such, AS-PCR relies on the inability of Taq polymerase to extend primers with un-
bound 3’ ends, where the mismatched base can discriminate between a DRM and the native 
nucleotide (Metzner et al. 2003). The sensitivity of a real-time PCR assay coupled with the AS-
PCR methodology, results in an affordable DRT alternative (Bergroth et al. 2005; Metzner et al. 
2005; Paredes et al. 2007). In contrast to Sanger genotyping however, AS-PCR may be more 
sensitive but is limited in the number of mutations that can be simultaneously sampled and thus 
limits mutation linkage studies. Similar to Sanger genotyping, AS-PCR relies on primer to template 
binding and is thus prone to false negative or positive results due to mismatches apart from the 
putative resistant and wild-type alleles, that the assays were designed to discriminate between 
(Rowley et al. 2010).  
1.3.4.2.2 Oligonucleotide ligation assay (OLA)  
OLAs discriminates between wild-type and mutant alleles using two, 20-mer DNA probes: one with 
an appended biotin and another with a hapten that corresponds to either the wild-type or mutant 
allele (Tobe et al. 1996). For a successful ligation reaction, both probes must perfectly complement 
the template (i.e.: there must be no mismatches in both probes binding areas) and the probes must 
bind directly adjacent to each other in the 5’ to 3’ direction (i.e.: with no intervening nucleotides). 
Any mismatches at the ligation site or mispriming would prevent ligation insomuch that a mutant-
specific hapten-appended probe could not be ligated to the biotin-attenuated probe when both 
probes are hybridised to a wild-type template. This hybridisation stringency confers allelic 
specificity to OLA. Ligated probes are captured by their attenuated biotin moiety on a streptavidin 
coated well and the hapten is identified using an enzyme-conjugated antibody. The identity of the 
hapten in turn the identifies the template allele as either the wild-type or mutant (Tobe et al. 1996; 
Edelstein et al. 1998; Jourdain et al. 2010). Similar to AS-PCR however, OLA too is limited in the 
number of mutations that can be assayed in parallel and thus limits mutation linkage study. In 
addition, OLA may return false negative results if there are additional mutations surrounding the 
DRM allele being interrogated.  
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1.3.5 Pooled viral load testing before DRT can reduce cost 
HIV DRT usually follows a detectable viral load. When the prevalence of virological failure is low, 
viral load testing of pooled samples could reduce diagnostic costs as most pools would be 
negative; with only a few positive pools requiring deconvolution to determine which of the individual 
samples making up the pool are positive (having a viral load above a failure threshold) (Smith et al. 
2009). Pooled testing of dried plasma spots would allow sample transport from peripheral sites, 
and has been shown to be efficient when a threshold for therapy failure of 1000 HIV-1 RNA 
copies/sample is used, and could reduce reagent costs by more than half (van Zyl et al. 2011).  
A novel approach that allows the identification of patients who are failing and distinguishes patients 
with drug resistance from those without (likely due to inadequate adherence) was proposed by 
Newman and colleagues (Newman et al. 2014). In short, samples are pooled and a qualitative 
PCR is performed. If a pool tests positive (indicating that one or more of the comprising members 
have virological failure) it is followed by PCR of the individual members making up a positive pool. 
Positive individual PCR products then undergo Sanger sequencing to detect HIV drug resistance. 
Negative pools or individual PCR products exclude failure and HIV drug resistance. When the 
expected failure rate is low, this approach combines the efficiency of pooled testing to qualitatively 
detect failure with in-house HIV DRT by Sanger sequencing. 
1.4 Next generation sequencing (NGS) 
NGS is also referred to as second generation sequencing, ultra-deep sequencing and massively 
parallel sequencing due to various characteristics of the sequencing methods:  
 Second generation sequencing relates to these platforms having followed the first 
generation Sanger sequencing platforms. Second generation sequencing is a more 
accurate description than NGS since third generation sequencing is already commercially 
available;  
 Massive parallel sequencing referrers to the vast number of DNA molecules that are 
sequenced in parallel.  
 Ultra-deep sequencing is a particular application where the high coverage achieved by 
massive parallel sequencing is focused on a short genome target to achieve high-resolution 
sequencing of rare variants from biologic samples.  
Second generation sequencing (referred to here as NGS) offers a viable alternative to first 
generation DRT methods. Because NGS identifies genomic sequences rather than differentiating 
single alleles, it allows for DRM linkage study that is not possible with AS-PCR and OLA, provided 
that the linked mutations are identified on the same DNA strand. The use of genetic barcodes or 
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molecular identifiers (MIDs) enables pooled testing and cost savings (Rohland & Reich 2012), 
while the redundant sampling enables minor variant detection (Wang et al. 2007).  
Various sequencing library generation options are available for NGS, however, they all require 
sequencing adaptors to capture the target and prime the sequencing reactions. Depending on the 
enrichment strategy employed, the MID sequences may be added as part of a fusion primer (as is 
the case of amplicon sequencing) or ligated to the sequence of interest in a fragmented library 
generation approach. NGS platforms require sample enrichment via bead-based emulsion PCR 
(Diehl et al. 2006) or bridge PCR amplification on a solid surface (Shendure et al. 2005), that is 
made possible by the flanking adaptor sequences. If a pooled sample testing approach is used, all 
the indexed samples are pooled at the same final concentration before the adaptor sequence is 
ligated to its bead- or solid-surface-anchored complement.  
NGS platforms available in South Africa use one of three approaches to detection nucleotide 
incorporation, including: 
 Sequencing-by-synthesis (SBS) – This approach directly detects incorporated nucleotides 
through either of the following methods:  
o By detecting the particular nucleotide that has been incorporated using reversible 
chain terminating (RCT) nucleotides linked to fluorophores (Ju et al. 2006). 
Solexa/Illumina’s (California, USA) NGS platforms, the MiSeq and HiSeq, use this 
RCT approach; 
o By detecting the release of a DNA polymerisation by-product: either H+ ions, as a 
change in the reaction pH (Rothberg et al. 2011), or a pyrophosphate, as used in 
pyrosequencing. Pyrosequencing monitors the production of pyrophosphate that 
indirectly results in the catalysis of luciferin, producing chemiluminescence 
(Ahmadian et al. 2000). The emitted light is detected using a high-resolution charge 
coupled device (CCD) camera and the luminescence intensity amplitude is 
translated into the number of incorporated nucleotides (Morey et al. 2013). The Life 
Technologies’ (California, USA) Ion Torrent Personal Genome Machine™ (PGM) is 
the only NGS platform that uses pH changes to detect nucleotide incorporation, 
while the 454 Life Sciences (Connecticut, USA) platforms, the Genome Sequencer 
(GS) Junior and the FLX Titanium, are the only pyrosequencing NGS platforms 
(now distributed by Roche Diagnostics, Basel, Switzerland).    
 Sequencing-by-ligation (SBL) – This sequencing chemistry detects the appended 
fluorophore on the end of eight-base-long probes. Each probe interrogates two bases. 
During probe binding  the colour of the appended fluorophore is recorded. Thus, this 
method employs a two-base interrogation strategy and requires that a base is dually 
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interrogated to determine its identity (Shendure et al. 2005). Currently, Agencourt’s 
(Massachusetts, USA) SOLiD™ sequencer is the only NGS platform to use this novel SBL 
sequencing chemistry (now distributed by Applied Biosystems, Massachusetts, USA).    
1.4.1 Ultra-deep and ultra-wide sequencing 
Various options exist for upstream HIV NGS sample preparation although amplicon sequencing or 
targeted resequencing offers optimal use of NGS coverage for DRT. Since most primary DRMs 
related to first and second-line cART failure are found in the viral protease and reverse 
transcriptase genes, enriching these regions prior to sequencing allows for sufficient sampling 
depth to identify minority populations of drug-resistant variants. Alternatively, if minor variant 
detection is not required, sequencing with multiple MIDs enables researchers to pool and genotype 
many samples in parallel, at sufficient depth to accurately identify drug resistance. Pooled 
sequencing of many indexed samples with “shallow coverage” is referred to as ultra-wide 
sequencing (Dudley et al. 2012) and is currently limited by the number of available specific MIDs 
and the platform-specific minimum sequencing depth needed to confidently call a specific base. 
1.4.1.1 Advantages and disadvantages  
Ultra-deep sequencing can identify minor variants with >99% confidence in nucleotides identity. 
This “base-calling confidence” and is a function of the platform-specific base-call signal quality. In 
addition, the number of times that specific base was accurately identified improves the average 
base-call quality and in turn, the base-call confidence. Coverage depth can increase the 
confidence in minor variant calling provided that the sequenced library is representative of the 
biologic diversity in the patient. However, this cannot be assumed: despite acceptable accuracy of 
current NGS platforms, upstream enrichment or library preparation could introduce mutations or 
misrepresentation of variant frequency compared to the true population diversity in the individual 
from whom the sample was collected.  
When many MIDs are used to sequence multiple samples in parallel, the per-sample costs are 
greatly reduced although, each sequencing platforms has a limit to the amount of per-run 
sequence data produced, which is divided between the number MIDs represented in the 
sequencing reaction. Thus, the more MIDs used, the lower the per-sample coverage and the lower 
the average base-call confidence.  
Another consideration is practical batch sizes; with high coverage platforms such as Illumina Miseq 
the pooling of up to 96 samples greatly reduces costs. However, these large batch sizes would 
practically result in delays in turnaround time in lower throughput laboratories, as it may take many 
days to fill a batch. 
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1.4.2 Various platforms 
There are currently four NGS technologies available in South Africa, each with their advantages 
and disadvantages (Hadfield & Loman 2014). Listed below are the various platforms, a brief 
description of their origins, a summary of their sequencing chemistries, and their specific strengths 
and weaknesses. As previously mentioned (see section 1.4 above), second generation sequencing 
platforms require specific sequences on the ends of the sequence amplicon to anchor the DNA for 
enrichment prior to sequencing.  
1.4.2.1 454 Life Sciences  
The 454 Life Sciences (Connecticut, USA) GS20 (distributed by Roche Diagnostics (Basel, 
Switzerland) since 2007), was the first commercially available second generation sequencing 
platform, introduced in 2005 (Margulies et al. 2005). The GS20 had an introductory read length of 
between 100 to 150 bp and generated up to 20 megabases (Mb) of sequence data per run 
(Margulies et al. 2005). The pyrosequencing technology used on 454 platforms (454 Life Sciences, 
Connecticut, USA) is based on the research conducted by Mostafa Ronaghi and Pål Nyrén at the 
Royal Institute of Technology (Stockholm, Sweden) (Ronaghi et al. 1996), and relies on the 
detection of pyrophosphates that are released after a polymerase incorporates a nucleotide 
(Margulies et al. 2005). The sequencing chemistry involves the steps below and is depicted in 
figure 1.8.1 in Appendix A: 
 After the enrichment with a bead-based emulsion PCR, single-stranded, bead-bound 
amplicons are immobilised in a 29 µm well located on a picotitre plate, in a flow-cell. The 
sequencing reaction is primed in the presence of a polymerase, an adenosine tri-phosphate 
(ATP) sulfurylase, and a luciferase. 
 Single nucleotides are washed over the flow-cell in a predetermined sequence. If the 
specific nucleotide that is washed over the picotitre plate is not incorporated, it is digested 
by an apyrase enzyme in the subsequent washing. However, when the polymerase 
incorporates a nucleotide, a pyrophosphate and a hydrogen ion are released.  
 ATP-sulfurylase uses the free pyrophosphate to convert adenosine di-phosphate to ATP, 
which in turn activates the luciferase. The luciferase catalyses the substrate luciferin, 
releasing a visual light signal before an apyrase wash degrades unincorporated 
nucleotides. 
 The amplitude of the emitted light is proportional to the number of nucleotides incorporated 
such that the luminescence produced from two incorporated nucleotides is double that 
observed when one nucleotide is incorporated.  
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Two 454 pyrosequencing platforms are currently available in South Africa: the 454 GS FLX and the 
smaller bench top version, the 454 GS Junior (454 Life Sciences, Connecticut, USA). While there 
are minor differences in these platforms adaptor sequences, the most noticeable difference is the 
sequence data capacity (i.e.: 450 Mb on the FLX and 35 Mb on the Junior) and the platform-
specific read lengths (450 bp on the FLX and 400 bp on the Junior) 
(http://454.com/products/index.asp).  
The greatest advantages of the 454 sequencing platforms are the long read length and the speed 
at which a sequencing run is completed. However, 454 platforms struggle with accurately 
sequencing homopolymer regions since there is not much difference in the observed luminescence 
when more than six bases are incorporated at once (Huse et al. 2007). In addition, the running 
costs for the 454 platforms are considerably more expensive than their competitors (Loman et al. 
2012). In October of 2013, Roche announced that it would no longer support the 454 sequencing 
platforms after mid 2016 as the platform was being overshadowed by the newer sequencing 
technologies (https://www.genomeweb.com/sequencing/roche-shutting-down-454-sequencing-
business). 
1.4.2.2 Solexa/Illumina 
Solexa (California, USA) released their first NGS platform, the Genome Analyzer (GA) in 2006, 
before being acquired by Illumina (California, USA) in 2007 (http://www.illumina.com/). The GA had 
an initial read-length of 50 bp and generated 1 gigabase (Gb) of sequence data per run, that was 
later improved in 2007 to 150 bp read length and 50 Gb per sequencing run. Solexa (California, 
USA) uses an SBS approach and the sequencing chemistry first described by Shankar 
Balasubramanian and David Klenerman from Cambridge University (Cambridge, United Kingdom) 
(Balasubramanian et al. 2004). Illumina platforms employ the reversibly-terminating fluorescent 
labelled nucleotides sequencing strategy as described below and depicted in figure 1.8.2 in 
Appendix A: 
 Sequence amplicons are enriched on a solid surface by bridge PCR to form amplicon 
colonies before a primer and a polymerase are added in solution. 
 One of the four different reversibly-terminating fluorescently labelled nucleotides is 
incorporated into the complementary DNA strand. Once incorporated, a scanning laser 
determines the identity of this nucleotide by the colour of its fluorescent tag.  
 A chemical wash is applied to cleave off the 3’ non-extendable part of the incorporated 
nucleotide, along with the fluorescent tag.  
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 Next, more reversibly-terminating nucleotides are washed over the reaction and the cycle is 
repeated. Based on the steps involved in this sequencing strategy, it is often referred to as 
cycling reversible-terminator or CRT sequencing. 
Solexa/Illumina platforms (California, USA) currently available in South Africa include the MiSeq 
and the HiSeq which produce 15 Gb and 1500 Gb sequence data per run, at read lengths of 600 
and 300 bp respectively (http://www.illumina.com/systems/sequencing-platform-
comparison.html?mode=iframe). The greatest advantage of the Solexa/Illumina platforms 
(California, USA) is their high sequencing throughput (generating many gigabases of data) while 
their greatest disadvantage is the short read lengths in relation to their competitors, however, 
through bidirectional sequencing, these platforms can achieve 600 bp read lengths.   
1.4.2.3 Life Technologies 
Life Technologies (California, USA) Ion Torrent Personal Genome Machine™ (PGM) was first 
introduced to the commercial market in February of 2010 (Rusk 2011). Similar to the 454 
sequencing platforms, the PGM detects bi-products of a DNA polymerisation. However, the PGM 
(Life Technologies, California, USA) differs from the above-mentioned NGS platforms in that it 
does not use optics to detect base incorporation signals, which allows a much smaller instrument 
footprint. Rather, the PGM (Life Technologies, California, USA) detects minute changes in the 
hydrogen concentration (pH) of the sequencing reaction taking place on a complementary metal–
oxide–semiconductor (CMOS) chip (Rusk 2011). The CMOS chips used on the PGM (Life 
Technologies, California, USA) differ in the number and density of embedded reaction wells and in 
turn, the amount of sequence data output, insomuch that three chips are available for the PGM 
(Life Technologies, California, USA): the 314 chip, the 316 chip and the 318 chip that produce up 
to 100 mb, 1 Gb and 2 Gb of sequence data, respectively 
(https://tools.lifetechnologies.com/content/sfs/brochures/PGM-Specification-Sheet.pdf).  
Initial PGM sequencing chemistries produced 50 bp read lengths and generated 100 Mb of 
sequence data. In 2011, these characteristics improved to 400 bp reads and more than 2 Gb of 
sequence data on a 318 sequence chip. The PGM (Life Technologies, California, USA) measures 
the hydrogen ions (protons) produced during complementary strand synthesis of bead-bound, 
emulsion-PCR-enriched amplicons. The sequencing strategy is depicted in figure 1.8.3 (in 
Appendix A) and uses the following steps: 
 The bead-bound amplicon is primed and a single-nucleotide-species wash is flushed over 
the sequencing chip in a predetermined sequence. 
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 If the base is not incorporated into the complementary DNA strand, it is discarded in the 
next wash step. However, if the nucleotide is incorporated by the polymerase, a 
pyrophosphate and a hydrogen ion are released as bi-products of DNA polymerisation.  
 The released hydrogen ion results in a localised change in the reaction pH, which is 
detected by the CMOS circuitry embedded beneath the sequence well. The amplitude of 
the detected pH change is proportional to the number of hydrogen ions released, which in 
turn is proportional to the number of nucleotides incorporated. 
 The chip is subsequently washed, and the next predetermined nucleotide wash is applied. 
The PGM is currently the only semiconductor sequencing platform commercially available in South 
Africa through the Stellenbosch University Central Analytical Facility (Western Cape Province, 
South Africa) or the Division of Biochemistry at North-West University (North West Province, South 
Africa). The per-base sequencing cost of the PGM is by far its biggest advantage accompanied by 
its quick turnaround time of roughly two hours (Loman et al. 2012). On the other hand, similar to 
the 454 platforms (454 Life Sciences, Connecticut, USA), the PGM (Life Technologies, California, 
USA) has difficulty sequencing homopolymers (Metzker 2005) as the pH change, measured as 
voltage amplitude, loses linearity with the number of bases incorporated for runs of six or more 
identical bases. 
1.4.2.4 Agencourt/Applied Biosystems 
The Sequencing by Oligo Ligation Detection™ (SOLiD) sequencing platform was introduced to the 
commercial market by Agencourt (Massachusetts, USA) in 2006 before the company was acquired 
by Applied Biosystems (Massachusetts, USA). At introduction, the SOLiD sequencer produced 
35 bp reads and 3 Gb of sequence data per run, with greater than 99.85% accuracy owing to its 
SBL technology (Liu et al. 2012). The read length and total data output were soon improved to 
85bp and 30 Gb per run with the introduction of the SOLiD 5500xl in 2007 
(http://www.appliedbiosystems.com/absite/us/en/home/applications-technologies/solid-next-
generation-sequencing/next-generation-systems.html). After the bead-based emulsion PCR, the 
novel SBL strategy depicted in figure 1.8.4 (in Appendix A), is applied as follows: 
 Enriched beads with bound single-stranded amplicons are immobilised on the surface of 
the flow-cell. An eight-base probe with a 5’ fluorescent dye is ligated to the amplicon. The 
colour of the fluorescent dye is visually recorded.  
 Next, the dye is cleaved off from the probe along with the last three probe bases. The 
cleaved dye is washed away, and the next probe is ligated. 
 Since the first two bases of the probes are known and correspond to a specific fluorescent 
dye colour, this sequencing method interrogates two-bases-at-a-time.  
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 Once the amplicon has been sequenced to the end, the complementary strand is washed 
away and a new primer (one base shorter than the first round primer) is used to again 
primer the sequencing reaction. This sequencing round once again interrogates the 
template two-bases-at-a-time, starting from a -1 base position.  
 This cycle is repeated five times, each time the primer length is decreased by one 
additional base and the two-base interrogation is offset by -2, -3 and -4 nucleotides from 
the original starting position. 
One of the greatest advantages of this sequencing approach is that, since nucleotides are 
essentially interrogated multiple times, the error rate of this platform is exceptionally low (Liu et al. 
2012). Although, due to the short read lengths characteristic of this platform, investigation of 
mutation linkage is limited and post-sequencing read mapping requires powerful computational 
hardware.    
1.4.3 Homopolymer error  
Of the sequencing platforms described above, two are particularly prone to read length error in 
homopolymer regions. These errors result from the PGM (Life Technologies, California, USA) and 
454’s (454 Life Sciences, Connecticut, USA) inability to discriminate more than five of the same 
nucleotide species incorporated in one nucleotide wash. Incorrect homopolymer read length errors 
present as insertion or deletions, collectively referred to as indels. On the 454 platform (454 Life 
Sciences, Connecticut, USA), when seven or more nucleotides are incorporated, the luciferase 
luminescence is incrementally more than when six nucleotides are incorporated, and the charge 
coupled device (CCD) camera cannot accurately distinguish the difference in luminescence 
amplitude (Margulies et al. 2005). Similarly on the PGM (Life Technologies, California, USA), the 
incremental difference between six or more hydrogen ions (released during base incorporation) 
causes diminutive changes in the reaction pH, which the embedded sensors struggle to identify 
(Bragg et al. 2013).  
Sequencing chemistry on the other SOLiD (Agencourt, Massachusetts, USA) and Solexa/Illumina 
platforms (California, USA) circumvent homopolymer errors using the following strategies:  
 The SOLiD’s SBL protocol (Agencourt, Massachusetts, USA) can only incorporate one 
probe at a time (per sequenced fragment) since the 5’ ligation-terminator (attached to the 
probe) must be cleaved before the ligase can incorporate the next probe (see figure 1.8.4 in 
Appendix A). If two probes were incorporated simultaneously, the scanning laser would 
detect two fluorophores with an abnormal emission wavelength.  
 CRT sequencing used on the Solexa/Illumina (California, USA) platform terminates 
sequencing after every nucleotide incorporation, preventing more than one nucleotide 
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incorporation at a time. Once the terminator is chemically cleaved, the next nucleotide can 
be added. This one-nucleotide-at-a-time sequencing strategy produces accurate 
homopolymer read length calls (see figure 1.8.2 in Appendix A).   
1.4.4 Comparative NGS  
As the first commercially available NGS platform, Roche 454 sequencing has been the preferred 
technology used to identify drug-resistant HIV minority populations, despite the homopolymer read-
length limitations of its’ SBS chemistry. Recently, Li and colleagues demonstrated the affordability 
and accuracy of Illumina’s CRT sequencing homopolymer reading accuracy when compared to the 
454 technology (Li et al. 2014). These favorable characteristics and the 600bp bi-directional, read 
lengths (http://www.illumina.com/systems/sequencing-platform-comparison.html?mode=iframe) 
paint the Illumina sequencers as the preferred drug resistance NGS platforms in the future.        
1.4.5 Application to HIV DRT and pooling potential 
Homopolymer reading errors are of particular concern when resequencing HIV since 17 drug 
resistance mutations (DRMs) are known to occur in homopolymer regions (Dudley et al. 2012). 
Moreover, while the SOLiD (Agencourt, Massachusetts, USA) and MiSeq (Solexa/Illumina, 
California, USA) platforms are immune to homopolymer errors, the SOLiDs (Agencourt, 
Massachusetts, USA) read lengths do not facilitate mutation linkage studies and the MiSeq 
(Solexa/Illumina, California, USA) sequencing runs are costly.  
To compensate for the PGM (Life Technologies, California, USA) and 454’s (454 Life Sciences, 
Connecticut, USA) homopolymer errors, bioinformatic software uses logistically corrective mapping 
algorithms. By translating sequence reads into amino acids and mapping them to a consensus 
codon sequence, the software identifies indels as codon frame shifts. Once identified, 
homopolymer indels are corrected such that the codon sequence is in frame with the consensus, 
and the read is realigned. Two codon-aware sequence alignment programs are used for HIV 
mapping in this thesis:  
 Datamonkey was developed by Sergei Kosakovsky Pond in 2005 and is available online at 
http://www.datamonkey.org (Pond & Frost 2005). This software was used in chapter three 
to align PGM and MiSeq HIV data.  
 In chapter four we used RAMICS, developed by Simon Travers and Imogen Wright in 2014 
to map 454 GS Junior sequences. This software package is accessible online at 
http://hiv.sanbi.ac.za/tools/#/ramics (Wright & Travers 2014). 
 
Stellenbosch University  https://scholar.sun.ac.za
17 
 
1.4.5.1 Targeted resequencing  
NGS platforms can sequence entire genomes depending on the sequence library preparation 
methods employed. For example, if viral RNA is isolated from patient material, the entire viral 
genome can be reverse transcribed, PCR amplified with random or specific primers and 
sequenced using a DNA fragmentation and sequencing adaptor ligation library preparation 
protocol. While this approach generates useful sequence data on recombination and evolution, 
since most first and second-line cART DRMs occur in protease and reverse transcriptase, roughly 
20% of genes sequenced are relevant to drug resistance.  
Targeted resequencing of these “drug-resistance-related” areas (i.e.: protease and reverse 
transcriptase) is achieved through PCR enrichment of these specific areas. This enrichment 
strategy optimally uses the available sequence coverage to improve the sampling depth and in 
turn, minor variant detection, and can be achieved by two sequencing strategies: 
 Amplicon sequencing with fusion primers – Fusion primers contain 5’ platform-specific 
adaptor sequences and may include patient-specific MIDs, while the 3’ gene-specific 
sequence facilitates targeted enrichment of drug-resistance-related areas. Although the 
final amplicon should not exceed the maximum platform-specific sequencing read length, 
determined by the sequencing strategy (either unidirectional of bidirectional). To improve 
mutation linkage study, amplicons may be generated with overlapping ends, as seen in 
thesis chapter two. While effective, the use of fusion primers has been linked to strong 
primer-induced selection bias, as described in thesis chapter four.  
 PCR enrichment followed by fragmentation and adaptor ligation - Enriching drug-
resistance-related areas with primers that bind in conserved genomic regions reduces the 
primer-induced selection bias. The selection bias is reduced because most conserved-area 
primers should not discriminate between various viral species and should reduce the 
effects of PCR resampling. Considering these factors, enriching the viral protease and 
reverse transcriptase with conserved primers, reduces selection bias. Following this 
enrichment with amplicon fragmentation and adaptor ligation, results in NGS-platform-
sequenceable amplicons, generated with reduced selection bias and sequenced with an 
optimal use of coverage. In addition, the amplicons generated before adaptor ligation are 
sequenceable on multiple NGS platforms, provided that the appropriate adaptor is 
appended. This adaptor ligation strategy was used in thesis chapter three to validate the 
PGM (Life Technologies, California, USA) for HIV DRT by sequencing the same sequence 
library on an alternative NGS platform, the Solexa/Illumina MiSeq. 
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1.4.5.2 Coverage and depth  
Confident identification of a minor variant mutation in a sequenced library is dependent on 
coverage and sequence accuracy, provided that the sequenced library is representative of the 
biologic diversity in the patient. Therefore, a higher coverage is associated with higher base-call 
accuracy (Meynert et al. 2013). However, the nucleic acid enrichment process, prior to sequencing, 
could introduce errors either since the patient sample is inadequate to represent patient diversity 
(e.g. small volume and low sample HIV RNA load, resulting in a high random sampling error) or the 
reverse transcription and PCR amplification process could introduce errors or biased amplification 
of particular variants. These sampling or enrichment errors could not be overcome by increased 
coverage but could be improved by adequate sampling (increased sample volumes in patients with 
low viral loads) and enrichment processes with lower error and bias (discussed in more detail 
below).   
When pooling many samples for NGS there are many considerations: The data limit of the 
sequencing platform, the sequencing platform-specific error rate (how often a base is incorrectly 
identified), the platform read-length (and whether mutation linkage is important for the investigator), 
any AT:GC bias, the target amplicon size, and the frequency (percentage) of minor variants that 
one aims to detect. For instance, with high coverage platforms such as the Illumina HiSeq 
(California, USA) many more samples can be pooled than with 454. However, the relative shorter 
read-length may make the Illumina platform less suitable for the study of mutation linkage across 
long genome targets compared to the new Pacific Biosciences (California, USA) RS II sequencing 
platform, which is able to sequence up to 15 kb 
(http://investor.pacificbiosciences.com/releasedetail.cfm?ReleaseID=876252).   
1.5 NGS implementation challenges  
In resource-limited countries, the greatest deterrent to NGS is the costs associated with sample 
preparation and sequencing. These costs include high fidelity PCR reagents, parallel reactions, 
fusion primer costs, commercial sample extraction and reaction purification kits, library preparation 
kits (including ligation of sequencing adaptors) for sequencing platforms and labour costs. In 
addition, the resultant sequence data analysis is complex and requires some bioinformatics or 
programming knowledge to translate sequence data into clinical results.  
As previously described, the per sample cost may be reduced by using multiple MIDs to pool 
samples together on NGS platforms that provide sufficient sequencing depth to accurately 
sequence all variants with therapeutic relevance. This approach would, however, require seasoned 
laboratory personnel and sufficient sample volumes to adequately represent the variation in the 
patient, and to reduce random PCR sampling error, parallel processing. In addition, sequencing 
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libraries and reactions may take a few days to complete, resulting in patients being lost to follow-
up.  
1.5.1 Sample preparation 
The use of high fidelity PCR is advised for upstream NGS to reduce homopolymer transcription 
error and spurious base substitutions which may present as minor variant populations after 
sequencing (McInerney et al. 2014). These enzyme systems, with their proofreading ability, 
improve assay fidelity at the expense of assay sensitivity and processivity. Additionally, for small 
genome targets, such as for HIV drug resistance testing, the most efficient use of NGS coverage 
requires an amplicon sequencing approach which employs fusion primer PCR, but which is 
associated with a strong selection bias and template resampling (Berry et al. 2011). Nevertheless, 
the selection bias and processivity issues can be partially addressed by parallel PCRs for each 
patient, since limiting dilution PCR and single genome amplification are not feasible for routine 
diagnostics.     
1.5.2 Additional precautions prior to sequencing 
1.5.2.1 DNA degradation by ultraviolet light 
Exposing DNA to ultraviolet (UV) light can cause degradation and point mutations that appear as 
minor variants after sequencing (Hori et al. 2007). To avoid this problem, when separating 
sequence amplicons in agarose, it is advisable to use a nucleic acid stain that allows DNA to be 
visualised without UV exposure. Typical examples of applicable gel stains are GR Green 
(Labgene, Châtel-Saint-Denis, Switzerland) and GelStar (Lonza, Basel, Switzerland), which permit 
DNA to be visualised over blue light with an orange filter.  
1.5.2.2 No-template control validation 
When using “high-resolution” sequencing with the ability to sample minor variants, low copy 
number reaction contamination may appear as minor variant populations if they are enriched 
through the fusion primer PCR (i.e.: they contain sequencing adaptors and MIDs). Screening for 
low-level contamination requires that a sensitive nested PCR be conducted on all no-template 
controls (NTCs) even when no bands are visible in the NTC after the fusion primer PCR. This 
nested reaction enables the sensitive detection of contamination that warrants remedial 
decontamination and repeating fusion primer PCRs. 
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1.5.2.3 Sequencing-by-synthesis (SBS) template validation  
When PCR products undergo manipulation such as gel extraction it is prudent to confirm that DNA 
remained intact and amplifiable, by performing a screening nested PCR prior to sequencing on a 
next generation platform.  
1.5.2.4 Sampling error and bias 
Amplicon generation using fusion primers may introduce primer-induced selection bias and 
increase PCR template resampling. Once the template-specific 3’ end of the fusion primer binds to 
its genomic target, DNA polymerisation begins, and the fusion primer is incorporated into the 
complementary DNA strand. In the subsequent PCR rounds, this template becomes the perfect 
match for the same species of fusion primer, and this template will be resampled. This occurrence 
is referred to as PCR resampling (Liu et al. 1996). After enrichment mismatched variants will be 
under-represented as a result of biased priming of perfectly matched variants. 
Random sampling error may misrepresent the original sample population when only a few variants 
are sampled from a patient with a low viral load or when PCR randomly primes a particular 
template. When primers randomly prime particular templates earlier than others, and due to the 
exponential nature of PCR, these early-selected variants will be over-represented in relation 
subsequently selected ones. This type of selection bias is also called “primer resampling error” (Liu 
et al. 1996). Various PCR enrichment methods are available to circumvent the PCR resampling 
error however limiting dilution PCR (LD-PCR) is currently the only means of eliminating it. 
1.5.2.4.1 Limiting dilution (LD)-PCR 
Currently, LD-PCR is the only approach that obviates the PCR resampling error and is used for 
single genome sequencing (Ramachandran et al. 2008; Salgado et al. 2010). LD-PCR requires 
quantifying starting cDNA and diluting the sample to one cDNA copy per pre-nested PCR. At this 
resolution, the PCR resampling error is eliminated since there is no competition between templates 
for primer hybridisation. However, LD-PCR is laborious, not feasible for diagnostic implementation 
and expensive to perform when considering the number of PCRs required.  
1.5.2.4.2 Indexing cDNA with a unique ID tag  
The primer ID strategy (described in chapter 4, section 4.1.6) involves synthesising cDNA with a 
gene-specific primer that contains a 5’ PCR tag and an ID of random bases (eight or ten bases 
depending on the assay version) (Jabara et al. 2011; Boltz et al. 2015). Each cDNA strand thus 
contains a unique ID sequence that is later incorporated into the sequenced amplicon. Post-NGS, 
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the ID tag is used to determine the origin of each sequence read. Because the IDs are unique, 
reads with the same ID are aligned, and the consensus corrects for spurious PCR error and PCR 
resampling (Jabara et al. 2011; Boltz et al. 2015). While this enrichment strategy provides a 
reference point for accurate minor variant identification, it has been linked to biased sampling and 
insensitivity (Zhou et al. 2015; Keys et al. 2015; Brodin et al. 2015).  
1.5.2.4.3 Emulsion PCR (em-PCR)  
Emulsification of an aqueous PCR in oil essentially mimics the LD-PCR on a micro- to atto-litre 
scale (fully described in thesis chapter 4, section 4.1.8). Provided that template concentrations are 
at least three-fold less than the number of emulsion droplets produced, each reaction droplet 
should rarely contain more than one template. Thus, primer binding completion is eliminated along 
with the PCR founder effect. 
To employ em-PCR for upstream NGS sample preparation, high fidelity PCR is a minimum 
requirement. A commercial high fidelity em-PCR kit is available from Roche Diagnostics (Basel, 
Switzerland) however this kit is part of their NGS amplicon library preparation protocol and is 
designed to enrich bead-bound amplicons in an em-PCR. Another high fidelity commercial em-
PCR platform is available from RainDance Technologies (Massachusetts, USA), although this 
technology is not yet available in South Africa. In thesis chapter 4, we attempt an in-house high 
fidelity em-PCR to correct fusion primer sampling error.   
1.5.3 Bioinformatics 
Parallel to sequence platform development has been the improvement of software, capable of 
processing NGS data, since these platforms produce large sequence datasets (Li & Homer 2010). 
These software packages make use of read alignment algorithms to align sequence reads to a 
consensus sequence in a process called “mapping”. Post-sequencing data processing basically 
requires the exclusion of poor quality bases, read mapping to a consensus sequence, and minority 
population identification.  
Base-call quality relies on the platform-specific confidence in a nucleotide being accurately 
identified. For NGS platforms like the MiSeq (Solexa/Illumina, California, USA) and the 454 FLX 
(454 Life Sciences, Connecticut, USA) that visually detect base incorporation, the quality score is 
partially based on the amplitude and wavelength of emitted fluorescence or observed 
luminescence. On the PGM however, these factors are substituted for pH change measured as 
voltage amplitudes since the PGM does not detect visual signals. Base-call signals are converted 
into PHRED Q-scores using platform-specific base-calling algorithms. The PHRED scoring system 
is a logarithmic accuracy measurement scale wherein a Q-score of 10 equals a 90% accurate 
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base-call probability, a Q-score of 20 equals a 99% accurate probability and a Q-score of 30 
equals a 99.9% accurate probability (Ewing & Green 1998; Ewing et al. 1998).   
NGS bioinformatics software makes use of these Q-scores to trim poor quality-called bases usually 
at the 3’ ends of read and in homopolymer regions. Once these bases are excluded, reads are 
mapped to a consensus sequence. Segminator (Archer et al. 2010) can be used to align sequence 
reads to an HIV consensus sequence using “K-mer mapping” (Altschul et al. 1997). K-mer 
mapping breaks both the reference sequence and the read sequence into shorter “words”, while 
recording the location of the reference words. Then, the mapper aligns the reference and read 
words and records the reference location where the first read word maps. Finally, the mapper 
excludes the reference words located before the location where the first read word mapped and 
continues to align the rest of the read words to the reduced number of reference words (Archer et 
al. 2010). In essence, this mapping algorithm excludes unused parts of the reference sequence 
and makes mapping more efficient.   
Datamonkey (Pond & Frost 2005) and RAMICS (Wright & Travers 2014) make use of codon aware 
mapping algorithms; Briefly, the reference sequence and the reads are translated into amino acid 
sequences. Next, the read amino acid sequence is mapped to the reference amino acid sequence 
and any indels would appear as an amino acid frame shift. Finally, identified frame shifts are 
interrogated on a nucleotide level, and indels are corrected before the read is realigned.  
1.6 Study rationale 
Considering that next generation sequencing (NGS) is a viable solution for pooled, low-cost, HIV 
drug resistance testing, we set out to test various up-stream sample preparation methods for 
amplicon sequencing on multiple NGS platforms. In an attempt to broaden the clinical application 
of NGS for studying HIV-1 minor variants in patients, we included understudied patient populations: 
adult patients who failed a second-line PI regimen, using 454 sequencing (454 Life Sciences, 
Connecticut, USA), and studied infants who were exposed to a PMTCT regimen consisting of NVP 
and AZT, using the novel Ion Torrent PGM (Life Technologies, California, USA) and Illumina MiSeq 
(California, USA) sequencing. After realising the limits of current library generation methods we 
further interrogated PCR resampling error by assaying plasmid mixtures and quantifying the 
relative representation in a sequenced library, followed by an attempt to reduce resampling error 
through partitioning reactions in minute droplets, during the first few PCR steps with an emulsified 
PCR mastermix. Accurate representation of minor variant populations in sequence-libraries is 
critical to improving the resolution of minor variant discrimination with NGS. The investigations in 
this dissertation, therefore, focus on the enrichment of patient samples to allow accurate minor 
variant drug resistance detection. 
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In light of the rationale above, our study hypothesis were twofold: 
 Hypothesis A: NGS can be used to detect minor variant drug resistant mutations in 
understudied population such as 2nd line cART failed patients and in infants who failed 
PMTCT. 
 Hypothesis B: Using water-in-oil emulsification to partition templates during fusion primer 
PCR can reduce PCR resampling error. 
Hence, our specific objectives were as follows: 
 To characterise minor variant resistance in patients failing a second-line LPV/r-based 
regimen. 
 To characterise minor variant resistance in children exposed to the Western Cape 
prevention of mother-to-child HIV transmission (PMTCT) regimen. 
 To compare deep sequencing results from the PGM (Life Technologies, California, USA) 
and MiSeq (Illumina, California, USA) platforms to “gold standard” clonal sequencing. 
 To measure primer-induced selection bias and PCR resampling attributed to the use of 
fusion primers. 
 To test the ability of emulsification of the first few PCR cycles in reducing primer-induced 
selection bias.  
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1.8 Appendix A: Supplementary figures 
 
Figure 1.8.1 Life Technologies 454 sequencing strategy: Amplicons are bound to a bead via adaptor ligation. After 
these beads undergo clonal enrichment through emulsion PCR, they are placed onto a flow-cell where the amplicon is 
primed for pyrosequencing to begin. In box 1, cytosines (C) are washed over the well but cannot be incorporation into 
the complementary DNA strand being synthesised, since they are not commentary to the template strand. These 
nucleotides are then washed away with the subsequent wash step and no luminescence is observed. In box 2, 
adenosines (A) are washed over the well and one is incorporated into the complementary DNA strand, resulting in the 
release of a pyrophosphate as a DNA polymerisation by-product. ATP sulfurylase combines this free pyrophosphate with 
an ADP molecule to produce ATP. The ATP molecule activates luciferase which in turn catalyses luciferin, producing a 
chemiluminescent signal. The luminescence is captured by a CCD camera and the amplitude is converted into the 
number of adenosines incorporated. In box 3, two guanines (G) are incorporated into the complementary DNA strand, 
causing the release of two pyrophosphate molecules. Once again, ATP sulfurylase combines these two pyrophosphates 
with two SDP molecules to produce two ATPs. These ATPs then excite two luciferases and two luciferins are broken 
down to emit luminescence twice as strong as when one luciferin is catalysed. The CCD camera records this 
luminescence and translates the amplitude into the incorporation of two guanosines.  
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Figure 1.8.2 Solexa/Illumina sequencing strategy: Amplicons are bound to a solid surface via adaptor ligation. After 
these amplicons undergo clonal enrichment by bridge PCR, the amplicon is primed for CRT sequencing. In box 1, an 
adenosine (A) with a 3’ fluorophore is incorporated into the complementary DNA strand being synthesised. Since the 
polymerase cannot cleave off the fluorophore, sequencing is temporarily terminated. An excitatory laser excites the 
fluorophore and a high-resolution camera captures the fluorescence. Since each nucleotide has a specific fluorophore, 
the observed fluorescence wavelength determines the identity of the incorporated nucleotide. In box 2, the fluorophore is 
chemically cleaved and washed away, and complementary strand synthesis termination is reversed. In box 3, a guanine 
(G) is incorporated and once again the wavelength of its’ specific fluorophore is recorded by the high-resolution camera. 
Since the polymerase cannot cleave the fluorophore, synthesis is once again terminated until the fluorophore is 
chemically cleaved. By recording the sequence of detected fluorophores at a specific location on the slide, the sequence 
of the amplicon colony is determined. Using this strategy, Solexa/Illumina NGS platforms are able to accurately 
sequence homopolymer stretches, one base at a time. 
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Figure 1.8.3 Life Sciences Ion Torrent sequencing strategy: Amplicons are bound to a bead via adaptor ligation. 
After these beads undergo clonal enrichment through emulsion PCR, they are placed onto a CMOS sequencing chip 
where the amplicon is primed for semiconductor sequencing to begin. In box 1, cytosines (C) are washed over the 
sequencing chip but cannot be incorporation into the complementary DNA strand being synthesised, since they are not 
commentary to the template strand. These nucleotides are then washed away with the subsequent wash step and no 
changed is observed in the reaction pH. In box 2, guanosines (G) are washed over the sequencing chip and one is 
incorporated into the complementary DNA strand, resulting in the release of a hydrogen molecule (a proton) as a DNA 
polymerisation by-product. The release of this proton is detected by the semiconductor pH sensor embedded in the 
sequencing chip. This pH change is translated into the incorporation of a single nucleotide. In box 3, two adenines (A) 
are incorporated into the complementary DNA strand causing the release of two protons. This results in a two-fold 
change in the reaction pH which is recorded by the semiconductor pH sensor and translated into the incorporation of two 
nucleotides.  
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Figure 1.8.4 Agencourt/ABI sequencing strategy: Amplicons are bound to a bead via adaptor ligation. After these 
beads undergo clonal enrichment through emulsion PCR on a solid surface, they are primed for sequencing-by-ligation 
(SBL). In box 1, an eight-base probe with a 3’ fluorophore is ligated to the template DNA strand. The identity of the first 
two bases of the probe are known and correspond to one of four fluorophores. This probe interrogates bases one and 
two of the template sequence and once ligated, the fluorophore is identified using an excitatory laser and a high-
resolution camera. In box 2, the last three bases of the probe are chemically leaved, along with the 3’ fluorophore. The 
next probe is ligate to the template, interrogating bases six and seven, before the last three bases and the fluorophore 
are again cleaved. In box 3, the template has been fully complemented by the ligation of multiple probes. In box 4, the 
complementary DNA strand and the first primer are denatured and washed away before a new, “-1 primer" (with one less 
base on the 3’ end) is bound to the template DNA strand. Next, another probe is ligated to the template strand, this time 
binding at the minus one position and interrogating template bases minus one and one. This sequence of ligation and 
cleavage events are repeated until each base has been interrogated twice (each time with a separate probe). By 
recording the sequence of detected fluorophores at a specific location on the solid surface, the sequence of the amplicon 
is determined. This strategy enables SBL NGS platforms to accurately sequence homopolymer stretches, using two base 
interrogation. Box 5 shows the various fluorophore colours and the first and second bases which they represent. Using 
this strategy, each fluorophore represents four nucleotide pairs and 16 pairs in total. The identity of a specific base can 
only be determined once both fluorophores interrogating that base, are known. 
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2 Deep sequencing reveals minor protease resistance mutations in patients failing a 
protease inhibitor regimen.  
2.1 Background 
Antiretroviral therapy (ART) reduces human immunodeficiency virus (HIV) replication through the 
inhibition of various steps in the replication cycle (Clavel & Hance 2004). HIV-infected adults who 
qualify for treatment are initiated on first-line combination antiretroviral therapy (cART) (Palella et 
al. 1998; Gulick et al. 1997). The World Health Organisation (WHO) recommends a non-nucleoside 
reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors 
(NRTIs), one of which is lamivudine (3TC), for first-line therapy in resource limited settings (World 
Health Organisation 2010). These combinations have low genetic barriers since therapy failure 
requires few drug resistance mutations (DRMs) to confer a high level of drug resistance. 
Nevertheless patients may remain on these low barrier regimens for many years when maintaining 
good adherence as the risk of therapy failure decreases with good adherence (Rosenblum et al. 
2009).  
At the time of this study, virologic failure (VF) was defined as a persistent viral load (VL) >1000 
c/ml, after a period of adherence intensification. Patients with VF qualified for second-line cART 
consisting of two NRTIs and a protease inhibitor (PI), lopinavir (LPV) boosted with a low dose of 
ritonavir (LPV/r) (National Department of Health 2010). The addition of ritonavir increases the half-
life and trough levels resulting in a higher genetic barrier. Study participants were included from a 
larger study monitoring the relationship between low plasma and hair drug titres and second-line 
therapy failure (van Zyl et al. 2011). For the purpose of this study, patients with a VL>500 HIV-1 
RNA c/ml obtained by HIV-1 real-time viral load assay (Abbott Laboratories, Illinois, USA), received 
HIV drug resistance testing (DRT) with an in-house PCR and sequencing method. Participants had 
experienced VF on an NNRTI-based first-line cART with at least the 3TC drug resistance mutation 
(DRM) M184V/I, in addition to VF on the second-line PI-based cART.  
Six of the seven patients exhibited insufficient plasma-LPV concentrations (<0.87 µg/ml) and 
inadequate LPV and ritonavir drug-hair titres (<3.15 and 0.54 ng/mg-hair respectively), as assayed 
by liquid chromatography-mass spectrometry. These low concentrations were indicative of poor 
therapy adherence: LPV-plasma and hair concentrations less than 1µg/ml and 3.63ng/mg, 
respectively were shown to predict therapy failure (van Zyl et al. 2011).  
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2.2 Methods 
2.2.1 Inclusion criteria 
Study participants were part of a larger study investigating the relationship between second-line 
cART failure and plasma and hair-LPV/r concentrations (van Zyl et al. 2011). Inclusion in our study 
required previous first-line cART failure with at least the lamivudine DRM M184V/I and current 
second-line failure (defined for the purpose of this study as a VL >500 c/ml), as well as sufficient 
(1 ml) stored plasma from a historical EDTA blood sample. As part of routine clinical practice, study 
participants had their viral loads measured. For the study, in-house HIV drug resistance testing 
(DRT) by PCR and Sanger sequencing were performed at both first and second-line cART failure, 
while next generation sequencing (NGS) was only performed at second-line failure.  
2.2.2 In-house DRT 
In-house DRT (or bulk sequencing) consisted of a two-step reverse transcription-PCR (RT-PCR), a 
nested PCR and a sequencing reaction. These experiments are described below.  
2.2.2.1 RT-PCR 
Viral RNA was extracted using the QIAamp® UltraSence® (Qiagen, Nimburg, Netherlands) virus kit 
according to the manufacturer specified protocol and stored at -80 °C until needed. RT-PCR was a 
variation of a previously described method (Plantier et al. 2005) and was carried out using the pre-
nested primers listed in table 2.2.2.1.1 (below), the Access RT-PCR kit (Promega, Wisconsin, 
USA) and the reaction conditions that follow.  
Table 2.2.2.1.1 RT-PCR pre-nested primers 
Description Name Sequence (5’-3’) HXB2 binding  
Forward primer 5’PROT1 TAATTTTTTAGGGAAGATCTGGCCTTCC 2082 to 2109 
Reverse primer Mj4 CTGTTAGTGCTTTGGTTCCTCT  3399 to 3420 (RC) 
(RC) = Reverse complement. 
The RT-PCR was compiled using the reagents listed below at their indicated concentrations. All 
reactions were prepared on ice in a mastermix and aliquoted before the extracted RNA was added. 
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 Reagent       Final concentration (in 50 µl) 
1. 5 x AMV/Tfl Reaction Buffer    1 x 
2. dNTP Mix (10mM of each)    0.2 mM  
3. 10 µl extracted RNA     Unknown 
4. 25 mM MgSO4     1 mM 
5. 5’prot1 FWD Primer     1 μM 
6. Mj4 REV Primer     1 μM 
7. AMV Reverse Transcriptase (5 U/μl)   0.1 U/μl 
8. Tfl DNA Polymerase (5 U/μl)    0.1 U/μl 
9. 23 µl Nuclease free water     1 x 
Thermocycling was done using an ABI 9700 thermocycler (Applied Biosystems, 
Massachusetts, USA) with the heat lid activated at 105 °C and the following cycling conditions: 
45 °C for 45 min (reverse transcription) 
94 °C for 2 min 
94 °C for 30 sec 
40x  60 °C for 1 min 
68 °C for 2 min 
68 °C for 7 min 
4 °C soak  
On completion, reactions were purified using the QIAquick® PCR clean-up kit (Qiagen, Nimburg, 
Netherlands) following the manufacturer’s spin column protocol, before the PN-PCR products were 
eluted in 50µl of elution buffer. This pre-nested product was used for both the bulk sequencing 
nested PCR (described below) and the 454 fusion primer nested PCR (described in section 2.2.3). 
2.2.2.2 Nested PCR 
Nested PCR was performed using the GoTaq® Flexi kit (Promega, Wisconsin, USA) according to 
the manufacturer’s specifications, using the primers listed in table 2.2.2.2.1 below. 
Table 2.2.2.2.1 Nested PCR primers 
Description Name Sequence (5’-3’) HXB2 binding  
Forward Primer 5’prot2 TCAGAGCAGACCAGAGCCAACAGCCCCA 2136 to 2163 
Reverse Primer NE135 CCTACTAACTTCTGTATGTCATTGACAGTCCAGCT 3300 to 3334 (RC) 
(RC) = Reverse complement. 
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The reaction mastermix was prepared on ice and aliquoted in a DNA-free area before pre-nested 
template was added in a post-amplification, nested PCR hood. The mastermix contained the 
following: 
 Reagent       Final concentration (in 50 µl) 
1. 5 x Reaction Buffer     1 x 
2. dNTP Mix (10mM of each)    0.2 mM  
3. 25 mM MgCl2      2 mM 
4. 5’prot2 FWD Primer     500 nM 
5. Mj4 REV Primer     500 nM 
6. 2 µl PN-PCR template    Unknown 
7. GoTaq® Flexi DNA Polymerase (5 U/μl) (Pormega) 1.25 U/rxn 
8. 30.75 µl Nuclease free water    1 x 
Nested PCR thermocycling conditions are seen below: 
 94 °C for 2 min 
94 °C for 30 sec 
40x  55 °C for 30 sec 
72 °C for 1 min 
72 °C for 7 min 
4 °C soak  
Once completed, nested amplicons were purified using the QIAquick® PCR clean-up kit (Qiagen, 
Nimburg, Netherlands) and the products were separated on a 1% agarose gel prepared in TBE 
buffer (data not shown).  
2.2.2.3 Sanger sequencing  
Sequencing reactions used an in-house optimised method using the BigDye® Terminator Direct 
Cycle (V3.1) sequencing kit (Applied Biosystems, Massachusetts, USA), and each of the primers 
listed in table 2.2.2.3.1.  
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Table 2.2.2.3.1 Sequencing reaction primers 
Description Name Sequence (5’-3’) HXB2 binding  Tm 
Forward Primer POL1D TCCCTCAAATCACTCTTTGGC 2251 to 2271 56.3 °C 
Forward Primer AK11 GTACCAGTAAAATTAAARCCAG 2571 to 2592 48.4 °C 
Forward Primer POL3D CAGTACTGGATGTGGG 2869 to 2884 48.7 °C 
Forward Primer ABB20-3F ATCAGTACAATGTGCTTCCA 2980 to 2999 51.6 °C 
Reverse Primer AK12 TGGTGTYTCATTRTTTRYACTAG 2947 to 2969 (RC) 50.6 °C 
Reverse Primer POL3REV CTGAAAAATATGCATCCCCC 2882 to 2901 (RC) 51.1 °C 
Reverse Primer JA217 CTTTTATTTTTTCTTCTGTCAATGG 2622 to 2646 (RC) 49.5 °C 
Reverse Primer R2051 TATRTTGACAGGTGTAGGT 2486 to 2504 (RC) 49.5 °C 
(RC) = Reverse complement. 
Sequencing reaction mastermix was comprised of the following reagents, aliquoted in a 96 well 
plate: 
 Reagent      Final concentration (in 10 µl) 
1. 5 x Terminator sequencing reaction buffer  1.5 x 
2. BigDye® Terminator reaction mix   1 x 
3. Fwd or Rev Sequencing Primer    5 pMoles 
4. Nested PCR Product     15 to 20 ng 
 
Sequencing reactions were performed using the following in-house-optimised reaction conditions in 
an ABI 9700 thermocycler (Applied Biosystems, Massachusetts, USA): 
95 °C for 10 sec  
25 x  45 or 50 °C for 5 sec*  
60 °C for 4 min 
On completion, the sequencing reaction was purified using an in-house-optimised BigDye® X-
terminator (Applied Biosystems, Massachusetts, USA) clean up protocol (below). The SAM 
Solution™ (Applied Biosystems, Massachusetts, USA) used in the purification reaction was heated 
to room temperature before use. 
 Reagent      Volume added to Mastermix  
1. SAM™ solution (Applied Biosystems)  49 µl 
2. X-terminator solution (Applied Biosystems)  11 µl 
* Primers were annealed at 
the sequence-primer-specific 
annealing temperature.  
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Fifty-five microlitres of the above reaction mixture was added to each sequencing PCR in the 96 
well plate before the wells were sealed and the reaction was vortexed for 30 to 45 min. The purified 
sequencing reaction was then centrifuged at 1000 xg for 5 min to pellet the X-terminator particles 
and the sequencing reaction was read on an ABI Genetic Analyser 3130xL (Applied Biosystems, 
Massachusetts, USA).  
2.2.2.4 Post-sequencing analysis 
Sequences were analysed using Sequencher V4.7 software (Gene Codes Corporation, Ann Arbor, 
USA) to exclude poor quality bases and to construct sequence contigs. Contiguous sequences 
were submitted to the Stanford University online HIV drug resistance database 
(http://hivdb.stanford.edu) for HIV drug resistance interpretation.  
2.2.3 NGS sample preparation 
An overview of the NGS enrichment strategy can be seen in Appendix B, along with the list of 
DRMs sampled by each of the overlapping sequence amplicons. 
2.2.3.1 Nested fusion primer PCR 
Since enriched pol fragments were available from the RT-PCR (section 2.2.2.1 above), the nested 
PCR was prepared using previously published 454 primers, amplifying the entire protease gene 
and the first 245 codons of reverse transcriptase in three overlapping fragments (Varghese et al. 
2010). These primers were modified with the addition of six bases to the four-base molecular 
identifier (MID) and the 3’ end of two primer species were extended to improve 3’ conservation. 
The detailed primer schematics are attached in Appendix B, however, the condensed format of the 
454 fusion primers are seen in table 2.2.3.1.1 below: 
Table 2.2.3.1.1 Condensed fusion primers 
Description Name Mandatory additions – MID
# 
– Gene-specific Sequence HXB2 binding 
Forward Primer PR-F Adaptor-A-TCAG‐MID-CCTCARATCACTCTTTGGC 2253 to 2271 
Reverse Primer PR-R Adaptor-B-TCAG‐MID-YTTGGGCCATCCATTCCTGG 2589 to 2608 (RC) 
Forward Primer RTA-F Adaptor-A-TCAG‐MID-TGCACAYTAAATTTTCCAATTAGa* 2535 to 2557 
Reverse Primer RTA-R Adaptor-B-TCAG‐MID-ACTAGGTATGGTGAATGCAG 2932 to 2951 (RC) 
Forward Primer RTB-F Adaptor-A-TCAG‐MID-CTRGATGTGGGRGATGCAta* 2874 to 2891 
Reverse Primer RTB-R Adaptor-B-TCAG‐MID- TGTWTWGGCTGTACTGTCC 3265 to 3284 (RC) 
(RC) = Reverse complement. 
#
 Ten-base MIDs varied for each patient. * Bases added for 3’ conservation are in lower case. 
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Expand High Fidelity PCR (Roche Diagnostics, Basel, Switzerland) system was used in 
conjunction with each of the fusion primer pairs listed in table 2.2.3.1.1 above (i.e.: PR, RTA and 
RTB), to produce the 454 FLX (454 Life Sciences, Connecticut, USA) sequence amplicons. The 
reagents and reaction conditions are described below: 
 Reagent       Final concentration (in 50 µl) 
1. 10 x Reaction buffer     1 x 
2. dNTP Mix (10 mM of each)    0.2 mM 
3. MgCl2 (25 mM)     3 mM 
4. PR/RTA/RTB Forward Primer   800 nM 
5. PR/RTA/RTB Reverse Primer   800 nM 
6. Expand HiFi Polymerase (Roche)   2.625 U/rxn 
7. 2.5 µl Pre-nested product    Unknown 
8. 37.25 µl Nuclease free water    1 x 
Since each primer pair had a unique optimal annealing temperature, each reaction was amplified 
separately in an ABI 9700 thermocycler (Applied Biosystems, Massachusetts, USA) using the 
thermocycling conditions seen below.  
 94 °C for 2 sec 
94 °C for 30 sec   
40 x  *45-50 °C for 30 sec   
72 °C for 1 min    
72 °C for 7 min 
4 °C soak  
2.2.3.2 Amplicon size selection and purification 
On completion, nested amplicons were separated in a 0.8% agarose gel prepared in sodium 
borate buffer. To prevent DNA degradation by ultraviolet light (UV), a non-UV-dependant DNA 
stain, GelStar (Lonza, Maryland, USA), was used to visualise amplicons over blue light with an 
orange exclusion filter on a Dark Reader (Clare Chemicals, Colorado, USA). Once separated, 
amplicons were size selected by excising specific bands from the electrophoresis gel using a 
different scalpel blade for each fragment. These gel slices were weighed and gel purified using the 
Wizards Gel and PCR purification kit (Promega, Wisconsin, USA) according to the manufacture’s 
specification. Amplicons were eluted in 30µl of warm nuclease free water and quantified in 
triplicate with a NanoDrop ND1000 (Thermo Scientific, Massachusetts, USA), according to the 
*The PR fragment was annealed at 
48 °C, the RTA fragment at 45 °C 
and the RTB fragment at 50 °C 
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manufacturer directions. These size-selected amplicons were sent to Inqaba Biotech in Pretoria of 
South Africa, for NGS on the 454 FLX Titanium platform (454 Life Sciences, Connecticut, USA). 
2.2.4 FLX Titanium sequencing  
For NGS library preparation, the 454 Life Sciences FLX Titanium Lib-A emPCR protocol was 
followed according to the manufacturers’ specifications for bidirectional amplicons sequencing 
(Roche Diagnostics, Basel, Switzerland).  
2.2.5 Data analysis 
After sequencing, data was available in standard flowgram format (.sff) which contains both the 
amplicons nucleotide sequence and the quality score assigned to each base-call. Using CLC 
Genomics Workbench V5.1 (CLC Bio, Aarhus, Denmark), these sequence strings (referred to here 
as “reads”) were de-multiplexed according to patient-specific MIDs. Reads were quality filtered with 
a 95% base-call quality confidence: In short, a 5-base sliding window interrogated bases starting at 
the 3’ end of the sequence. If the average quality score within the window was less than 95%, the 
last base was truncated and the window was incremented by one base towards the 5’ end. If the 
average score was more that 95%, the window was once again incremented but no bases were 
removed. 
A South African HIV-1 subtype C consensus sequence was generated from 317 whole genomes, 
sequenced between 1997 and 2010 and downloaded from HIV online database (attainable at 
http://www.hiv.lanl.gov/components/sequence/HIV/search/search.html). These sequences were 
aligned using the Geneious align tool in Geneious V6.0 (Biomatters, Auckland, New Zealand) to 
produce the consensus sequence that was used as a reference for read alignment. 
The “cleaned” reads were mapped to the generated subtype C reference sequence using 
Segminator V1.3.3, an online read mapping tool (available at 
http://www.phylogenetictrees.com/segminator.php#2) designed specifically for HIV NGS data 
analysis (Archer et al. 2010). Segminator results were available in comma separated format (.csv) 
and were imported into Excel 2007 (Microsoft, Washington, USA). In Excel (Microsoft, Washington, 
USA), the range of possible amino acids were pared against protease and reverse transcriptase 
codons and minority, drug-resistant variants were seen as subpopulations of the total coverage at 
a DRM loci. For each patient, the list of observed minority DRMs greater than 0.5% prevalence 
was submitted to the Stanford University drug resistance database (version 6.0.11) for 
susceptibility analysis (available online at:  http://sierra2.stanford.edu/sierra/servlet/JSierra).   
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2.3  Results 
2.3.1 Cohort 
The study cohort demographics are seen in table 2.3.1.1 below as well as the first and second line therapy formulations. At therapy 
failure events, the patient viral loads (as determined by the Abbot Laboratories (Illinois, USA) HIV-1 real-time viral load assay) and the 
CD4 cell counts were available in viral c/ml and CD4 cells/µl respectively, as seen below.  
Table 2.3.1.1 Demographic and therapy information of patients  
 
Demographic information First line therapy Second line therapy (AZT, DDI, LPV/r) 
Study 
no 
Age 
(current) 
Gender 
Ethnic 
group 
ART 
Therapy 
duration 
(months) 
Failure 
period 
(months) 
VL CD4 
Therapy 
duration 
(months) 
Failure 
period 
(months) 
VL CD4 
LPV-
plasma 
LPV-
hair 
1 24 F 
mixed 
race 
d4T, 3TC, 
NVP 
33 2 4000 276 10 7 2100000 358 LDL 0.54 
2 35 F 
mixed 
race 
d4T, 3TC, 
NVP(EFV)* 
37 20 2500 137 28 18 1300000 132 LDL 0.87 
3 46 F 
mixed 
race 
d4T, 3TC, 
NVP 
7 2 18000 278 16 10 520 592 7.35 6.28 
4 31 F 
mixed 
race 
AZT, 3TC, 
NVP 
19 7 3300 367 21 15 94000 195 LDL LDL 
5 51 M 
mixed 
race 
d4T, 3TC, 
EFV 
12 1 120000 115 9 7 320000 160 LDL 0.43 
6 48 M 
mixed 
race 
d4T, 3TC, 
NVP 
7 1 5400 131 21 14 91000 168 0.81 0.73 
7 30 M 
mixed 
race 
d4T, 3TC, 
NVP 
6 1 15000 102 12 7 300000 199 0.33 
Not 
done 
* Single drug switch from NVP to EFV in August 2007. Second line therapies: AZT: Zidovudine, DDI: Didanosine; LPV/r: Lopinavir with low dose ritonavir. CD4: most recent CD4 count 
in cells/µl while on the current regimen. VL: Viral load. Lopinavir plasma concentration: µg/ml. Lopinavir hair concentration: ng/mg hair. Failure period: Time VL>500 copies/ml. LDL: 
Lower than the detection limit.  
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2.3.2 In-house DRT summary 
As expected, bulk sequencing detected multiple NNRTI DRMs when patients failed first-line cART. 
However, Sanger genotyping detected no PI-related DRMs after second-line failure, since patients 
showed poor adherence to the PI-based therapy, resulting in inadequate resistance selection 
pressure. Nevertheless, bulk sequencing detected remnants of the NNRTI DRMs, K103N (patient 5) 
and V179D (patient 7) at second-line failure. While the K103N detection was substantiated by its NGS 
prevalence (~55%), V179D was quantified at 6.12% of the sequenced sample. In addition, mutations 
at amino acid 103 (in reverse transcriptase) in patient 1 totalled 53% of the sampled population 
(44.66% K103R, 5.13% K103N and 3.21% K103E), however, they were undetected by bulk 
sequencing. These inconsistencies allude to possible primer-induced selection bias and PCR re-
sampling error. The comparative NGS results are displayed in table 2.3.3.1 on the next page. 
2.3.3 NGS summary 
For NGS, 155 074 sequence reads obtained from the FLX Titanium (454 Life Technologies, 
Connecticut, USA) and the highest locus coverage was seen at the amplicon overlap between the 
protease (PR) and the first reverse transcriptase region (RTA), as indicated in figure 2.3.3.1 below. 
There was an average per-fragment coverage of approximately 9 400 reads or roughly 4 700 in both 
forward and reverse directions. The increased sensitivity characteristic of redundant sampling was 
able to detect variants present at less than 0.1% however, an arbitrary prevalence threshold of <0.5% 
was use to report drug-resistant minor variants.  
 
 
 
 
 
 
 
Figure 2.3.3.1 Coverage across HIV pol: The figure above shows the NGS coverage depth for all patients across the first 
352 amino acids of HIV pol. The highest coverage is seen where amplicons overlap. There was no coverage across RT-A for 
patient 3 since the amplicon failed to amplify. 
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Table 2.3.3.1 Comparative in-house DRT and NGS DRT results   
 
NNRTI failure episode - NRTI mutations are in standard typescript and NNRTI mutations in italics.  
NGS mutations - PI resistance mutations are in bold and other amino acid variants at PI resistance loci in standard type-script 
Patient 
 
 
NNRTI failure episode PI failure episode 
Bulk sequencing 
(mutations) 
Time on 
LPV/r 
Viral load Bulk sequencing 
(mutations) 
NGS mutations (frequency) 
Reverse 
transcriptase 
Protease (Days) (copies/ml) 
RT (NNRTI-
only) 
Protease 
NRTI-mutations 
(percentage) 
NNRTI mutations 
(percentage) 
PI mutations 
(percentage) 
1 
A62V, M184I, 
V108I, Y181C, 
H221Y 
None 280 2100000 None None 
K65R(1.11); 
D67N(0.93); 
D67E(0.86); 
K219R(0.71) 
V90I(0.77); A98E(0.91); 
K101E(5.88); 
K103R(44.66); 
K103N(5.13); K103E(3.21); 
V179I(0.51); Y181C(0.58); 
F227L(0.82); F227S(0.57); 
K238R(0.50) 
I54T(0.50) 
2 M184V, V106M None 841 1300000 None None 
K65R(3.81); 
D67N(8.39); 
F77L(0.73); 
M184V(8.02); 
L210S(0.69); 
T215I(0.77) 
V90I(0.78); K101R(0.69); 
K103R(2.23); Y181C(1.93); 
F227S(0.51) 
L23P(0.51) 
3 
M184V, V90I, 
K103N, Y181C 
None 476 520 None None 
V118A(0.54); 
K219E(0.54) 
V179I(5.78) I54M(0.67) 
4 
M184V, V108I, 
Y181C, H221Y 
None 616 94000 None None 
K65R(2.73); 
D67N(1.51); 
F116S(0.53); 
M184V(2.55) 
K101E(0.61); K101R(0.61); 
P225T(1.50); F227L(0.55); 
K238T(3.31); K238R(0.74) 
M46V(0.67); 
F53L(0.56); 
F53S(0.51) 
5 M184V None 266 320000 K103N None 
K65R(1.59); 
K65E(0.53); 
D67N(2.60); 
M184V(3.14) 
K101E(1.34); K101R(0.63); 
K103N(55.15); 
V179D(0.98); P225T(0.97); 
F227L(0.63); F227S(0.56); 
K238T(2.91) 
F53L(0.73); 
N88S(0.68); 
N88D(0.58) 
6 M184V, K103N None 617 91000 None None 
K65R(1.09); 
K65E(0.55); 
K219E(0.50) 
K103E(0.81); G190E(0.69) V82A(0.62) 
7 
M41L, K65R, 
V75I, M184V, 
K103R, V179D 
None 366 300000 V179D None 
K65R(2.19); 
T215A(0.69); 
K219R(0.70); 
K219E(0.51) 
V90I(1.04); V179D(6.12) None 
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NGS confirmed the bulk sequencing results and detected minor PI-resistant population undetected by 
the bulk sequencing (by PCR and Sanger sequencing), in five of the seven patients. Moreover, NGS 
was able to detect the remnants of lamivudine resistance (M184V/I) in patient 4, nevirapine/efavirenz 
resistance (K103N/E/R) in patients 1, 2, 5 and 6, and nevirapine/efavirenz/etravirine resistance in 
patients 1 and 2 (Y181C). The complete list of mutations detected by both bulk sequencing and NGS 
are summarized in table 2.3.3.1 above.  
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2.4 Discussion 
2.4.1 Summary findings  
The present study used amplicon sequencing on the 454’s next generation sequencing (NGS) 
platform to detect drug-resistant minority HIV populations in patients who failed the first-line non-
nucleoside reverse transcriptase inhibitor (NNRTI)-based combination antiretroviral therapy (cART) 
with M184V/I and second-line protease inhibitor (PI)-based cART. Second-line failure NGS drug 
resistance testing (DRT) results were compared to bulk sequencing results (available at both failure 
events), where viral load (VL) and CD4 cell count data were also available. Six of the seven patients 
included in this study had very low plasma- and hair-lopinavir concentrations (<0.81 µg/ml and 
0/87 ng/ml respectively) and VLs >90 000 c/ml blood. Patient 3 had mid-to-high lopinavir adherence 
that was confirmed by high pressure liquid chromatography performed on this patient’s plasma and 
hair samples extracts. Despite patient 3’s a low VL of 520 c/ml and the absence of major PI 
resistance, remnants of first-line therapy NRTI and second-line NNRTI therapy resistance were 
identified by NGS.    
Bulk sequencing detected no major PI DRMs at second-line failure while NGS detected only minority 
population with major PI DRMs (<0.7% of the sequenced sample). After second-line failure, bulk 
sequencing identified K103N in patient 5, from a population that NGS quantified at ~55%. However, 
bulk sequencing failed to identify K103R in patient 1, a variant that was quantified at 44.66% of the 
sequenced sample. Surprisingly, bulk sequencing also detected V179D in patient 7, a variant that 
contributed only 6.12% of that patient sample and was below the conventional Sanger sequencing 
detection threshold of ~20% (Palmer et al. 2005). 
2.4.2 Resistance evolution 
Resistance evolution begins with primary mutations which appear soon after the onset of cART 
(Bangsberg et al. 2006). Considering protease inhibitors, primary DRMs confer drug resistance at a 
fitness cost. In patients with intermittent adherence, wild-type virus may outgrow these less fit variants 
with the result that minor drug-resistant variants would not be detectable by HIV drug resistance 
testing through PCR and Sanger ‘bulk’ sequencing. If viral replication continues on the current 
regimen, compensatory mutations could arise through successive mutations or through recombination 
events, which would result in viral strains with drug resistance and improved fitness (Maguire et al. 
2002; Rosenbloom et al. 2012).  
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The emergence of multi-drug-resistant viral strains requires ongoing viral replication in the presence of 
therapy and involves a number of mechanisms: a high mutation rate (due to reverse transcriptase 
lacking proofreading), enrichment of resistant variants through selection pressure (exerted by 
therapy), and viral recombination events of variants harboring different mutations. For example: Under 
first-line cART selection pressure (Tenofovir, Lamivudine and Efavirenz), viral strains with an 
evolutionary survival advantage (e.g.: a single DRM) are selectively enriched. These variants have 
characteristic single base-pair mutations such as K65R, M184V, V106M or K103N, which can arise 
sequentially or through recombination with other single mutation variants. At the time of first-line 
failure, two or more of these mutations are often detected by bulk sequencing as major variant drug 
resistance mutations. 
2.4.3 Low frequency minor variants 
The low frequency variants identified in this study are probably single mutation variants that lack the 
compensatory or secondary mutations needed to improve replication competency. They do not 
predominate as they experience inadequate drug pressure to favor a specific variant. Under 
intermittent selection pressure, they lack the survival benefit with their compromised fitness, resulting 
in an insufficient resistant population size to allow recombination and multi-drug-resistant variants to 
emerge. In addition, more resent research by Swenson et al, suggests that the genotypic detection of 
drug resistance mutations at low frequencies are predictive of therapy failure (Swenson et al. 2014).  
2.4.4 Therapy failure and adherence 
For low genetic barrier first-line regimens, resistance develops quickly under intermittent therapy 
adherence which results in insufficient blood-drug concentrations to effectively suppress viral 
replication (Luber 2005). Upon failure, patients are switched to the second-line therapy with a higher 
genetic barrier. At the time when we conducted this study, second-line cART consisted of two NRTIs 
(one of which was didanosine or DDI), and the boosted PI, LPV/r. Both of these ARVs have 
gastrointestinal side effects and consequentially, the second-line therapy is poorly tolerated to the 
extent that individuals who fail on this regimen did so as a result of poor adherence rather than viral 
resistance. For the patient group sampled in this study, adherence was determined by measuring 
plasma and hair drug concentrations and was seen to be less than adequate (van Zyl et al. 2011). 
These findings were in concordance with a previous study that correlated low PI-hair concentrations 
with therapy failure (Gandhi et al. 2009). Poor adherence and the detection of minor variant drug 
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resistance are both predictive of therapy failure, with the hazard ratio for failure in patients with minor 
variant drug resistance, versus without, the highest in adherent patients (Li et al. 2012).   
2.4.5 Sanger DRT 
The routine diagnostic DRT uses low fidelity PCR which limits the accuracy of DRM detection in 
homopolymer regions. Bulk sequencing is however capable of sampling and identifying majority drug-
resistant variant populations greater than 20% of the sequenced sample. In 30 to 40% of second-line 
failures, DRMs are not detected by Sanger DRT since failure, in these cases, is due to poor therapy 
adherence (El-Khatib et al. 2010; van Zyl et al. 2011). Consequently, the inadequate selection 
pressure maintains these variants below the assay sensitivity threshold. 
2.4.6 454 NGS and DRT 
As the first commercially available massive parallel sequencing platform, 454 Life Sciences platforms 
(now distributed by Roche Diagnostics, Basel, Switzerland) are well established in amplicon 
sequencing for HIV DRT (Simen et al. 2014). In 2005, the 454 Genome Sequencer 20 had an 
introductory read length of up to 100bp which improved to ~450bp through bidirectional sequencing on 
the FLX Titanium system (454 Life Sciences, Connecticut, USA) at the time of our study. While 
running costs for the 454 pyrosequencing platforms are high in comparison to other commercially 
available NGS platforms (Loman et al. 2012), the use of sample molecular identifiers (MIDs) 
incorporated into the fusion primers, facilitated sample pooling and reductions in per sample costs. 
However, the advantage of the FLX platform was the relatively long read length (compared to other 
NGS platforms at this time), allowing for mutation linkage study. As seen in the present study, the 
median read length was only 278 bp after quality filtering, although DRM linkage detection was 
improved through long read-length and an overlapping amplicon approach. 
Hindering the utility of the 454 NGS platforms however, is the inability to accurately sequence 
homopolymer regions, a fault owing to the sequencing chemistry and detection methods. On 454 
sequencers, bases are sequentially washed over the picotitre plate and the luminescence amplitude 
resulting from base incorporations is proportional to the number of incorporated bases (Morey et al. 
2013). This luminescence recorded by a charge coupled device or CCD camera and the intensity is 
translated into the number of bases incorporated (the specific base that was washed over the flow-cell 
when the image was captured). For example: The luminescence signal amplitude for two incorporated 
bases is double that of one incorporated base. However, when more than five bases are incorporated 
at once, the change in luminescence is incremental and difficult for the CCD camera to distinguish, 
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insomuch that homopolymer lengths are sometimes over- or under-called, presenting as a base 
insertion or deletion (collectively referred to as “indels”) (Marinier et al. 2015).   
Misalignment due to spurious indels may appear in 454 sequences and could result in the false 
detection of DRMs which are not present, since 17 known DRMs fall within or just after homopolymer 
regions in HIV-1 subtype B (Dudley et al. 2012). Considering K65R in subtype C viruses, this DRM 
occurs at the end of a homopolymer stretch, where misalignment due to spurious “indels” could result 
in the spurious detection of K65R (Varghese et al. 2010). The high rate of emergence of K65R in HIV-
1 subtype C has been ascribed to a high frequency of enzyme dissociation at this site resulting in a 
higher rate of mutation; this has been shown to be dependent on the particular RNA template 
sequence in HIV subtype C (Wainberg et al. 2011; Coutsinos et al. 2009). When detected with NGS, 
K65R could either be the result of a true high occurrence in HIV-1 subtype C or due to homopolymer 
sequencing error. Regardless of this DRMs origin, the use of high fidelity polymerase systems is 
advised for upstream NGS sample preparation since it improves accuracy in homopolymer 
amplification (McInerney et al. 2014). In our study, we used a high fidelity PCR system for our nested 
PCR however, our two-step reverse transcription/pre-nested PCR (RT-PCR) was performed with a low 
fidelity enzyme system.  
2.4.7 Compensatory mutations in gag 
Due to the high genetic barrier of second-line protease inhibitor regimens, drug resistance resulting in 
regimen failure often require multiple drug resistance mutations and compensatory mutations to yield 
a virus that is sufficiently resistant and fit to replicate. The evolution of drug resistance to high genetic 
barrier regimens is an intricate process (Flynn et al. 2015). In addition to the resistance mutations in 
protease, second-line failure may be associated with compensatory mutations in the gag gene. Other 
researchers have documented the co-evolution of protease and gag (Fun et al. 2012), suggesting that 
during viral replication, a less fit drug-resistant protease requires compensatory mutation in its 
substrates found in gag, which the viral protease cleaves from the gag-pol poly-protein (van 
Maarseveen & Boucher 2006). 
Since most protease inhibitors have similar functions and target the substrate binding region of the 
viral protease, primary resistance mutations occurring in this region enable protease functionality at a 
great fitness cost (Nijhuis et al. 2007). The secondary or compensatory mutations arise in the gag-pol 
poly-protein cleave sites restoring viral fitness (Flynn et al. 2015). These compensatory mutations are 
seen around the matrix (MA) -capsid (CA), CA-p2, p2-nucleocapsid (NC), NC-p1 and p1-p6 cleavage 
sites depicted in figure 2.4.7.1 below. 
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Figure 2.4.7.1 Compensatory mutations in gag: The figure above depicts the gag-pol poly-protein with the amino acid 
number where the viral protease cleaves the protein subunit, seen in black. In the table below the diagram are the loci 
between which PI therapy failure compensatory mutations are known to occur. (Figure adapted from Fun 2012 and Flynn 
2015) 
Under intermittent selection pressure (as seen in this cohort), single mutation drug-resistant variants 
may wax and wane as conditions for their selection are created during periods of improved adherence, 
followed by replacement by wild-type during periods of poor adherence (Rosenbloom et al. 2012). This 
would prevent drug resistance evolution and is supported by models which suggest that the highest 
risk for protease inhibitor resistance is at levels of moderate to high levels of adherence (Gardner et al. 
2009). At a low frequency, single drug-resistant variants may be more likely to recombine with wild-
type virus than with other strains carrying DRMs and compensatory mutations and would remain 
below the expected 20% sensitivity threshold of bulk sequencing (Palmer et al. 2005). Since the 
development of minor variant drug resistance in patients failing a second-line, LPV/r-based regimen is 
poorly characterized we set out to investigate this with NGS. Our findings indicate a lack of HIV drug 
resistance evolution in a poorly adherent cohort receiving this high genetic barrier, second-line 
regimen. 
2.4.8 Study limitations 
This study had the following limitations.  
 Specimens were only available to perform deep sequencing at the time of second-regimen 
failure. Additional samples for NGS before therapy initiation and at first-line therapy failure 
would have enabled a more informative investigation of drug resistance development.  
 The use of high fidelity PCR is advised for up-stream sample preparation for NGS (McInerney 
et al. 2014) as spurious PCR-induced errors would be detected with the high resolution of NGS 
(Brandariz-Fontes et al. 2015). In this study, low fidelity PCR was used for the pre-nested PCR 
which limited the accurate identification of minor variants.   
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 cDNA was not quantified prior to sequencing: While viral load (VL) data was available for study 
patients at the time of second-line failure and NGS, determining the number of cDNA species 
sampled is essential in estimating the limit of minor variant sampling. Low viral loads increase 
the minor variant threshold. Patient 3 had a low viral load of 520 copies/ml and was therefore 
more subject to PCR resampling error. 
 Specific primers may result in biased amplification: While the RT-PCR priming strategy used 
here does improve reverse transcription sensitivity, the use of specific primers may result in a 
sampling bias, which could influence the downstream representation of variants in the 
sequenced population. 
 The read-length was relatively short: The mean sequencing read-length seen in this study was 
278 bases. There was great reduction in coverage distal to the primers, characterised by a 
steep drop in base-call confidence for longer reads. With longer read-lengths, coverage would 
have been better at the overlapping regions and the distal ends of the first and last amplicon. 
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2.5 Conclusion  
This study compared in-house DRT by PCR and Sanger sequencing to NGS for detection of drug 
resistance in patients failing a second-line LPV/r-based regimen. PCR and Sanger sequencing (bulk 
sequencing) detected no major PI DRMs at second-line failure while NGS detected only minority 
population (<0.7% of the sequenced sample). Bulk sequencing identified K103N in patient 5, from a 
population that NGS quantified at ~55%. However, bulk sequencing failed to identify K103R in 
patient 1, a variant that was quantified at 44.66% of the sequenced sample. Surprisingly, bulk 
sequencing also detected V179D in patient 7, a variant that contributed only 6.12% of that patient 
sample and below the conventional Sanger sequencing detection threshold of ~20% (Palmer et al. 
2005). 
Further investigations of protease inhibitor resistance in patients who fail second-line regimens are 
required. Primary mutations in protease might confer resistance but require secondary compensatory 
mutations to regain fitness (Fun et al. 2012). The study of co-evolution of gag and envelope may share 
more light on protease inhibitor resistance development (Rabi et al. 2013; Flynn et al. 2015). 
Novel methods may also improve the overall accuracy of NGS. The introduction of the primer ID 
approach to targeted NGS resequencing has enabled the indexing of individual cDNA species 
sampled prior to PCR enrichment. Two variations of the primer ID method have been published 
(Jabara et al. 2011; Boltz et al. 2015); this method collapses all reads with the same random identifier 
into one and thereby allows for bioinformatic correction of resampling or PCR replication error.  
In this investigation NGS improved the DRM detection in five of the seven patients included in our 
study, although no major variants with protease inhibitor resistance were identified. This suggests that, 
in the absence of sustained selection pressure, the evolution of variants with multiple PI resistance 
mutations is halted at an early stage, whereas the potency of the regimen suppresses viral replication 
in patients with good adherence. This lack of evolution may help to explain the surprisingly low 
prevalence of protease inhibitor resistance, in previously PI-naïve patients, failing LPV/r-based 
regimens.   
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2.7 Appendix B: Supplementary data 
Figure 2.7.1 Schematic overview of NGS amplicon generation: This figure was generated in Geneious V6.0 (Biomatters) by mapping the pre-nested primers and the 
gene-specific regions of the fusion primers to the HXB2 reference sequence (seen at the top of the figure). It displays the overlapping amplicon generation strategy on the 
region of the viral genome enriched by the pre-nested PCR (green-boarded window). The pre-nested primers (dark blue) flank the nested fusion primers (green) and the 
three overlapping amplicons (light blue). The amplicon on the left amplifies the entire protease region (PR), and amplicons RT-A and RT-B amplify the first ~350 amino 
acids of reverse transcriptase, with RT-A overlapping with the 3’end of the PR amplicon and the 5’end of the RT-B amplicon.  
 
 
Table 2.7.1 DRMs distribution: The table below sequentially lists the DRMs sampled and the amplicon on which they appear. 
Amplicons Drug resistance mutations 
PR K20R L23P M36I/L M46V F53L/S I54T/M D60E I62V L63P/S A71T T74S V82A I84V N88S/D L89M I93L 
RT-A K65R/E* D67N* F77L* V90I
#
 A98E
#
 K101E/R
#
 K103R/N/E
#
 F116S* V118A* 
       
RT-B V179I/D
#
 Y181C
#
 M184V* G190E
#
 L210S* T215I/A* K219R/E* P225T
#
 F227L/S
#
 K238R/T
#
 
      
* NRTI resistance mutations 
# 
NNRTI resistance mutations 
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Table 2.7.2 Forward fusion primers: Tabulated below are the schematics of the forward fusion primers. At the 5’ end is the bolded adaptor-A sequence, followed by the 
underlined key sequence, the italicised molecular identifier (MID) and finally, the gene-specific region at the 3’ end. The “Adaptor-A” sequence mediates the binding of 
sequence amplicons to beads via a bead-bound adaptor compliment, after which the amplicon is enriched through bead-based emulsion PCR, as part of NGS library 
preparation. The “KEY” sequence is the first four bases read by the pyrosequencer to determine the baseline luminescence intensity for each picotitre sequence well in 
the 454 sequencing flow-cell.   
NAME 5’‐ Adaptor-A sequence - KEY sequence ‐ MID ‐ Template-specific-sequence ‐3’ HXB2 binding Codon 
PR-F-MID-1 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐ACGAGTGCGT-CCTCARATCACTCTTTGGC 2253→2271 PR1-PR7 
PR-F-MID-2 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐ACGCTCGACA-CCTCARATCACTCTTTGGC 2253→2271 PR1-PR7 
PR-F-MID-3 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐AGACGCACTC-CCTCARATCACTCTTTGGC 2253→2271 PR1-PR7 
PR-F-MID-4 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐AGCACTGTAG-CCTCARATCACTCTTTGGC 2253→2271 PR1-PR7 
PR-F-MID-5 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐ATCAGACACG-CCTCARATCACTCTTTGGC 2253→2271 PR1-PR7 
PR-F-MID-6 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐ATATCGCGAG-CCTCARATCACTCTTTGGC 2253→2271 PR1-PR7 
PR-F-MID-7 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐CGTGTCTCTA-CCTCARATCACTCTTTGGC 2253→2271 PR1-PR7 
   
 
RT-A-F-MID-1 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐ACGAGTGCGT-TGCACAYTAAATTTTCCAATTAGa 2535→2557 PR95-RT3 
RT-A-F-MID-2 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐ACGCTCGACA-TGCACAYTAAATTTTCCAATTAGa 2535→2557 PR95-RT3 
RT-A-F-MID-3 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐AGACGCACTC-TGCACAYTAAATTTTCCAATTAGa 2535→2557 PR95-RT3 
RT-A-F-MID-4 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐AGCACTGTAG-TGCACAYTAAATTTTCCAATTAGa 2535→2557 PR95-RT3 
RT-A-F-MID-5 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐ATCAGACACG-TGCACAYTAAATTTTCCAATTAGa 2535→2557 PR95-RT3 
RT-A-F-MID-6 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐ATATCGCGAG-TGCACAYTAAATTTTCCAATTAGa 2535→2557 PR95-RT3 
RT-A-F-MID-7 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐CGTGTCTCTA-TGCACAYTAAATTTTCCAATTAGa 2535→2557 PR95-RT3 
   
 
RT-B-F_MID-1 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐ACGAGTGCGT-CTRGATGTGGGRGATGCAta 2874→2891 RT109-114 
RT-B-F_MID-2 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐ACGCTCGACA-CTRGATGTGGGRGATGCAta 2874→2891 RT109-114 
RT-B-F_MID-3 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐AGACGCACTC-CTRGATGTGGGRGATGCAta 2874→2891 RT109-114 
RT-B-F_MID-4 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐AGCACTGTAG-CTRGATGTGGGRGATGCAta 2874→2891 RT109-114 
RT-B-F_MID-5 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐ATCAGACACG-CTRGATGTGGGRGATGCAta 2874→2891 RT109-114 
RT-B-F_MID-6 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐ATATCGCGAG-CTRGATGTGGGRGATGCAta 2874→2891 RT109-114 
RT-B-F_MID-7 5’‐CGTATCGCCTCCCTCGCGCCATCAG‐CGTGTCTCTA-CTRGATGTGGGRGATGCAta 2874→2891 RT109-114 
Bases added to improve 3’ conservation with South African subtype C are in lower case. PR = protease. RT= reverse transcriptase   
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Table 2.7.3 Reverse fusion primers: Below are the schematics of the reverse fusion primers. At the 5’ end is the bolded adaptor-B sequence, followed by the underlined 
key sequence, the italicised molecular identifier (MID) and finally, the reveres-complemented gene-specific region at the 3’ end. The “Adaptor-B” sequence mediates the 
binding of sequence amplicons to beads for bead-based emulsion PCR. The “KEY” sequence is the first four bases read by the pyrosequencer to determine the baseline 
luminescence intensity for each picotitre sequence well. 
NAME 5’‐ Adaptor-B sequence - KEY sequence ‐ MID ‐ Template-specific-sequence ‐3’  HXB2 binding Codons 
PR-R-MID-1 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐ACGAGTGCGT-YTTGGGCCATCCATTCCTGG 2608→2589 (RC) RT14-RT20 
PR-R-MID-2 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐ACGCTCGACA-YTTGGGCCATCCATTCCTGG 2608→2589 (RC) RT14-RT20 
PR-R-MID-3 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐AGACGCACTC-YTTGGGCCATCCATTCCTGG 2608→2589 (RC) RT14-RT20 
PR-R-MID-4 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐AGCACTGTAG-YTTGGGCCATCCATTCCTGG 2608→2589 (RC) RT14-RT20 
PR-R-MID-5 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐ATCAGACACG-YTTGGGCCATCCATTCCTGG 2608→2589 (RC) RT14-RT20 
PR-R-MID-6 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐ATATCGCGAG-YTTGGGCCATCCATTCCTGG 2608→2589 (RC) RT14-RT20 
PR-R-MID-7 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐CGTGTCTCTA-YTTGGGCCATCCATTCCTGG 2608→2589 (RC) RT14-RT20 
   
 
RT-A-R-MID-1 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐ACGAGTGCGT-ACTAGGTATGGTGAATGCAG 2951→2932 (RC) RT128-RT134 
RT-A-R-MID-2 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐ACGCTCGACA-ACTAGGTATGGTGAATGCAG 2951→2932 (RC) RT128-RT134 
RT-A-R-MID-3 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐AGACGCACTC-ACTAGGTATGGTGAATGCAG 2951→2932 (RC) RT128-RT134 
RT-A-R-MID-4 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐AGCACTGTAG-ACTAGGTATGGTGAATGCAG 2951→2932 (RC) RT128-RT134 
RT-A-R-MID-5 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐ATCAGACACG-ACTAGGTATGGTGAATGCAG 2951→2932 (RC) RT128-RT134 
RT-A-R-MID-6 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐ATATCGCGAG-ACTAGGTATGGTGAATGCAG 2951→2932 (RC) RT128-RT134 
RT-A-R-MID-7 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐CGTGTCTCTA-ACTAGGTATGGTGAATGCAG 2951→2932 (RC) RT128-RT134 
   
 
RT-B-R-MID-1 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐ACGAGTGCGT-TGTWTWGGCTGTACTGTCC 3284→3265 (RC) RT239-RT245 
RT-B-R-MID-2 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐ACGCTCGACA-TGTWTWGGCTGTACTGTCC 3284→3265 (RC) RT239-RT245 
RT-B-R-MID-3 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐AGACGCACTC-TGTWTWGGCTGTACTGTCC 3284→3265 (RC) RT239-RT245 
RT-B-R-MID-4 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐AGCACTGTAG-TGTWTWGGCTGTACTGTCC 3284→3265 (RC) RT239-RT245 
RT-B-R-MID-5 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐ATCAGACACG-TGTWTWGGCTGTACTGTCC 3284→3265 (RC) RT239-RT245 
RT-B-R-MID-6 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐ATATCGCGAG-TGTWTWGGCTGTACTGTCC 3284→3265 (RC) RT239-RT245 
RT-B-R-MID-7 5’‐CTATGCGCCTTGCCAGCCCGCTCAG‐CGTGTCTCTA-TGTWTWGGCTGTACTGTCC 3284→3265 (RC) RT239-RT245 
PR = protease. RT= reverse transcriptase (RC) = Reverse complement  
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2.8 Published article  
 
 
 
 
 
 
 
 
 
 
 
 
 
The full article is available online at http://jvi.asm.org/content/86/11/6231.full.pdf+html 
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3 Next generation sequencing improves detection of drug resistance mutations in infants 
after PMTCT failure  
3.1 Background  
3.1.1 Prevention of mother-to-child transmission in South Africa  
From 2004 to 2010, the human immunodeficiency virus (HIV) prevention of mother-to-child 
transmission (PMTCT) therapy in the Western Cape Province of South Africa consisted of a dual 
regimen of Zidovudine (AZT) and Nevirapine (NVP) (Draper & Abdullah 2008). When this study 
cohort was recruited (October 2006 to October 2009), pregnant women received AZT from their 
second trimester and single dose NVP (sdNVP) intrapartum. Neonates received sdNVP and AZT 
for one week and were formula fed to prevent postpartum HIV transmission. The HIV transmission 
rate was <10% during this period (Draper & Abdullah 2008). In 2010, the national guidelines 
replaced infant sdNVP with daily NVP for the first six weeks after birth causing the PMTCT-failure 
rate further declining to <3% (Barron et al. 2013).  
Children, infected despite prophylactic antiretrovirals (ARVs) are at high risk of acquiring 
transmitted ARV drug resistance mutations (DRMs) (Ton & Frenkel 2013). Studies using allele-
specific PCR (AS-PCR) demonstrated that even minority population variants containing non-
nucleoside reverse transcriptase inhibitor (NNRTI) DRMs have been shown to affect NNRTI-
containing regimen outcomes (Jourdain et al. 2010; Paredes et al. 2010; Li et al. 2012; Li et al. 
2013). In South Africa, however, PMTCT-failed children under the age of three years receive a 
first-line ritonavir-boosted protease inhibitor regimen: Lopinavir (LPV) boosted with low dose 
ritonavir (LPV/r) (Palumbo et al. 2010; Violari et al. 2012). The prevalence of minor variant DRMs 
to NVP nevertheless remains important in resource-limited settings with little or no LPV/r access 
for infant cART or where NNRTIs are required in second-line regimens.  
3.1.2 World Health Organisation Option B-Plus  
In 2013, the Western Cape adopted the World Health Organisation (WHO) Option B-Plus (B+) for 
PMTCT (Western Cape Provincial Govt. 2012). B+ prescribes combination antiretroviral therapy 
(cART) for all HIV-positive pregnant women, continued after pregnancy, despite their CD4 cell 
count or WHO diseased state, (World Health Organisation 2012). The implementation of option B+ 
meant a reduction in pre-therapy initiation testing (omitting CD4 count testing), translating into a 
cost saving of about eight USD per patient initiated on therapy (Phillips et al. 2014). These savings 
exclude the additional financial benefits of HIV-negative neonates and immunocompetent pregnant 
women, not susceptible to opportunistic infections.  
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Option B+ has been shown to decrease mother-to-child transmission in Malawi (Sinunu et al. 
2014), however, antiretroviral interventions have been linked to an increase in circulating drug 
resistance mutation accumulation (Sungkanuparph et al. 2012; Hattori et al. 2010). A recent 
manuscript  highlighted the necessity of drug resistance testing (DRT) (van Zyl et al. 2014), 
whether by allele-specific quantitative PCR (AS-qPCR) (Rowley et al. 2010; Palmer et al. 2012), 
oligonucleotide ligation assay (OLA) (Jourdain et al. 2010) or pol-targeted genotyping (Claassen et 
al. 2011), whenever possible to ensure therapy success and to limit transmitted drug resistance 
(TDR) (Estill et al. 2013; Braithwaite et al. 2011).  
3.1.3 HIV drug resistance testing  
When HIV is transmitted despite maternal cART, there is a high risk that infants could be infected 
with viruses harbouring HIV DRMs. Transmitted DRMs are especially of concern in settings without 
access to LPV/r infant formulas (which require refrigeration) and where NVP-based regimens are 
therefore used for infant therapy. These concerns emphasize the importance of access to HIV DRT 
for surveillance of PMTCT failures and for clinical management (van Zyl et al. 2014). However, the 
current DRT assays are sensitive to primer mismatches (Rowley et al. 2010) and have other 
limitations:  
 AS-qPCR and OLA are limited to specific individual point mutations and thus cannot 
detect or determine linkage.  
 Sanger genotyping is quite expensive (300 USD according to Chaturdhuj (Chaturbhuj et al. 
2014)), and is insensitive to variants contributing less than 20% of the sequenced sample 
(Palmer et al. 2005).   
3.1.4 Next generation sequencing  
By means of sample barcoding and pooling, next generation sequencing (NGS) potentially offers 
an affordable solution allowing for mutation linkage surveillance and in addition, is capable of 
identifying drug-resistant minor viral populations. Commercial NGS platforms available in South 
Africa include Life Technologies’ (California, USA) Ion Torrent Personal Genome Machine™ 
(PGM) and Applied Biosystems’ SOLiD™ sequencer (Massachusetts, USA), Roche Diagnostics’ 
454 GS Junior and FLX Titanium (454 Life Sciences, Connecticut, USA), and Illumina’s MiSeq and 
HiSeq (California, USA) (http://omicsmaps.com/). While each sequencing platform has its own 
strengths and weaknesses concerning sequence read length, accuracy, depth and scalability, the 
PGM (Life Technologies, California, USA) boasts the lowest per base cost (Loman et al. 2012).  
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Common to both the 454 (454 Life Sciences, Connecticut, USA) and PGM (Life Technologies, 
California, USA) platforms is the way in which bases are sequentially washed over the picotitre 
plate (in the case of 454 Life Sciences) or sequencing chip (in the case of Life Technologies PGM). 
On 454 platforms, a high-resolution charge coupled device or CCD camera captures the light 
emitted as bases are incorporated into the complementary DNA strand, and the 
chemiluminescence intensity amplitude is translated into the number of incorporated bases (Morey 
et al. 2013). For example, when two bases are incorporated, luminescence is twice as bright as 
when one base is incorporated. However, when five or more bases are incorporated, the 
luminescence increase is incremental and difficult to discriminate. The PGM (Life Technologies, 
California, USA) monitors base incorporation by measuring pH change in wells, embedded in a 
sequencing chip, and struggles to differentiate the pH change between five or more base 
incorporations (Morey et al. 2013). Consequently, both 454 (454 Life Sciences, Connecticut, USA) 
or PGM (Life Technologies, California, USA) sequencing is prone to homopolymer sequencing 
error, characterised by spurious insertions or deletions at homopolymer regions (Marinier et al. 
2015). 
3.1.4.1 NGS Homopolymer error and HIV 
Despite this disadvantage, Life Sciences’ 454 platforms (Connecticut, USA) have been established 
for HIV DRT as the first platform used for targeted resequencing with fusion primers. Moreover, it 
initially provided the longest read-length which allowed the study of mutation linkage. Compared to 
another commercial NGS platform from Illumina (California, USA), the MiSeq, the PGM (Life 
Technologies, California, USA) has 400bp read lengths while the MiSeq, 300bp (using bi-
directional sequencing in 2013). The MiSeq (Illumina, California, USA) however, is less prone to 
homopolymer sequencing error unlike the Life Technologies’ PGM (California, USA) whose 
homopolymer errors may be corrected using post-sequencing bioinformatics software, such as 
Datamonkey (Kosakovsky Pond et al. 2009) and RAMICS (Wright & Travers 2014). These open-
source online data analysis packages are able to map sequence reads to a reference sequence in 
a codon-aware manner: Once the sequence reads have been quality filtered, they are converted to 
an amino acid sequence and mapped to an amino acid reference sequence. Homopolymer regions 
with erroneous indels display a frame shift in the amino acid sequence. When these frame shifts 
are identified, a nucleotide interrogation-error correction protocol is initiated. Miscalled indels are 
corrected and the read, realigned.  
The combination of post-sequencing homopolymer error corrections and the low per-base 
sequencing cost of PGM (Life Technologies, California, USA) sequencing make it ideal for minor 
HIV variant sequencing of TDR before therapy initiation (baseline) and at therapy failure. To date, 
few studies have sequenced HIV using the Ion Torrent platform (Life Technologies, California, 
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USA) (Kijak et al. 2014; Chang et al. 2013; Archer et al. 2012) but neither has validated their 
findings through clonal sequencing. 
3.1.5 Sampling error 
This study used a high fidelity PCR system to minimise PCR substitution and DNA gel stains that 
do not require ultraviolet light to protect DNA from damage. Moreover, the most crucial factor we 
tried to counteract was sampling error introduced during PCR enrichment. Sampling error is either 
primer-induced bias or random error, both of which obscure the variant prevalence, as depicted in 
figure 3.1.5.1 below. These errors have the greatest impact on variant representation when they 
occur early on in the NGS target enrichment process (e.g.: during reverse transcription (RT) or pre-
nested PCR), and reduce the number of variants represented in downstream sequencing events. 
We addressed these errors separately below:  
To avoid primer mediated selection bias during RT, cDNA synthesis was optimised using random 
pentadecamers instead of the conventional specific primer-RT-PCR combination. Although 
pentadecamers have a random nucleotide composition, they have similar thermodynamic 
properties as other 15 base-long specific oligonucleotides (i.e.: GC-rich 15-mer primers have a 
higher melting temperature (Tm) than AT-rich 15-mer primers). These properties were exploited to 
prime cDNA synthesis in a GC-rich “island” downstream from the pre-nested amplicon by using a 
high RT priming Tm. To prevent primer mediated bias during pre-nested PCR (PN-PCR), primers 
complementary to the more conserved areas of HIV-1 subtype C reverse transcriptase were used.  
Random error is especially problematic with low frequency events and is predicted by the Poisson 
distribution: variance equals the mean of the distribution (therefore the coefficient of variation is 
highest for low frequency events). Practically, in the first few rounds of PCR, a particular randomly 
selected or primed template would become the most abundant at the endpoint. In any event, if a 
primer shows bias or randomly primes a particular template, once the primer is incorporated into 
the synthesised strand, the template has been mutated to perfectly complement the same primer 
species. This phenomenon is better known as PCR resampling (Liu et al. 1996). Particular 
template species are over-enriched with reference to other templates, so that the enriched 
population no longer represents the distribution of variants in the original template population. PCR 
resampling can be overcome through limiting dilution PCR (LD-PCR) (Ramachandran et al. 2008) 
or it can be corrected by random ID tagging of the original cDNA population with post-sequencing 
bioinformatics (Jabara et al. 2011).  
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Figure 3.1.5.1 Low selection bias results in greater diversity: The figure above demonstrates the effect of sampling 
bias on sampled variant diversity. In reverse transcription, random RT primers reduce the selection bias and produce 
more diverse cDNA species, in contrast to a specific RT primer. Similarly, degenerate PN-PCR primers, or primers 
bringing in conserved genomic regions, improve the diversity available for further interrogation. Using highly-specific 
primers reduce diversity but are essential for certain applications such as Sanger genotyping. 
While LD-PCR overcomes primer binding competition, it requires cDNA template dilution to one 
copy per PN-PCR and proves to be laborious and expensive when considering the total number of 
reactions needed. The cDNA ID approach compensates for PCR resampling by tagging each 
reverse transcribed species with a unique cDNA tag. This ID tag is incorporated into the sequence 
amplicon and, once sequencing is completed, bioinformatics is used to condense sequenced 
variants by their IDs. The sampled mutations are stacked and the consensus sequence is used for 
further analysis. While not completely compensatory, in this study a paralleled reaction approach 
was used by dividing two pentadecamer RT reactions into 14 PN-PCRs and subsequently pooling 
PN-PCR duplicates into seven nested PCRs.    
3.1.5.1 Fusion primer sampling error  
The selection bias introduced when using fusion primers was overcome with an alternative 
amplicon preparation method. Fusion primers are generally 50 to 60 bases long and consist of 
sequencing platform-specific adaptors, barcodes (or MIDs) and a gene-specific region. During 
PCR, the gene-specific region of the fusion primers binds to a template and the primer is 
incorporated into the synthesised DNA. Once complemented by the polymerase, this incorporated 
primer has generated the best match template for the same primer species in subsequent PCR 
cycles. This event effectively increases the required annealing temperature of the reaction, biases 
selection towards initially selected variants and reduces diversity. To compensate, we employ pre- 
and nested PCR to generate large sequence amplicons (approximately 1 kb) which are later 
randomly fragmented before sequence platform adaptors with sample indexing MIDs are ligated.  
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3.1.6 Study rationale  
A recent study screening PMTCT-exposed children (less than two years of age) prior to cART 
initiation using AS-PCR and 454 NGS, found a good correlation between K103N and Y181C (Hunt 
et al. 2014). While the advantages of AS-PCR are many it is limited with respect to the number of 
mutations that can be detected simultaneously. This also limits its utility for DRM linkage studies, in 
contrast to NGS and other sequence-based genotyping methods. Here, we optimised sample 
preparation reactions while implementing the concepts described above. We not only corroborated 
our NGS results on another NGS platform (the MiSeq (Illumina, California, USA)) and by clonal 
sequencing, but we also conducted the first PGM (Life Technologies, California, USA) genotyping 
study reporting on HIV drug resistance from infants who had been exposed to the Western Cape 
(South Africa) dual regimen of AZT and NVP. 
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3.2 Methods  
Deep sequencing of HIV has been well established on Life Sciences’  454 platforms (Connecticut, 
USA) (Simen et al. 2014) but data on the Life Technologies’ (California, USA) Ion Torrent Personal 
Genome Machine™ (PGM) and Illumina MiSeq platforms (California, USA) had been limited 
(Archer et al. 2012). These new platforms provide higher coverage and the potential to pool many 
samples in one run and have recently started to displace 454 (Life Sciences, Connecticut, USA) 
sequencing for other applications. Similar to 454 (Life Sciences, Connecticut, USA) sequencing, 
the PGM (Life Technologies, California, USA) has been reported to be prone to homopolymer 
sequencing error. We therefore performed this study to: 
 Detect minor variant resistance mutations in children exposed to the Western Cape 
prevention of mother-to-child HIV transmission (PMTCT) regimen and;  
 Compare deep sequencing results on the PGM (Life Technologies, California, USA) and 
MiSeq (Illumina, California, USA) platforms to clonal sequencing of PCR products, as 
reference. 
We followed the following step-wise approach:  
 Selected and collated suitable plasma samples from infants matching our inclusion criteria: 
PMTCT exposed and combination antiretroviral therapy-naïve. Historical plasma samples 
were stored at -20°C and had to be extracted before they could be processed in our study.  
 We investigated different methods for reverse transcription and set out to adapt a 
previously published HIV reverse transcription protocol (Salazar et al. 2007) for cDNA 
synthesis with random primers, to limit sampling bias during this first step; as specific 
primers are known to introduce sampling bias when sampling diverse populations.  
 We optimised pre- and nested PCRs and performed parallel PCR reactions in an effort to 
minimise sampling error.   
 To validate our next generation deep sequencing results on PGM (Life Technologies, 
California, USA) and MiSeq (Illumina, California, USA) platforms, we compared our results 
to clonal sequencing of the same PCR products.  
 We corrected for homopolymer sequencing error using a post-sequencing, codon-aware 
bioinformatic analysis workflow. 
The methods shown below demonstrate reaction optimisation and the rationale behind the 
optimisation steps taken to achieve the objectives listed above.  
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3.2.1 Reactions optimisations  
3.2.1.1 Reverse transcription optimisation 
The CHAVI–MBSC–2 protocol was specifically developed for the sequencing of the envelope gene 
of single HIV genomes (Salazar et al. 2007). This protocol uses a gene-specific primer to initiate 
cDNA synthesis (i.e.: OFM19) and thus selects for specific variants. As the use of specific primers 
during reverse transcription could result in biased cDNA synthesis (and skew the proportion of 
minor variants detected) we investigated the use of random primers. Reverse transcription kit 
manufacturers suggest the use of random hexamers to produce cDNA from the majority of RNA 
species present in the extracted sample. As a “promiscuous” primer species, hexamers 
compensates for the diversity and efficiently primes cDNA synthesis. In our initial reverse 
transcription optimisations, a high concentration of random hexamers appeared to yield more 
cDNA than specific cDNA primers, when the cDNA was quantified with an in-house qPCR (table 
3.2.1.1.1 below).  
Table 3.2.1.1.1 Quantification of cDNA: Below are the tabulated results of two in-house qPCRs, quantifying cDNA 
synthesised using either 2 µM of the CHAVI-prescribed HIV-1 RT-PCR primer (OFM19), or 697 pM random hexamers. In 
both experiments, template RNA was extracted from patient plasma that had been virologically quantified with a 
commercial viral load assay. While both primer species catalysed little of the input RNA to cDNA, random hexamers was 
more efficient than the proposed counterpart. 
Input RNA 
Copy No. 
RT-PCR 
Primer 
Ct Copy No. 
% cDNA 
Synthesized 
~480 
R. Hex 37.4 3.54E1 7.4 
OFM 19 37.8 1.84E1 3.8 
~650 
R. Hex 36.5 1.14E2 17.5 
OFM 19 38.2 3.84E1 5.9 
 
However, we observed that although a qPCR (targeting a short fragment) suggested a high cDNA 
yield, we could not amplify the cDNA using a larger fragment PCR. This dichotomy suggested that 
the cDNA largely consisted of short fragments, due to the initiation of primer extension at multiple 
sites along the RNA template during reverse transcription (figure 3.2.1.1.1 below). It is known that 
a high hexamer concentration is associated with the generation of short fragment cDNA due to 
frequent hybridisation to the RNA template with extension truncated at the next priming site due to 
the lack of 3’ to 5’ exonuclease activity of the reverse transcriptase.   
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Figure 3.2.1.1.1 Random Hexamer – qPCR dichotomy: The figure above depicts our assumption of the random 
hexamer – qPCR dichotomy. If many viral RNA species (red) are hybridised by hexamers (blue arrows) in numerous 
locations, many short cDNA fragments are catalysed (grey rectangles) by the 3’ to 5’ exonuclease-deficient reverse 
transcriptase. Quantifying the cDNA species with a short fragment qPCR (orange), would yield a higher copy number 
than the actual number of cDNA templates that contain the full PCR target.      
To produce more full length cDNA, reverse transcription kit manufacturers suggest titrating 
hexamers down to lower concentrations, ensuring less frequent reverse transcription priming. As 
part of the standard hexamer hybridisation protocol, they also advise linearizing RNA at 72 °C then 
allowing the hexamers to anneal at 25 °C, before adding the reverse transcriptase and reaction 
mixture. To this end we again synthesised cDNA using the modified CHAVI-MBSC-2 protocol and 
a variety of hexamer concentrations. We also decided to evaluate reaction efficacy using a 1.2 kb 
pre-nested PCR (PN-PCR), sensitive to 50 HIV DNA copies (figure 3.2.1.1.2 below), and gauge 
reverse transcription efficiency through endpoint band intensity, as seen in figure 3.2.1.1.3 below. 
The HIV-1 DNA control used for assay optimisation was the pZAC plasmid: an infectious clone 
containing a full HIV-1 subtype C genome isolated from a South African patient (Jacobs et al. 
2012).  
  
 
 
 
 
Figure 3.2.1.1.2 PN-PCR sensitivity: The figure depicts the results of reaction sensitivity testing for the 1.2 kbp PN-PCR 
amplicon, shown to be sensitive to 50 copies of the HIV-1 Subtype C plasmid, pZAC (lane 4 from the left). The 
experiment was validated by an NTC displaying no amplification. Also visible is the specific amplicon band, waning with 
the input copy number. 
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Figure 3.2.1.1.3 Unamplifiable cDNA: The figure above displays the gel electrophoresis result of the 1.2 kbp PN-PCR, 
amplifying the cDNA synthesised using various random hexamer concentrations, as listed above each lane. Bright, 
nonspecific bands are visible in all lanes below the 500 bp band (in relation to the 1 kbp DNA marker). However, no 
specific amplicons were produced, regardless of the hexamer concentration employed for cDNA synthesis. 
 
Failing to generate the pre-nested amplicon, we decided to examine the possible molecular 
interactions between our random primers and HIV RNA and soon realised that in case of random 
primers, the location and frequency of priming events would be determined not only by the 
concentration of primers with a good template sequence match, but also the stability of the primer 
template complex during the reverse transcription reaction.  
The melting temperature (Tm) is the temperature at which 50% of primers would be hybridized to 
the putative template as a template-primer complex. As temperatures increase above the Tm, 
these complexes are unstable and primer extension becomes increasingly unlikely. Random 
hexamers are single-stranded strings of six random nucleotides and, as an oligonucleotide, they 
exhibit a wide range of Tms. Using a neighbour-joining Tm calculator (available online at: 
https://www.exiqon.com/ls/Pages/ExiqonTMPredictionTool.aspx) revealed that hexamers 
consisting of alternating thymines (T) and adenosines (A) display a Tm of -27 °C, and hexamers 
consisting of guanine (G) and cytosine (C), a Tm of 35 °C.  
In view of the manufacturer prescribed annealing temperature of 25 °C, GC-rich random hexamers 
would predominate cDNA priming. While a lower annealing temperature would allow more AT-rich 
hexamers to prime cDNA synthesis, lower temperatures also result in more RNA secondary 
structure and in turn, truncated cDNA. When examining South African HIV-1 subtype C consensus, 
we found regions with short stretches where at least five bases were Gs or Cs, as displayed in 
figure 3.2.1.1.4 below. 
Stellenbosch University  https://scholar.sun.ac.za
 71 
 
Figure 3.2.1.1.4 GC-rich islands in HIV-1 Subtype C, ZA: For analysis a six base sliding window was used. The 
window steps forward one base at a time, and a positive event (counted as 1) was defined as any time when the 
preceding six bases contained at least five G’s or C’s. To visualise GC rich areas, the number of positive events were 
plotted per 20 base window for nucleotides 800 to 7800 (Subtype C). The pre-nested PCR target that we used for 
sample enrichment, seen in grey above, spans a region of the genome that contains many G/C rich islands; which 
suggest multiple hexamer priming cites within this template. 
Considering the binding energy of the matching random hexamers, our PCR target contained a 
region where a large proportion of hexamers would bind with sufficient stability to allow primer 
extension at the prescribed temperature of 25 °C used to prime the reaction. This region was also 
closely downstream from our qPCR target (2981 to 3133 on HXB2). The binding of hexamers 
inside of our target could have explained the dichotomy observed. We therefore investigated 
random pentadecamers and a higher annealing temperature (with an expected higher specificity) 
to prime reverse transcription as this would bias binding to another region with larger GC rich areas 
(roughly 6800 to 7100 on HXB2) upstream from (and not in) our PCR target (2136 to 3419 on 
HXB2). Figure 3.2.1.1.5 below displays our speculated variation in the produced cDNA when using 
random hexamer and random pentadecamers. 
 
 
 
 
 
 
Figure 3.2.1.1.5 Hexamer and pentadecamer cDNA species: The figure above displays the possible cDNA species 
produced when using random hexamers (annealed at 25 °C) or random pentadecamers (annealed at 48 °C). None of the 
random hexamer derived cDNA species contain the full pre-nested PCR amplicon in contrast to cDNA species catalysed 
using random pentadecamers.  
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Random pentadecamers are 15-base oligonucleotides with Tms ranging from 25 to 76 °C as 
calculated using the nearest neighbour Tm method. They display intermediary properties when 
compared to random hexamers and gene-specific primers as they have Tms closer to that of 
specific primers without the selection bias, similar to the hexamers. Using a higher Tm, we were 
able to randomly prime a GC-rich region of HIV RNA and produce longer cDNA species that 
contained our full PN-PCR amplicon. This reaction was optimised with respect to pentadecamers 
annealing temperature and concentration (figure 3.2.1.1.6 below) before it was used to process our 
cohort samples.    
 
 
 
 
 
 
Figure 3.2.1.1.6 Reverse transcription optimisation: The figure above on the left shows the successful amplification of 
the 1.2 kbp PN-PCR amplicon from cDNA generated using random pentadecamers at the µM concentration shown on 
top of each lane and a 45 °C annealing temperature. Pentadecamers used in the reaction shown above on the right were 
annealed at 48 °C and showed brighter bands than those seen in the pre-nested reaction annealed at 45 °C. From these 
results it was evident that a pentadecamers concentration of 7.5 µM with a 48 °C annealing temperature produced the 
most cDNA including our sequence amplicon. The PN-PCR positive control (+ctrl) reaction amplified 50 copies of the 
HIV-1 subtype C plasmid, pZAC. This reaction showed poor amplification since 50 copies was the assayed limit of 
detection.  
3.2.1.2 Pre-nested PCR optimisation 
The PN-PCR was optimised with respect to enzyme system used, MgCl2 concentration and 
annealing temperature. Initially, we matched Invitrogen’s Pfx50 (California, USA) high fidelity 
polymerase system against Roche Diagnostic’s Expand High FidelityPLUS (Basel, Switzerland) 
using the manufacturer’s standard protocols and 5 000 copies of a linearized HIV-1 subtype C 
plasmid, pZAC. Figure 3.2.1.2.1 below displays the successful Roche enzyme system and the 
failed Invitrogen reaction.   
 
Figure 3.2.1.2.1 Pre-nested high fidelity PCR system: The gel figure on the far left 
displays the successful production of the 1.2 kbp PN-PCR amplicon using the Roche 
Diagnostics enzyme system (Basel, Switzerland) and 5 000 copies of the HIV-1 pZAC 
plasmid. The gel figure on the right shows the failed pre-nested amplification using 
Invitrogen’s enzyme system (California, USA). While this system generates some high 
concentration PCR product (smear at the top of the well), the size is incorrect. For both 
systems the standard manufacturer prescribed conditions were used. 
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Next, the Expand High FidelityPLUS (Roche Diagnostics, Basel, Switzerland) PN-PCR was 
optimised with respect to MgCl2 final concentration, ranging from 0.5 mM to 6 mM, as depicted in 
figure 3.2.1.2.2 below. Empirically, 3.5 mM (lane eight from the left) produced the brightest band 
compared to other concentrations, and was used for further experimentation. The variation in band 
size between the positive control and the reactions could be attributed to a higher volume of the 
positive control loaded in the well. Since no nonspecific bands are seen, we assumed that the 
amplified product was the correct one. 
 
Figure 3.2.1.2.2 PN-PCR MgCl2 optimisation: In the figure above depicts the MgCl2 optimisation of the PN-PCR. While 
band intensity is not clearly visible in this gel picture, the brightest band was seen when using 3.5 mM final MgCl2 
concentration.  
Finally, the pre-nested reaction annealing temperature was optimised between 62 and 66 °C as 
the manufacturers (Roche Diagnostics, Basel, Switzerland) suggest higher cycling temperatures 
result in better enzyme processivity. Gel figure 3.2.1.2.3 below shows that an annealing 
temperature of 64 °C exhibited more efficient amplification than higher or lower annealing 
temperatures. 
 
Figure 3.2.1.2.3 PN-PCR annealing temperature optimisation: The above figure displays the effect of various 
annealing temperatures on the processivity of the PN-PCR, when amplifying a 1.2 kbp amplicon from 5 000 and 500 
copies of the HIV-1 Subtype C plasmid, pZAC. An annealing temperature of 64°C seems to generate a brighter band 
than the other two temperatures tested however, none of the Tms improved assay sensitivity.   
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Once optimised, the sensitivity of the PN-PCR was determined using a linearized subtype C 
plasmid, since linear DNA closely represents cDNA. The pZAC plasmid was linearized by digestion 
with Not I (New England Biolabs, Massachusetts, USA), a restriction enzyme known to cut the 
plasmid once, outside the pre-nested target. Once gel purified, the linearized plasmid was 
quantified and reconstituted in 1 log/µl stocks. Gel figure 3.2.1.2.4 below shows the results of the 
sensitivity testing using 5 µl of plasmid stocks, freshly diluted in nuclease free water. In figure 
3.2.1.2.5, the linearized plasmid was diluted in nuclease free water with 20 µg/µl glycogen DNA 
carrier (Roche Diagnostics, Basel, Switzerland). The addition of the carrier appears to increase the 
sensitivity of the assay however, this is not entirely true as glycogen merely blocks the binding of 
DNA to plastics and increases the number of template molecules available to the primers and 
polymerase. As glycogen is routinely used in our laboratory as a carrier, it was readily available. 
Figure 3.2.1.2.4 Optimised pre-nested sensitivity test: Gel figure 3.2.1.2.4 above displays the results of the sensitivity 
testing of our optimised PN-PCR. Sensitivity was estimated at 5 000 linearized plasmid copies per reaction. 
 
Figure 3.2.1.2.5 Improved pre-nested sensitivity: The addition of glycogen (a passive DNA carrier) to the DNA 
standards diluents improved the apparent sensitivity of the reaction however, the true sensitivity of the “un-assisted” PN-
PCR can be seen in figure 3.2.1.2.5 above. The addition of 20 µg/µl glycogen increases the apparent reaction sensitivity 
one hundredfold to 50 linearized plasmid copies per reaction. 
 
3.2.1.3 Nested PCR optimisation 
Nested reaction optimisation began by amplifying 20 000 and 2 000 plasmid copies at various 
annealing temperatures between 65 °C and 55 °C, with a final primer concentration of 500 nM. Gel 
figure 3.2.1.3.1 below depict the results of this optimisation reaction showing more efficient 
amplicon synthesis at 65 °C annealing temperature.  
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Figure 3.2.1.3.1 Nested PCR annealing temperature optimisation: This figure shows 20 000 and 2 000 plasmid 
copies amplified in our pre-nested PCR at various annealing temperatures, incremented by two degrees from 55 °C to 
65 °C. While the DNA marker is faintly visible, successful amplification is seen at approximately 1 kbp. Neither of the 
tested annealing temperatures improved assay sensitivity however, an annealing temperature of 65 °C seemed to 
increase assay efficiency. 
Next, MgCl2 was titrated between 3.5 and 2.9 mM final concentration to find the optimum. Once 
again, 20 000 and 2 000 plasmid copies were used to test any improvement in sensitivity. Gel 
figure 3.2.1.3.2 below displays the PCR results showing optimal amplification of the nested 
amplicon at a 3.5mM MgCl2 final concentration. In addition, very faint bands are visible in lanes 
three and four (from the left) corresponding to the 200 copies input reaction and demonstrating 
improved assay sensitivity. These bands are also seen in the 2.9 mM MgCl2 reaction, however, we 
selected the higher MgCl2 concentration for sample processing since it would allow for a less 
stringent PCR, considering HIV-1 diversity resulting in a high probability of primer template 
mismatches. 
 
Figure 3.2.1.3.2 Nested PCR MgCl2 optimisation: The gel figure above depicts the successful amplification of the 
nested amplicon in all reaction sampling 2 000 plasmid copies with a range of MgCl2 concentrations from 2.9 mM to 
3.5 mM. Faint bands are seen in the 200 plasmid copy input reactions for all MgCl2 concentrations except 3.1 mM. Since 
a higher MgCl2 concentration tolerates more primer mismatches, the 3.5 mM concentration was used for further analysis 
as we intended sampling diverse viral populations. 
Finally, primers were titrated at a 500, 300 and 200 nM final concentration, sampling 2 000 plasmid 
and using the previously optimised MgCl2 concentration and annealing temperature. Gel figure 
3.2.1.3.3 shows more efficient amplification using 200 nM rather than 500 nM final primer 
concentration and the previously optimised reaction conditions. For some unknown reason the 
300nM reaction was unsuccessful however, since it contained an intermediate primer 
concentration, we assume that if would have display intermediate efficiency. 
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Figure 3.2.1.3.3 Nested PCR primer concentration optimisation: Above brighter bands are seen in the 200 nM primer 
input reactions than in the 500 nM reaction. For unknown reasons, the reaction with 300 nM primers failed to amplify 
however, the results were validated by the proper functioning of the reaction controls.  
With the sample preparation reactions optimised, we turned our attention towards reducing PCR-
enrichment-associated resampling error. To this end, we planned a feasible workflow that would 
allow us to sample many viral variants through paralleled pre-nested and nested PCRs. Figure 
3.2.1.3.4 below illustrates our workflow to prepare the amplicon libraries for NGS. The figure also 
shows the conventional diagnostic DRT that was previously performed on the patient included in 
this study.  
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Figure 3.2.1.3.4 Sample processing workflow: The optimised sample preparation workflow is illustrated above. 
Plasma from patients fitting our inclusion criteria were extracted on the EasyMag
®
 (bioMérieux, Marcy l'Êtoile, France) 
system before the cDNA was generated through random pentadecamer-primed reverse transcriptions, performed in 
duplicate. After RNAse-H digestion, the two cDNA reactions were quantified by qPCR (to determine the number of 
species sampled) and amplified through 40 cycles in 14 paralleled PN-PCRs (to limit PCR sampling error and assay all 
available material from a patient). Duplicate PN-PCRs were pooled to form the template for seven paralleled nested 
PCRs, allowing an additional 40 amplification cycles. Nested PCR products were gel separated and purified before an 
aliquot was sent for Ion Torrent (Life Technologies, California, USA) and MiSeq (Illumina, California, USA) sequencing. 
Gel purified products of patients characterised as harbouring diverse viral population with minor variants, were ligated 
into a bacterial vectors. These recombinants were later transformed, enriched through culturing, extracted and 
sequenced using an in-house, M13 sequencing protocol and the Applied Biosystems (ABi) 3130xl Genetic analyser 
(Massachusetts, USA). Deep sequencing results were analysed by a bioinformaticist and clonal population sequences 
were analysed using Stanford University’s online drug resistance profiling tools, Sierra.  
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3.2.2 Sample processing  
Samples from a sub-study of the “Factors affecting the evolution of HIV-1 antiretroviral resistance 
mutations in patients treated at the Infectious Diseases Clinic at Tygerberg Academic Hospital and 
Referring Hospitals” were included in this study (Ethics Number: N06/05/081). As the included 
patients were all younger than 16 months, their parents gave written informed consent for their 
inclusion. In accordance with the Stellenbosch University’s Research Ethics Policy, participants 
were anonymized and assigned study numbers before data analysis.       
3.2.2.1 Patient samples and nucleic acid extraction  
Infants fitting our inclusion criteria were selected from a larger study investigating antiretroviral 
resistance in combination antiretroviral therapy-naïve patients. As such these infants were HIV-
positive and PMTCT exposed but otherwise ARV untreated with approximately 1ml of plasma 
available from previous EDTA blood samples. Untreated children often have high viral loads and 
therefore limited plasma volumes were adequate to sample minor variants. The isolated plasma 
was then extracted on the EasyMag® DNA and RNA extraction machine (bioMérieux, Marcy 
l'Êtoile, France) and the resultant 25 µl nucleic acid extract was stored at -80 °C. To preserve the 
integrity of the viral RNA, the extract was only defrosted for reverse transcription when needed. 
Diagnostic drug resistance testing was conducted as described elsewhere (Claassen et al. 2011). 
3.2.2.2 Reverse transcription (RT) 
Reverse transcriptase is prone to dissociate from the RNA template when it encounters RNA 
secondary structure, which results in premature termination of cDNA synthesis. It is therefore 
important to ensure that RNA is denatured before and remains denatured during reverse 
transcription. We consequently synthesised cDNA using the CHAVI-MBSC-2 protocol with 
Invitrogen’s SuperScript® III RT (California, USA), and include a denaturing step. Moreover the 
thermo-stability of this reverse transcriptase allows for cDNA extension at higher temperatures 
when less RNA secondary structure is expected, and which would increase yield and produce 
longer cDNA fragments.  
An accurate representation of the isolated viral population is essential for minor variant 
quantification and requires initial sampling methods with little or no selection bias. To this end, we 
tested random hexamers to prime the RT reaction, which seemed to generate lots of quantifiable 
cDNA, as measured with a short fragment qPCR. The resultant cDNA was however, discontinuous 
and un-amplifiable using our pre-nested PCR (PN-PCR), sensitive to >50 DNA copies. We 
therefore investigated and implemented the use of pentadecamers and a higher temperature 
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(48 °C) to prime reverse transcription, as this would bias binding to a larger GC rich area upstream 
from, and not in, our PCR target. 
Our final modified protocol is as follows: 
Each reaction was prepared in duplicate, in a 200 µl thin-walled PCR tube (eight tube strip) and all 
thermocycling was carried out in ABI 9700 thermocyclers (Applied Biosystems, Massachusetts, 
USA). The following reagents were prepared in a mastermix and aliquotted at the relevant 
concentrations: 
 Reagent       Final concentration (in 27 µl) 
1. Random pentadecamers      11.11 µM 
2. dNTP Mix      0.741 µM  
3. 12 µl extracted RNA     Unknown  
4. 10 µl Nuclease free water (N.F.H2O)   1 x 
The reaction was then heated to 72 °C for 2 min to linearize the RNA and then at 48 °C for 5 min to 
allow the pentadecamers to anneal. Next, the reaction was rapidly cooled (-20 °C) in an aluminium 
chilling block (UltraCruzTM, Texas, USA) before the following reagents were added at the required 
concentration, making up a 40 µl final reaction volume: 
 Reagent       Final concentration (in 40 µl) 
1. RiboLock (RNAse inhibitor) (Thermo Scientific) 80 U/rxn 
2. DTT       5 µM 
3. SuperScript® III RT (Invitrogen)   200 U/rxn 
4. 5 x Reaction buffer     1 x  
This reaction was incubated at 56 °C for 1.5 hrs before another 200 U of SuperScript® III 
(Invitrogen, California, USA) RT enzyme was added. The reaction was once again incubated at 
56 °C for 1.5 hrs before the enzymes were deactivated by heating the reaction to 85 °C for 5 min. 
Once on ice, four units of E. coli RNAse H (Thermo Scientific, Massachusett, USA) were added 
and the reaction was incubated at 37 °C for 20 min. The resultant cDNA was stored at -20 °C until 
needed for the PN-PCR. 
3.2.2.3 cDNA quantification 
As it is critical to estimate the starting cDNA population size prior to PCR enrichment (as the 
starting population size would determine the limit for minor variant detection) we performed 
quantitative PCR (qPCR) to quantify the cDNA starting concentration. A 5 µl aliquot of patient-
derived cDNA was quantified using a SYBR green qPCR, GoTaq® HotStart DNA polymerase 
system (Promega, Wisconsin, USA) and the primers seen in table 3.2.2.3.1 below. qPCRs were 
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performed on an ABI 7900HT real time PCR platform (Applied Biosystems, Massachusetts, USA) 
and analysed using the supplied Applied Biosystems Software (SDS version 2.3) (Massachusetts, 
USA). A melt curve analysis step was included at the end of the qPCR assay to discriminate 
between double-stranded DNA from PCR amplification and nonspecific signals (primer-dimer) 
fluorescence.   
For the standard curve, plasmid DNA standards (pZAC – a South African HIV-1 subtype C 
plasmid) were amplified in triplicate at 1 log dilutions from 5 x 106 to 5 x 100 input copies. Non-
template controls and patient cDNA samples were assayed in duplicate. 
Table 3.2.2.3.1 qPCR primers 
Description Name Sequence (5’-3’) HXB2 binding  
Forward primer F1_F/RealT RGCTCTMTTAGAYACAGGAGCAGAT 2315 to 2339 
Reverse primer F1_R_RT ACTTTGATAAAACCTCCAATTCCYCC 2394 to 2419 (RC) 
(RC)= Reverse complement 
The following qPCR was compiled using the listed reagents at their indicated concentration: 
 Reagent       Final concentration (in 25 µl) 
1. 5 x Reaction buffer     1 x 
2. F1_F/RealT FWD Primer    400 nM 
3. F1_R_RT REV Primer    400 nM 
4. dNTP Mix      200 µM 
5. MgCl2       3 mM 
6. 25 mM ROX reference dye    500 µM 
7. 50 x SYBR green Gel stain    0.5 x 
8. GoTaq® HotStart DNA Polymerase   0.625 U/rxn 
9. 5 µl synthesised cDNA / pZAC   Unknown / Varied 
10. 9.62 µl N.F.H2O with 1 mg/ml Glycogen (Roche) 1 x 
The following thermocycling conditions were used: 
95 °C for 120 sec*   
94 °C for 30 sec* 
40 x  54 °C for 30 sec* 
72 °C for 30 sec* 
 Melt curve analysis  
95 °C for 15 sec 
65 °C for 5 sec 
   Thermal ramp at 0.2 °C/sec*   
   95 °C for 5 sec* 
(*acquisition on green channel) 
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On completion, these results were analysed using the SDS (V2.3) software (Applied Biosystems, 
Massachusetts, USA). An acceptable standard curve was defined as having a Y-intercept of 
greater than 38 cycles, an efficiency coefficient greater than 0.97 and a slope gradient between      
-3.2 and -3.6. The final batch of cDNA samples (A339, A345, A364, A428, A437 and A93) could 
not be quantified due to 7900HT (Applied Biosystems, Massachusetts, USA) laser malfunction. For 
each sample, the sampled copy number is calculated by multiplying the estimated cDNA copy 
number by seven, since, from each 40 µl cDNA reaction, one 5 µl aliquot was used for qPCR and 
the remaining seven aliquots, for PN-PCRs. The total number of variants sampled per patient is the 
sum of the sampled copy number for duplicated cDNAs.  
3.2.2.4 Pre-nested PCR 
PCR induced errors, while infrequent, may misrepresent the sampled starting population in 
downstream next gen genotyping. Even low frequency PCR errors, not seen with bulk Sanger 
sequencing, could be observed with deep sequencing due to the high template coverage. It is 
therefore critical that a high fidelity enzyme system is used during PCR to minimize PCR error, 
such as misincorporation resulting in base substitutions, insertions or deletions. To this end, we 
optimised our pre- and nested PCRs using Roche Diagnostics’ Expand High FidelityPLUS (Basel, 
Switzerland), an enzyme system with six-times better fidelity than regular Taq DNA polymerase.  
Once 5 µl of the cDNA had been removed and quantified, the remaining 35 µl were split between 
seven paralleled PN-PCR’s (5 µl/rxn) to limit random PCR sampling error. This phenomenon is 
known as PCR resampling and results from one initially amplified template being resampled in 
subsequent rounds of PCR. When this occurs, the proportion of variants in the enriched population 
is different to that of the starting population. Since the RTs were performed in duplicate, a total of 
14 pre-nested reactions originated from each patient sample. Our optimised Expand High 
FidelityPLUS (Roche Diagnostics, Basel, Switzerland) reaction used the following PN-PCR primers in 
table 3.2.2.4.1 below: 
Table 3.2.2.4.1 PN-PCR primers 
Description Name Sequence (5’-3’) HXB2 binding  
Forward primer 50Prot2 TCAGAGCAGACCAGAGCCAACAGCCCCA 2136-2163 
Reverse primer NE135 CCTACTAACTTCTGTATGTCATTGACAGTCCAGCT 3334-3300 (RC) 
(RC)= Reverse complement 
The pre-nested reactions were compiled using the listed reagents at their indicated concentration: 
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 Reagent       Final concentration (in 50 µl) 
1. 5 x Reaction buffer     1 x 
2. 50Prot2 FWD Primer     500 nM 
3. NE135 REV Primer     500 nM 
4. dNTP Mix      200 µM 
5. MgCl2        3.5 mM 
6. Expand HiFi Plus Polymerase (Roche)  2.625 U/rxn 
7. 5 µl cDNA      Unknown 
8. 24.25 µl N.F.H2O with 1 mg/ml Glycogen (Roche) 1 x 
The following thermocycling conditions were used for this PN-PCR: 
94 °C for 2 min 
94 °C for 30 sec 
40 x  64 °C for 30 sec 
72 °C for 90 sec 
72 °C for 7 min 
4 °C soak  
On completion, the duplicate pre-nested reactions were combined to form seven, 100 µl PN-PCR 
products for each patient sample. These pre-nested products were then stored at -20 °C until 
needed for nested PCR. 
3.2.2.5 Nested PCR 
These nested PCR’s were performed in replicates of seven, resulting in a total of seven nested 
reactions per patient sample. Expand High FidelityPLUS (Roche Diagnostics, Basel, Switzerland) 
was once again used for all nested PCR’s along with the following nested PCR primers, shown in 
table 3.2.2.5.1:  
Table 3.2.2.5.1 Nested PCR primers 
                                      (RC)= Reverse complement 
The nested reaction was compiled using these listed reagents at their indicated concentration: 
 
 
Description Name Sequence (5’-3’) HXB2 binding  
Forward primer F1_F CTCTCTTAGACACAGGAGCAGAT 2317 to 2340 
Reverse primer F3_R_alt_3 CCATTTGTCAGGATGGAGTTCATA 3267 to 3243 (RC) 
Stellenbosch University  https://scholar.sun.ac.za
 83 
 
 Reagent       Final concentration (in 50 µl) 
1. 5 x Reaction buffer     1 x 
2. F1_F FWD Primer     200 nM 
3. F3_R_alt_3 REV Primer    200 nM 
4. dNTP Mix      200 µM 
5. MgCl2       3.5 mM 
6. Expand HiFi PLUS Polymerase (Roche)  2.625 U/rxn 
7. 4 µl Pre-nested product    Unknown 
8. 25.25 µl N.F.H2O with 1 mg/ml Glycogen (Roche) 1 x 
The following thermocycling conditions were used for this nested PCR: 
94 °C for 2 min 
94 °C for 30 sec 
40 x  65 °C for 30 sec 
72 °C for 80 sec 
72 °C for 7 min 
4 °C soak  
On completion, these nested products were then stored at -20 °C until needed for separation by 
electrophoresis. 
3.2.2.6 Gel electrophoresis 
An additional precaution taken to prevent point mutations and DNA degradation due to ultraviolet 
light exposure during gel electrophoresis was the use of GelStar™ nucleic acid stain (Lonza, 
Basel, Switzerland). This gel stain allows for the visualisation of DNA over blue light and through 
an orange exclusion filter. 50 µl of each nested PCR products were separated on a 1% agarose 
gel made in sodium borate buffer, stained with 1x GelStar™ (Lonza, Basel, Switzerland). 
Electrophoresis gels were photographed over a blue light with orange exclusion.  
3.2.2.7 Re-PCR 
Once photographed and documented, reactions which yielded less than five out of seven positive 
nested PCR’s were repeated to verify results, and to exclude non-detection due to operator error. 
However, if the number of positive samples remained less than five out of seven on repeat, these 
cases were excluded from the investigation, as this would indicate that the cDNA sampled was too 
close to the limit of detection to allow an accurate estimation of low frequency variants. Random 
sampling error is at its highest close to the limit of detection as the coefficient of variation for the 
number of events detected, predicted by the Poisson distribution, is the highest when the number 
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of cDNA species sampled is at its lowest. Electrophoreses was repeated as described above. Of 
the 46 initial samples processed, only 15 samples were included since most of the others either 
failed to produce an amplicon after the nested reaction or failed to produce an amplicon in more 
than five out of seven positive nested PCRs. 
3.2.2.8 Purification and quantification  
Nested PCR reactions yielding five or more positive results (~1 kbp amplicon) were excised from 
the electrophoresis gel, pooled together and weighed on a fine balance. Amplified DNA was 
purified from the gel slices using a Promega’s (Wisconsin, USA) Wizard® SV Gel and PCR clean-
up system according to the manufacturer’s specification. Briefly: 10 µl of membrane binding buffer 
was added for every 10 mg of gel slice; this mixture was then vortexed for two minutes and 
incubated at 65 °C for ten minutes; with the gel dissolved, the mixture was centrifuged through a 
silica-membrane column at 14700 xg; this membrane was then washed twice with 500 and 700 µl 
membrane wash solution before nuclease-free water (preheated to 50 °C) was used to elute the 
DNA from the purification column. 
Two microliters of these purified products were quantified on a NanoDrop® ND1000 (Thermo 
Scientific, Massachusetts, USA) in triplicate, before 30 µl of each sample was sent for PGM 
sequencing at the Stellenbosch University Central Analytical Facility. The remaining 14 µl we 
stored at -20 °C until needed for clonal sequencing. 
3.2.2.9 PGM and MiSeq library preparation 
The IonXpress™ Plus library preparation manual, rev. M was followed for Ion Torrent amplicon 
library construction (Life Technologies, California, USA). The purified amplicons were digested 
using the Ion Shear Enzyme II kit and protocol (Life Technologies, California, USA), followed by 
barcode ligation and size selection using the E-Gel system (Invitrogen, California, USA), for an 
average insert size of 200 bp. Template enrichment and sequencing was performed according to 
manufacturer recommendation with the Ion 200 Sequencing V1 kit 3.3.2 (Life Technologies, 
California, USA).  
For the MiSeq (Illumina, California, USA) library construction, the Nextera XT DNA sample 
preparation manual, rev. C was followed (Illumina, California, USA). The digestion and adaptor 
ligation was performed simultaneously followed by the PCR mediated index addition. AmPure XP 
reagent (Beckman-Coulter, California, USA) was used to size select 300-500 bp fragments and 
sequencing was performed using the MiSeq Reagent Kit V2 (Illumina, California, USA).  
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3.2.2.10 Ion Torrent and MiSeq bioinformatic analysis 
A South African HIV-1 Subtype C consensus sequence was generated from 317 whole genomes, 
sequenced between 1997 and 2010 and downloaded from HIV online database (available at 
http://www.hiv.lanl.gov/components/sequence/HIV/search/search.html). These sequences were 
aligned using the Geneious align tool in Geneious V6.0 (Biomatters, Auckland, New Zealand). 
Reads were filtered using instrument quality scores and aligned to the subtype C reference 
sequence using a codon-aware version of the Smith-Waterman algorithm that corrects for 
homopolymer errors. Figure 3.2.2.10.1 below illustrated the remedial action of the codon-aware 
algorithm that considers both nucleotide and amino-acid homology and directly penalizes for length 
miscall.  
 
Figure 3.2.2.10.1 Datamonkey codon-aware mapping algorithm: This figure illustrates the corrective action of the 
codon-aware version of the Smith-Waterman read mapping algorithm. The algorithm maps quality filtered sequence 
reads to an HIV-1 Subtype C reference sequence in codon space. When a frame shift is encountered in the mapping, the 
algorithm interrogates the nucleotide sequence and removes erroneously called homopolymer bases. The corrected 
sequence it then realigned to the consensus.  
Bioinformatics analysis was performed by our collaborators from the University of California San 
Diego, Bioinformatics Core (Sergei Kosakovsky Pond and Ben Murrell). A mixture of multinomial 
probabilistic model was used to distinguish sequencing error from true low-frequency variants with 
posterior probabilities of ≥99.99%, excluding bases identified as errors. For each sample, they 
computed the mean of all pair-wise Tamura-Nei 93 distances between reads with at least 100 
overlapping base pairs to quantify nucleotide diversity. As bidirectional sequencing was provided 
on the MiSeq (Illumina, California, USA), only minor variants recorded by both reverse and forward 
sequencing, at a threshold of ≥0.5%, were included in further analysis. 
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3.2.2.11 Phylogenetic analysis 
We constructed a maximum likelihood tree (GTR + CAT model in FastTree), based on the first 630 
nucleotides of reverse transcriptase (the region that was uniformly well-covered for all sequencing 
runs) using NGS majority consensus and Sanger bulk sequences. 
3.2.2.12 Clonal sequencing  
3.2.2.12.1 Amplicons 
As quality control for NGS, amplicons sequenced on the PGM, and which revealed the presence of 
quantifiable drug-resistant variants (patients A124, A313, A157 and A158) were cloned for bi-
directional, M13-based Sanger sequencing. Since the M13 primer binding region is vector-derived 
and identical in each vector, this clonal sequencing approach was unbiased. 
3.2.2.12.2 Ligation 
One-hundred-and-sixty-six nano grams of A124, 178 ng of A313, 249.3 ng of A157 and 193.7 ng of 
A158 purified amplicons were ligated into 100 ng of the pGEM®-T Easy Vector (Promega, 
Wisconsin, USA) using the reaction mixtures and thermal incubations described below. The 
ligation reaction was validated using the relevant reaction controls that included a ligation positive 
control insert and a background/no-insert control. Each reaction was prepared individually (i.e.: a 
mastermix was not prepared) in a 200 µl thin-walled PCR tube and all thermal incubations were 
carried out in an ABI 9700 thermocycler (Applied Biosystems, Massachusetts, USA), with the heat-
lid activated at 105 °C. 
Reagent       Final concentration (in 20 µl) 
1. 2 x Rapid ligation reaction buffer    1 x 
2. T4 DNA Ligase (3 U/µl) (Promega)   3 U  
3. Control DNA insert (4 ng) or DNA amplicon  Various  
4. 10 µl Nuclease free water (N.F.H2O)   1 x 
5. pGEM® T-Easy vector (50 ng/µl) (Promega)  100 ng 
Ligation reactions were then incubated at 25 °C for 2 hrs, followed by 4 °C for 16 hrs, 75 °C for 
5 min and an indefinite hold at 4 °C. On completion, recombinants were immediately transformed 
using an in-house optimised transformation protocols seen below. 
3.2.2.12.3 Transformation of A124 and A313 recombinants 
The recombinant A124 and A313 constructs were transformed using the following optimised 
protocol, along with a transformation efficiency control plasmid:  
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 Prepare and chill a 5x concentrate KCM transformation additive solution consisting of 
5.1 mM KCl, 1.5 mM CaCl2 and 2.5 mM MgCl2. 
 Pre-chill 1.5 ml tubes and SOC media while thawing 250 µl JM109 chemically competent 
bacteria (Promega, Wisconsin, USA) on ice. 
 Once the competent bacteria have thawed, add 62 µl of the KCM additive and mix by 
gently swirling and flicking the bacteria stock.  
 Add 5 µl of the ligation constructs to the pre-chilled tubes. 
 Add 50 µl JM109 cells (Promega, Wisconsin, USA) with the 1x KCM additive to each pre-
chilled tube. Mix once by slow up and down pipetting. 
 Incubate tubes on ice for 1 min then heat shock at exactly 42 °C for 50 sec. 
 Incubate reactions on ice for 2 min before adding 950 µl cold SOC. 
The reaction was then incubated at 37 °C for 1.5 to 2 hrs with gentle shaking before being spread 
on to a 400 cm2, semisolid, ampicillin-selective LB media culture plate for IPTG/X-Gal mediated 
blue/white colony selection. These plates (Q-trays) were incubated at 37 °C for 16 hrs, before 
being stored at 4 °C for colour intensification. 
3.2.2.12.4 Transformation of A157 and A158 recombinants 
The recombinant A157 and A158 constructs were transformed using the following optimised 
protocol, along with a transformation efficiency control plasmid:  
 Pre-chill 1.5 ml tubes and SOC media while thawing 250 µl JM109 chemically competent 
bacteria (Promega, Wisconsin, USA) on ice. 
 Add 5 µl of the ligation constructs to the pre-chilled tubes. 
 Add 50 µl JM109 cells (Promega, Wisconsin, USA) to each transformation tube. Mix once 
by slow up and down pipetting. 
 Incubate tubes on ice for 1 min and heat shock at exactly 42 °C for 50 sec. 
 Incubate reactions on ice for 2 min before adding 950 µl cold SOC. 
The reaction was then incubated at 37 °C for 1.5 to 2 hrs with gentle shaking before being spread 
on four, semisolid Ampicillin-selective LB media culture plates, for IPTG/X-Gal mediated blue/white 
colony selection.  
3.2.2.12.5 Culturing and recombinant constructs recovery 
Using the Q-Pix II automated colony picker (Molecular Devices, California, USA), 276 and 253 
white colonies were selected for samples A124 and A313 respectively. These colonies were 
inoculated into 200 µl of ampicillin-selective liquid LB media in a 96 welled plate before being 
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sealed and incubated overnight at 37 °C with orbital shaking at 200 rpm. On completion, 100 µl of 
each culture was diluted in an equal volume of a sterile, 50% glycerol solution before being frozen 
at -80 °C overnight. These glycerol stocked cultures were then couriered to the European branch 
of Macrogen (Seoul, South Korea) for plasmid extraction and M13-mediated forward and reverse 
sequencing.  
From samples A157 and A158, 250 white colonies were inoculated by hand into 4 ml of ampicillin-
selective liquid LB media and incubated overnight, at 37 °C with orbital shaking at 200 rpm. These 
hand-picked cultures were miniprepped using the manufacturer’s specified protocol (Promega, 
Wisconsin, USA) and 2 µl of the purified constructs, quantified on a NanoDrop® ND1000 (Thermo 
Scientific, Massachusetts, USA). 
3.2.2.12.6 A157 and A158 recombinant sequencing 
Between 150 and 450 ng of the purified pGEM® constructs extracted from A157 and A158 cultures, 
were sequenced using the following in-house optimised BigDye® Terminator (V3.1) Cycle 
Sequencing kit reaction (Applied Biosystems, Massachusetts, USA), primed with standard M13 
forward or reverse oligos.  
 Reagent      Final concentration (in 10 µl) 
1. 5 x Terminator sequencing reaction buffer  1.5 x 
2. BigDye® Terminator reaction mix (ABi)  1 x 
3. M13 Fwd or Rev Primer     5 pMoles 
4. pGEM®-T DNA construct    150 to 450 ng 
Sequencing PCRs were performed using the following in-house-optimised reaction conditions in an 
ABI 9700 thermocycler: 
95 °C for 10 sec 
95 °C for 5 sec 
25 x  72 °C for 4 min 
4 °C soak  
 
On completion, the sequencing PCR reaction was purified using an in-house-optimised BigDye® X-
terminator clean-up (Applied Biosystems, Massachusetts, USA), seen below. The SAM solution™ 
(Applied Biosystems, Massachusetts, USA) used in the purification reaction was heated to room 
temperature before use. 
 Reagent      Volume added to Mastermix  
1. SAM™ solution (Applied Biosystems)  49 µl 
2. X-terminator solution (Applied Biosystems)  11 µl 
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Fifty-five microlitres of the above reaction mixture was added to each sequencing PCR in a 96 well 
plate, before the wells were sealed and the reaction, vortexed for 30 to 45 min. The purified 
sequencing PCR product was then centrifuged at 1000 xg for five minutes to pellet the X-
terminator particles and the sequencing reaction was read on an ABI Genetic Analyser 3130xl 
(Applied Biosystems, Massachusetts, USA). 
3.2.2.12.7 A157 and A158 false positive correction  
Unsuccessful sequencing reactions were repeated and inconclusive sequencing results were 
substituted. For species characterised as containing no HIV insert as revealed by the National 
Centre for Bioinformatics Information (NCBI) blast results, alternative white colonies were 
inoculated into fresh LB broth. These cultures were then miniprepped, quantified and sequenced 
as previously described. These methods resulted in 252 positively screened species for both 
samples A157 and A158. 
3.2.2.12.8 A124 and A313 bioinformatic analysis  
The .fastq sequence files downloaded from Macrogen were uploaded into Stanford University’s 
Calibrated Population Resistance (CPR) tool (V6.0) (available online at 
http://cpr.stanford.edu/cpr.cgi), as all the NNRTI mutations of interest were included in the 
surveillance drug resistance mutations list (SDRM) (Bennett et al. 2009). The CPR tool aligns the 
nucleotide sequences to an HIV-1 Subtype B, HXB2 amino acid sequence using a local alignment 
program, before translating them into an in-frame amino acid sequence. CPR then excludes 
sequences containing undocumented insertion, deletions and stop codons, as well as poor quality 
sequences. The bioinformatic process is explained in full detail in the CPR release notes (available 
at http://cpr.stanford.edu/pages/releaseNotes.html). Analysed results were exported to Excel 2010 
(Microsoft, Washington, USA), where drug-resistant mutation frequencies are viewed as 
percentages. 
3.2.2.12.9 A157 and A158 bioinformatic analysis 
Chromatograms from the in-house sequencing reactions were imported into Geneious V6.0 
(Biomatters, Auckland, New Zealand) and blasted against the NCBI nucleotide sequence database 
to determine the sequence specificity. Sequences were named according to their sample origin 
followed by their construct number and finally, the sequence direction (e.g.: Sequence name 
“8.214F” notates a sequence from sample A158; is the 214th construct sequenced; and is the 
forward sequence for that construct). The 252 forward and reverse sequences for each sample 
were converted to .fasta format using a 60% base-call confidence threshold.  
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Each forward and corresponding reverse sequence was aligned to produce one contiguous “read” 
for each recombinant. The drug resistance profile of these 504 contiguous reads (252 contigs for 
both A157 and A158) were generated using Stanford University’s Sierra HIV drug resistance 
database (available at http://sierra2.stanford.edu/sierra/servlet/JSierra?action=sequenceInput). 
The results were exported in .csv format and imported into Excel (Microsoft, Washington, USA) 
where mutation frequencies were calculated.  
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3.3 Results 
3.3.1 Patient samples and nucleic acid extraction  
We conducted a retrospective cross sectional study in 15 HIV-infected and PMTCT-failed infants, 
born between October 2006 and October 2009. At the time of sample collection all participants 
were treatment-naïve (baseline sampling). The PMTCT regimen consisted of maternal zidovudine 
(AZT) from 28 weeks gestation, intrapartum nevirapine (NVP), and neonatal single dose NVP with 
seven days of AZT. The median age of participants at sample collection was 3.4 months (inter-
quartile range (IQR) 2.4–4.5), and 11 (73%) of the 15 infants were female. Other clinically relevant 
patient information is summarized in table 3.3.1.1. 
Table 3.3.1.1 Patient demographics: The table below displays clinically relevant information of our study participants 
when sampled at baseline. The median viral load at sampling was 5.8 log10 HIV RNA copies/ml (IQR 5.1–6.2); median 
CD4 count was 1693 cells/µl (IQR 650–2025) and the median CD4% of 26% (IQR 21–35%). All patients’ viruses were 
genotyped as HIV-1 subtype C species. Values indicated with ‘NA’ were not available. 
Study No. Gender 
Age 
(months) 
Baseline sampling 
HIV-1 
Subtype CD4 count Viral load 
A124 Female 16 1208 2,900,00 Subtype C 
A137 Female 4 4150 29,000 Subtype C 
A144 Female 2 2036 82,000 Subtype C 
A157 Female 2 540 660,000 Subtype C 
A158 Female 2 2913 650,000 Subtype C 
A202 Female 3 430 NA Subtype C 
A207 Female 2 NA NA Subtype C 
A297 Male 4 2030 180,000 Subtype C 
A300 Female 4 1744 120,000 Subtype C 
A302 Female 2 801 500,000 Subtype C 
A312 Male 5 2009 3,200 Subtype C 
A313 Female 14 1886 >1,000,000 Subtype C 
A318 Male 7 518 2,300,000 Subtype C 
A326 Male 4 1641 >3,000,000 Subtype C 
A364 Female 3 600 4,300,000 Subtype C 
3.3.2 cDNA quantification 
Once reverse transcribed, the viral RNA was digested and the cDNA was quantified using our in-
house qPCR as described in the methods (section 3.2.2.3). The qPCRs were conducted in four 
batches of which only the first three batches were successful. The fourth qPCR batch run was 
unsuccessful due to mechanical failure on the ABI 7900HT (Applied Biosystems, Massachusetts, 
USA), resulting in sample A364 cDNA not being quantified. The results of the successful first 
qPCR batch are seen in figures 3.3.2.1 and 3.3.2.2 below, as well as in tables 3.3.2.1 and 3.3.2.2. 
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This first batch quantified cDNA duplicates from patients A124, A137, A144 and A157 using a 
linearized HIV-1 subtype C plasmid (pZAC) standard in triplicate. An acceptable standard curve 
gradient was defined as being between -3.2 and -3.6 (defined as the change in Ct divided by the 
change in labelled concentration), with a Y-intercept (theoretical Ct to detect one copy) above 38 
cycles and an R2 value (accuracy measurement) greater than 0.97. 
Table 3.3.2.1 Quantified plasmid standards: The table below shows the averages of the triplicate standards, their 
measured Ct, and their input copy number. 
 
 
   
 
 
 
 
 
 
 
 
 
Figure 3.3.2.1 Batch 1 qPCR standard curve: The straight line graph above displays the observed Ct of the first batch 
of pZAC plasmid standards in relation to their concentration. The gradient of the slope, R
2
 value and the Y-intercept were 
within our acceptable range. 
 
Using the accepted standards curve displayed above, cDNA duplicates from samples A124, A137, 
A144 and A157 were successfully quantified. Their estimated copy numbers are seen in table 
3.3.2.2 below, along with their dissociation curve analysis in figure 3.3.2.2. 
 
 
 
 
 
 
Label Content Ct Copy No. 
5x10
1
 Standard 36.074 50 
5x10
2
 Standard 32.649 500 
5x10
3
 Standard 28.485 5000 
5x10
4
 Standard 25.347 50000 
5x10
5
 Standard 21.534 500000 
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Table 3.3.2.2 qPCR Batch 1 quantified cDNA: Below are the Cts and estimated cDNA copy numbers as estimated 
using the previously described standard curve. All cDNA samples were quantified except for the first replicate from 
sample A157 which failed to amplify for unknown reasons. The sample’s copy number is calculated by multiplying the 
estimated cDNA copy number by seven, since, from each 40 µl cDNA reaction, one 5 µl aliquot was used for qPCR and 
the remaining seven aliquots, for pre-nested PCRs.  
 
 
 
 
 
 
As SYBR green-based qPCRs measure general amplification and not the production of a specific 
amplicon, dissociation analysis is performed after amplification. Briefly, well fluorescence is 
measured as the temperature is increased from 60 to 95 °C at a rate of 0.2 °C per second. The 
derivative of the observed fluorescence is plotted against the temperature, forming an amplicon 
dissociation/melt curve. Nonspecific products, such as primer dimers, melt at relatively low 
temperatures in comparison to the specific amplicons. These specific products display similar melt 
curve signatures, since they gave similar compositions (i.e.: similar nucleotide sequence and G-C 
content). Alternatively amplified products can be distinguished from specific products by their melt 
curve signature. 
 
 
 
 
 
 
Figure 3.3.2.2 qPCR Batch 1 melt-curve analysis: The line graph above displays the dissociation curve of the 
amplicons produced from patient cDNA. The green vertical line indicates the average melting temperature for specific 
amplicons at approximately 79 °C. The faint pink line showing almost no fluorescence change represents the first cDNA 
replicate from patient A157 which failed to amplify.  
The second batch of qPCR results are seen in figures 3.3.2.3 and 3.3.2.4, and in tables 3.3.2.3 
and 3.3.2.4 below. This qPCR batch quantified cDNA duplicates from patients A158, A202, and 
Label Ct Copy No. 
Sampled 
Copy No. 
A124-1 32.307 549.28 3844.98 
A124-2 33.605 241.65 1691.58 
A137-1 35.309 82.17 575.19 
A137-2 35.690 64.57 451.98 
A144-1 35.305 82.39 576.75 
A144-2 33.144 323.49 2264.40 
A157-1 N/A 0.00 0.00 
A157-2 34.143 171.85 1202.96 
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A207 using the previously described subtype C plasmid (pZAC) standard in triplicate. Standard 
curve acceptance was based on the previously mentioned criteria. 
Table 3.3.2.3 Quantified plasmids standards: The table below tabulates the average of the triplicate standards, their 
measured Ct and their input copy number. 
Label  Content Ct Copy No. 
5x10
1
 Standard 34.518 50 
5x10
2
 Standard 31.776 500 
5x10
3
 Standard 27.962 5000 
5x10
4
 Standard 25.032 50000 
5x10
5
 Standard 21.187 500000 
 
 
 
 
 
 
Figure 3.3.2.3 Batch 2 qPCR standard curve: The straight line graph displays the observed Ct of the second batch’s 
pZAC plasmid standards in relation to their concentration. The gradient of the slope, R
2
 value and the Y-intercept were 
within our acceptable range.  
 
The standard curve above was used to estimate the cDNA concentration of samples A158, A202 
and A207. Table 3.3.2.4 below collates the cDNA samples’ Cts and their relative estimated 
concentration.  
 
Table 3.3.2.4 qPCR Batch 2 quantified cDNA: The table below shows the Cts and estimated cDNA copy numbers as 
estimated using the second batch’s standard curve shown above. All cDNA samples were successfully quantified. The 
sample copy number was again calculated by multiplying the cDNA copy number by 7 (see table 3.3.2.2). 
 
 
 
 
 
Label Ct Copy No. 
Sampled 
Copy No. 
A158-1 33.106 158.06 1106.43 
A158-2 32.442 249.79 1748.55 
A202-1 28.977 2722.57 19057.98 
A202-2 28.836 2999.55 20996.84 
A207-1 29.916 1425.49 9978.46 
A207-2 28.776 3127.32 21891.24 
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The dissociation curves of the amplified cDNA samples are seen below in figure 3.3.2.4. As 
previously described, our specific amplicon has an average melting temperature of roughly 79 °C 
(as seen in figure 3.3.2.2). The specific dissociation temperature of each amplicon is determined 
by its nucleotide composition as G/C rich amplicons will have a higher melting temperature than its 
analogues. Similarly, amplicons from various viral species will have slightly varied compositions 
and thus varied dissociation temperatures. 
 
 
 
 
 
 
 
Figure 3.3.2.4 qPCR Batch 2 melt-curve analysis: The line graph above displays the dissociation curve of the 
amplicons produced from patient-derived cDNA sample. The green vertical line indicates the average melting 
temperature for specific amplicons at approximately 79 °C. The additional peaks seen at approximately 84 °C suggests 
the presence of larger, nonspecific amplicons or spurious G/C rich amplicons which could skew the quantification of 
sample A158. 
 
The final batch of qPCR results are seen in figures 3.3.2.5 and 3.3.2.6, and tables 3.3.2.5 and 
3.3.2.6 below. The cDNA duplicates from patients A297, A300, A302, A312, A313, A318, and 
A326 were quantified in this third batch using the linearized subtype C plasmid as triplicate DNA 
standards. Once again, standard curve acceptance was based on the previously mentioned criteria 
(section 3.3.2 above). 
Table 3.3.2.5 Quantified plasmid standards: The table below shows the average of the triplicate standards, their 
measured Ct values and their input copy number. 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 96 
 
 
 
 
 
 
 
Figure 3.3.2.5 Batch 3 qPCR standard curve: Above is the straight line graph of the observed pZAC plasmid 
standards’ Cts in relation to their concentration. The gradient of the slope, R
2
 value and the Y-intercept were within our 
acceptable range.  
The tabulated data below shows the HIV cDNA copy number in samples A297, A300, A302, A312, 
A313, A318, and A326 duplicates, as estimated using our in-house qPCR (table 3.3.2.6). 
Table 3.3.2.6 qPCR Batch 3 quantified cDNA: The table below shows the Cts and estimated cDNA copy numbers as 
estimated using the standard curve shown above. All cDNA samples were successfully quantified. Sampled copy 
number is calculated by multiplying the estimated cDNA copy number by seven (as in table 3.3.3.2 above). 
 
 
 
 
 
 
 
 
 
 
A dissociation curve gives some insight into the specificity of the qPCR reaction and impacts the 
confidence in the estimated copy number. For example: if a nonspecific peak is seen to be higher 
or of the same height as the specific peak in the dissociation curve, there is no means of 
estimating the contribution of the nonspecific fluorescence to that well reaching Ct. Hydrolysis 
probes are used as an alternative to intercalating dye based qPCR as the probes bind to specific 
Label Ct Copy No. 
Sampled 
Copy No. 
A297-1 32.915 201.05 1407.35 
A297-2 34.216 85.36 597.54 
A300-1 36.981 13.83 96.83 
A300-2 36.694 16.72 117.02 
A302-1 31.789 421.65 2951.53 
A302-2 32.207 320.39 2242.72 
A312-1 35.100 47.72 334.04 
A312-2 34.925 53.54 374.77 
A313-1 31.313 576.96 4038.75 
A313-2 31.586 482.08 3374.53 
A318-1 34.723 61.14 427.98 
A318-2 32.540 257.22 1800.55 
A326-1 26.949 10196.17 71373.20 
A326-2 26.415 14493.81 101456.64 
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genomic targets and quantify only amplification of that target. Most commercial qPCR assays 
employ hydrolysis probe technology which is prone to under quantification if the probe target is 
sufficiently uncomplimentary to the probe. The dissociation curve in figure 3.3.2.6 below shows 
high, nonspecific peaks contributing to the fluorescence of cDNA duplicates from samples A297, 
A302 and A312. The source of these nonspecific products are unknown but could be the result of 
pentadecamers carried over from the reverse transcription. In the subsequent qPCR they prime the 
cDNA template in random areas, generating nonspecific PCR amplicons.   
 
  
 
 
 
 
 
Figure 3.3.2.6 qPCR Batch 3 melt curve analysis: The above line graph displays the dissociation curve of the 
amplicons produced from patient-derived cDNA samples. The green vertical line indicates the expected melting 
temperature for specific amplicons at approximately 79 °C. The additional peaks seen at approximately 84 °C suggests 
the presence of larger, nonspecific amplicons or spurious G/C rich amplicons which could have resulted in 
overquantification of cDNA duplicates A297, A302 and A312. 
3.3.3 Nested and re-PCR  
The full volume of each nested PCR was separated in a 1% agarose gels made in sodium borate 
buffer and stained with 1 x GelStar (Lonza). GelStar is a DNA gel stain that permits DNA 
visualization using blue light with an orange filter as opposed to ultraviolet light which degrades 
DNA. Nested PCRs with less than five out of seven positive results were repeated to exclude 
operator error. However, the repeated nested PCRs remained negative and these samples were 
excluded from further analysis. Gel figure 3.3.3.1 below displays the results of the successfully 
amplified samples A297, A300, A312, A313, A318 and A326. The gel figures of the remaining nine 
samples (A124, A137, A144, A157, A158, A202, A207, A302 and A364) are appended at the end 
of this chapter (Appendix C). 
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Figure 3.3.3.1 Concatenated nested PCR gels: The above figure depicts the results of four joined electrophoresis gel 
photographs with excluded samples removed. This figure shows successful amplification of the 1 Kbp nested PCR 
amplicon from samples A297, A300, A312, A313, A318 and A326. Half of the samples were positive in all seven nested 
PCRs, A318 was positive for six reactions and A300 and A312, positive for five.  
Separated amplicons were immediately gel purified as described in the methods (section 3.2.2.8 
above).  
3.3.4 Amplicon quantification before sequencing  
Once gel extracted, 2 µl of the 15 size-selected, patient-derived sample amplicons were quantified 
in triplicate on the NanoDrop® ND1000 (Thermo Scientific, Massachusetts, USA). The 
concentrations and purity measurements are tabulated below (table 3.3.4.1):  
Table 3.3.4.1 Concentrations of sequence amplicons: The table below shows the number of positive nested PCRs 
per sample and the results of the spectrophotometric quantification of the purified amplicons. Preferable 260/280 and 
260/230 ratios are 1.8 and 2 respectively, achievable when purifying DNA directly from the PCR product. While our 
samples displayed favourable 260/280 values, the carried over electrophoresis buffer contributes to the optical density 
seen at 230nm, resulting in lower than expected 260/230 ratios. 
 
 
 
 
 
 
 
 
 
 
 
  Average gel purified product values 
Sample 
No of PCR’s 
Positive 
conc. (ng/µl) A260 260/280 260/230 
A124 07 of 07 33.25 0.66 1.99 1.50 
A137 07 of 07 39.89 0.80 1.95 1.59 
A144 07 of 07 56.78 1.14 1.92 1.13 
A157 07 of 07 49.86 1.00 1.98 1.56 
A158 07 of 07 38.73 0.77 1.92 1.24 
A202 07 of 07 27.86 0.56 1.86 1.02 
A207 06 of 07 37.13 0.74 1.86 1.46 
A297 07 of 07 45.45 0.91 1.88 1.65 
A300 05 of 07 25.60 0.51 1.86 1.21 
A302 07 of 07 20.21 0.40 1.84 1.06 
A312 05 of 07 41.41 0.83 1.94 1.65 
A313 07 of 07 35.67 0.71 1.85 1.70 
A318 06 of 07 34.08 0.68 1.87 1.27 
A326 07 of 07 30.17 0.60 1.84 1.41 
A364 07 of 07 25.82 0.52 1.91 0.93 
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3.3.5 Diagnostic drug resistance testing results  
Using in-house drug resistance testing (DRT), only two patients had major NNRTI resistance 
mutations: Patient A157 had K103N and A313 had Y181I. These mutations were also detected in 
the other sequencing events: K103N was quantified at 73.8% by the PGM (Life Technologies, 
California, USA), 51.6% by the MiSeq (Illumina, California, USA) and 47.9% by clonal sequencing, 
while Y181I was seen at 72.4%, 73.3% and 74.4% for the respective platforms. 
3.3.6 PGM results summary  
Considering the coverage for both the PGM (Life Technologies, California, USA) and MiSeq 
(Illumina, California, USA) data sets, and the high cDNA yield in most cases, a threshold of 0.5% 
was used to distinguish minor variants. In addition to the NNRTI mutation detected by Sanger 
sequencing, the PGM (Life Technologies, California, USA) detected K103N in patient A124 and 
Y181C in A158. The median read coverage (the median number of times a locus is sampled) on 
the PGM (Life Technologies, California, USA) was seen at 8 939 (IQR: 4 521 - 12 585) and the 
median proportion of bases with quality scores of 30 or greater (error ≤ 0.1%) was 43.2% (40.5–
46.0%). Table 3.3.6.1 below displays the post quality filtering median coverage per amino acid 
while figure 3.3.6.1 shows the coverage for all samples across the sequence amplicon.   
 
Table 3.3.6.1 PGM per codon coverage: The table below shows the average and median coverage per codon for each 
patient sample. The values in the table were calculated after quality filtering and mapping.  
Coverage: Average Median 
A124 11525.03 12284.0 
A137 12316.49 11660.5 
A144 16534.87 17785.0 
A157 4333.01 4263.5 
A158 4583.94 4370.0 
A202 14194.31 13535.0 
A207 4026.27 3699.0 
A297 9250.93 9843.5 
A300 2484.74 2379.5 
A302 6343.35 6358.5 
A312 8680.82 7295.0 
A313 9197.21 8893.5 
A318 7063.44 6095.5 
A326 4011.135 3296.0 
A364 13389.22 11482.0 
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Figure 3.3.6.1 PGM sample coverage: This figure shows the amino acid coverage for each patient. This figure was 
constructed in R-commander by plotting each codon’s coverage values against the first approximately 240 amino acids 
of the HIV-1 Reverse Transcriptase gene. 
3.3.7 MiSeq results summary  
The median read coverage with MiSeq (Illumina, California, USA) was 74 181 (IQR: 50 173 -
 104 089) and the median proportion of bases with <0.1% error was 89.1% (84.7 – 93%). Table 
3.3.7.1 below displays the post quality filtering median coverage per amino acid while figure 3.3.7.1 
shows the coverage for all samples across the sequence amplicon.   
Table 3.3.7.1 MiSeq per codon coverage: This table shows the average and median coverage per codon for each 
patient sample. The values in the table were calculated after quality filtering and mapping. 
Coverage: Average Median 
A124 33173.74 33037.00 
A137 31668.16 36875.00 
A144 20905.12 23753.00 
A157 106433.03 120014.00 
A158 107216.38 122231.50 
A202 112606.88 127778.00 
A207 84326.64 93773.50 
A297 81423.86 86060.00 
A300 66938.11 73928.50 
A302 55838.76 61950.00 
A312 92616.70 103221.50 
A313 57013.34 64062.50 
A318 105063.56 118473.50 
A326 103764.10 108687.50 
A364 32921.07 32504.00 
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Figure 3.3.7.1 MiSeq sample coverage: The above figure shows the amino acid coverage for each patient of the 
combined forward and reverse MiSeq reads. This figure, constructed in R-commander, plots codon coverage values 
against the first approximately 240 amino acids of the HIV-1 Reverse Transcriptase gene. 
3.3.8 Maximum likelihood tree  
The NGS consensus sequences and bulk sequencing, Sanger sequences formed well-supported, 
monophyletic groups, as seen in figure 3.3.8.1 below. MiSeq (Illumina, California, USA) consensus 
sequences were in much better agreement with Sanger sequences than PGM’s (Life 
Technologies, California, USA). When considering the chromatograms used to resolve mixed 
bases in the Sanger sequences, the bulk of Sanger sequences and MiSeq (Illumina, California, 
USA) consensus sequences were identical, whereas the mean difference between PGM (Life 
Technologies, California, USA) consensus and Sanger sequences for a given patient were 2.2/630 
nucleotides (IQR:1–3, maximum 4). 
 
 
 
 
 
 
 
 
  
RT amino acid 
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Figure 3.3.8.1 Maximum likelihood tree of inferred evolutionary relationship: A maximum likelihood phylogenetic 
tree of NGS consensus and Sanger sequences (GTR + CAT model in FastTree). In the tree above, MiSeq R1 and R2 
indicate the forward and reverse reads respectively. The scale is expected substitutions per site per unit of time. Each 
intra-host clade has a bootstrap support of >95%. 
 
3.3.9 Clonal sequencing results  
Two hundred and fifty recombinants were sequenced for A124, A157, A158 and 269 recombinants 
for A313. Clonal sequencing was able to detect DRMs at less than 1% frequencies and confirmed 
the minor variant population identified in the PGM (Life Technologies, California, USA) sequencing. 
There was better agreement between the clonal sequencing and the MiSeq (Illumina, California, 
USA) data than with the clonal sequencing and the PGM (Life Technologies, California, USA) data 
as shown in table 3.3.10.1 below (at the end of the results section).  
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3.3.10 Comparative DRT results  
Table 3.3.10.1 displays the comparative DRT results across all four sequencing events: our in-
house diagnostic DRT, Ion Torrent PGM (Life Technologies, California, USA) amplicons 
sequencing, MiSeq (Illumina, California, USA) amplicon sequencing, and recombinant sequencing. 
For both NGS events, the table displays the median read coverage per template and the 
percentage template sampling ratio. This ratio is calculated by dividing the median read coverage 
per template by the sampled cDNA copy number provided by the qPCR. 
Table 3.3.10.1 Comparative DRT across sequencing events: Four of the five patients shown to have diverse viral 
populations were included for clonal sequencing (i.e.: A124, A157, A158, and A313 but not A300). Major variant drug 
resistance mutations were detected by genotyping with an bulk sequencing (Sanger DRM). Major and minor variant drug 
resistance mutations detected with the PGM are labeled as PGM DRMs and those detected with the MiSeq, MiSeq 
DRMs. The DRMs respective frequencies, at a threshold of >0.5%, are shown in parenthesis. A364 cDNA was not 
quantified and thus the percentage template sampling ratio could not be calculated. K65R was detected in all samples; 
and is commonly detected by deep sequencing in HIV-1 subtype C. Clonal sequencing confirmed the presence of DRMs 
>1%. Agreement with clonal sequence frequency was better for MiSeq than Ion PGM. 
Patient 
No 
Sanger 
DRM PGM DRMs  
PGM: median 
coverage (per 
template) MiSeq DRMs  
MiSeq: median 
coverage (per 
template) 
Clonal 
sequencing 
A124 None 
K65R (1.4%), 
K103N (32.0%) 
5748 (0.9) 
K65R (1.0%), 
K103N (15.7%) 
33,037 (5.2) 
K65R (0.4%), 
K103N (11.2%) 
A137  None K65R (1.2%) 11,429 (9.7) K65R (1.0%) 36,875 (31.2) NA 
A144  None K65R (2.0%) 17,020 (6.2) K65R (1.8%) 23,753 (8.7) NA 
A157  K103N 
K65R (1.4%), 
K103N (73.8%), 
V106M (1.4%), 
V106A (1.0%), 
Y181C (4.4%) 
4 210 (3.8) 
K65R (0.9%), 
K103N (51.6%), 
V106M (1.4%), 
V106A (1.0%), 
Y181C (4.4%) 
120,014 (107.1) 
K65R (0.4%), 
K103N (47.9%), 
V106M (0.4%), 
V106A (0.4%), 
Y181C (0.82%) 
A158  None 
K65R (2.9%), 
Y181C (2.0%) 
4 190 (1.3) 
K65R (1.3%), 
Y181C (2.6%) 
122,232 (37.4) 
K65R (1.2%), 
Y181C (1.2%) 
A202 None K65R (1.9%) 13,178 (0.3) K65R (0.7%) 127,778 (2.9) NA 
A207  None K65R (1.2%) 3 677 (0.1) K65R (1.1%) 93,774 (2.8) NA 
A297 None K65R (1.3%) 9 781 (4.6) K65R (1.0%) 86,060 (40.5) NA 
A300  None K65R (2.5%) 2 387 (9.8) 
K65R (1.1%), 
G190E (0.7%) 
73,929 (304.2) NA 
A302  None K65R (1.5%) 6 155 (1.1) K65R (1.5%) 61,950 (11.5) NA 
A312  None K65R (1.4%) 6 925 (8.9) K65R (1.1%) 103,222 (132.8) NA 
A313 Y181I 
K65R (1.2%), 
Y181I (72.4%) 
8 545 (1.1) 
K65R (0.7%), 
Y181I (73.3%) 
64,063 (8.5) 
K65R (0.7%), 
Y181I (74.4%) 
A318  None K65R (1.5%) 5 940 (2.5) K65R (1.1%) 118,474 (50.5) NA 
A326 None K65R (1.2%) 3 296 (0.02) K65R (1.1%) 108,688 (0.7) NA 
A364 None K65R (0.9%) 11,218 (NA) K65R (0.9%) 39201(NA) NA 
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3.4 Discussion  
To date, the present study was the only one comparing two modern NGS platforms for DRT of 
infants failing PMTCT, to our knowledge. More recently, viral quasispecies from 19 pre-therapy 
patients were sequenced on 454 (454 Life Sciences, Connecticut, USA) and on Illumina’s MiSeq 
(California, USA) (Keys et al. 2015), however, these were adult patients who were not PMTCT 
exposed and DRM transmission was horizontal. This study employed PCR enrichment and the 
ligation of sequencing adaptors, which is an alternative method to the conventional fusion primer 
PCR. Since the commercial ligation kits are costly, the fusion primer method is more feasible for 
targeted resequencing of small genome targets such as for HIV drug resistance genotyping. 
However, fusion primers are especially prone to resampling error (discussed in more detail in the 
next chapter). Nevertheless, using NGS this study improved the DRT in 15 infants who became 
infected despite being exposed to a PMTCT regimen of maternal and infant AZT and NVP.  
Sanger genotyping before cART initiation detected major NNRTI DRMs, K103N and Y181I in A157 
and A313, respectively, while no patients had minor or major variant AZT-associated DRMs. Ion 
Torrent sequencing detected K103N in A124; Y181C and V106A/M in A157; and Y181C in A158 in 
addition to the Sanger DRMs. The clinical implication of detecting Y181C in A157 would be 
reduced susceptibility to the second-line NNRTI, etravirine, since the presence of drug-resistant, 
minor populations have been linked to therapy failure (Li et al. 2011). MiSeq (Illumina, California, 
USA) sequencing further improved DRT over Ion PGM with the detection of G190E in patient 
A300. The higher coverage, and higher read quality obtained in MiSeq data may have contributed 
to this additional DRM detection, when compared to PGM (Life Technologies, California, USA). 
Both the PGM (Life Technologies, California, USA) and the MiSeq (Illumina, California, USA) had 
good agreement with clonal sequencing but the overall agreement with clonal sequencing was 
better with MiSeq (Illumina, California, USA). 
At the time of patient sample collection the PMTCT regimen was AZT from 28 weeks of gestation 
and sdNVP intra-partum, while the neonate received sdNVP and AZT for 1 week and was formula-
fed to prevent post-natal transmission. This strategy reduced vertical HIV transmission to less than 
10% (Draper & Abdullah 2008) but was later improved in 2010 when infant sdNVP with daily NVP 
for the first 6 weeks of life and the PMTCT-failure rate decreased to <3% (Barron et al. 2013). In 
2013 the WHO option B plus was adopted in the Western Cape, which recommends lifelong cART 
for pregnant women regardless of CD4 count or disease stage, to further decrease the PTMCT 
failure rate.  
A recent South African study reported 56.8% of children having NNRTI resistance by bulk 
sequencing after PMTCT exposure; however, the majority of the infants received only NVP (Kuhn 
et al. 2014). In a large randomized study the addition of ZDV and 3TC for four or seven days to the 
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infants’ regimens significantly reduced drug resistance when compared to sdNVP (NVP alone – 7/8 
(88%), four days – 4/25 (17%) and seven days – 0/10 (0%)) (McIntyre et al. 2009). Data on the 
prevalence of minor DRMs after PMTCT remains limited and most studies of minor variant DRMs 
after PMTCT used allele-specific PCR targeting only a few important mutations (Rowley et al. 
2010; McMahon et al. 2013; Boltz et al. 2012). A larger global study (ACTG A5175) not only 
stressed the value of viral genotyping before therapy initiation (wherever possible), but also 
demonstrated that subtype C infected patients are at a higher risk of disease progression, 
regardless of ART (Kantor et al. 2015).  
Special precautions were taken to reduce both RT sampling bias and PCR resampling, through the 
use of random cDNA primers and partitioning the PCR assay into a few parallel reactions. We 
used random pentadecamers to reduce our RT selection bias and yielded longer cDNA fragments. 
Other researchers suggest that pentadecamer-mediated RT produces cDNA more efficiently than 
random hexamers, when used in combination with Invitrogen’s SuperScript enzyme (California, 
USA) (Stangegaard et al. 2006) and at higher concentrations (Nardon et al. 2009). Moreover, 
pentadecamers have been shown to improve assay limit of detection in quantitative RT-PCR for 
genomics studies (Ross et al. 2008). 
Cabrera et al were aware of the primer-induced RT selection biases and used three RT replicates 
to increase the number of sampled variants (Cabrera et al. 2006), while others tried to circumvent 
early primer selection bias by increasing the number of PN-PCR replicates, which they later pooled 
before nested amplification (Mavigner et al. 2009). In the present study duplicate random 
pentadecamer primed reverse transcriptions were done with low selection bias, followed by 14 PN-
PCRs. Due to selection events occurring early which result in diminished population variants, 
duplicate reactions were only pooled after pre-nesting. Alternative methods for reduced PCR 
resampling include limiting dilution PCR (Salgado et al. 2010) and single molecule emulsion PCR 
(Metzger et al. 2013). However, both of these methods are laborious, either incurring exorbitant 
reagent costs or require specialized equipment.  
More recently, random primer-ID tagging during reverse transcription has been used to allow post-
hoc correction of PCR resampling bias (Jabara et al. 2011). Using this approach, the quantity of 
variants is not calculated from the final proportion of variants (after PCR enrichment) in the 
sequenced population, but by counting the number of unique species that share the same random 
primer ID and which represents the original pre-enriched population (Jabara et al. 2011). The 
primer ID approach improved accuracy of minor variant quantification by reducing both PCR 
resampling and PCR-induced error (Zhou et al. 2015; Keys et al. 2015). However, it has been 
shown to substantially underestimate the number of variants in the original population, as it cannot 
obviate PCR bias introduced by the use of large fusion primers (Boltz et al. 2015). Moreover, the 
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primer ID technique is applicable only for patients with sufficiently high viral loads so as to allow 
sufficient cDNA recovery. As primer ID requires a highly-specific chromatographic separation of the 
cDNA and large fusion primers, the method can be technically challenging, since any downstream 
ID primer contamination would invalidate the results.  
Forty-six samples were initially included in our cohort however two thirds of the reactions failed to 
generate a specific amplicon for five of the seven nested PCR’s. This result could possibly be due 
to a number of confounding factors: the poor sensitivity of the high fidelity pre-nested PCR; the 
fragmentation of the extracted RNA during sample storage; or the generation of incomplete or 
truncated cDNA templates. When the number of variants sampled is close to the limit of assay 
detection, very few variants are selected and post sequencing analysis could overestimate the 
number of variants sampled. In these instances, many of the observed minor variant mutations are 
as a result of PCR error and recombination. To this end, samples that failed to amplify in more than 
five of the seven nested PCRs were excluded. 
Another major limitation of 454 (454 Life Sciences, Connecticut, USA) and PGM (Life 
Technologies, California, USA) sequencing is homopolymer read error (Loman et al. 2012), which 
has been associated with false positive detection of K65R in HIV-1 subtype C using the 454 
platform (454 Life Sciences, Connecticut, USA) (Varghese et al. 2010). On both the 454 (454 Life 
Sciences, Connecticut, USA) and PGM (Life Technologies, California, USA), nucleotides are 
sequentially presented to the polymerase and incorporation is measured by monitoring the 
increase in luminescence on the 454 (454 Life Sciences, Connecticut, USA) or pH increase on the 
PGM (Life Technologies, California, USA) (Marinier et al. 2015). The fold-increase in these 
parameters is translated into the number of bases incorporated, resulting in difficulty in 
distinguishing the incorporation of more than five of the same bases. The frequency of K65R in our 
study was higher in PGM (Life Technologies, California, USA) reads than MiSeq (Illumina, 
California, USA), suggesting that homopolymer read error contributed to K65R variant calling.   
Nevertheless, K65R was also present, albeit at lower frequency, in MiSeq (Illumina, California, 
USA) and clonal sequences. Previous reports have indicated that using high fidelity PCR enzymes 
could limit the proportion of K65R minor variants (Varghese et al. 2010). Despite the use of high 
fidelity PCR, K65R >0.5% was detected in all infants, which would be unexpected in a tenofovir-
naïve cohort (Recordon-Pinson et al. 2012). NVP-containing regimens have been associated with 
an increased risk of K65R detection (Brenner & Coutsinos 2009; Tang et al. 2013), though the 
mechanism has not yet been described. Overall, while HIV-1 subtype C has an increased risk of 
K65R under drug pressure (Brenner & Coutsinos 2009; Coutsinos et al. 2011), the proportion of 
these K65R mutations that occur due to in vivo rather than in vitro reverse transcription error, is 
unclear. 
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3.5 Conclusion 
Our study showed that NGS using PGM (Life Technologies, California, USA) or MiSeq (Illumina, 
California, USA), combined with a bioinformatic ‘pipeline’ could enable the detection of minor 
variant reverse transcriptase DRMs after PMTCT. The read quality was best for MiSeq (Illumina, 
California, USA), probably as it is less prone to homopolymer error, and the higher coverage 
increased the confidence of minor variant calling. As NGS platforms become more affordable they 
may prove invaluable in the investigation of infants, where antiretroviral therapy for PMTCT failed 
to prevent transmission, for the following reasons:  
 NNRTI minor variant DRMs are associated with subsequent failure on a particular regimen 
(Paredes et al. 2010; Li et al. 2012), 
 PMTCT failure of regimens relying on maternal cART may be associated with an increased 
risk of complex resistance patterns, and  
 DRM detection using NGS, in contrast to allele-specific PCR, allows for detection of all 
DRMs across a particular sequence.  
Laboratories that process PCR-enriched microbial or viral samples (such as HIV) do not require 
onsite NGS capability but could make use of commercial or academic core facilities that provide 
NGS on a fee-for-service basis. Nevertheless it is critical that a specimen which is PCR-enriched 
for NGS should be a representative sample of the source: in this study cDNA was quantified to 
confirm that the sample contained sufficient species to enable minor variant detection and 
amplification was separated in parallel PCRs to limit random PCR error. Of equal importance is the 
post-analytical processing of NGS data to correctly identify haplotypes (variants) from PCR and 
sequencing error.  
Although several published programs are freely available, they often require some programming 
capability and the integration across different bioinformatics platforms. A versatile and openly 
available bioinformatics ‘pipeline’ for processing of NGS sequences would be greatly beneficial. 
This study’s ‘pipeline’ combined the following processing and analysis functions: exclusion of low 
quality reads, correction for homopolymer errors or random sequencing error and construction of 
consensus reads and frequent haplotypes (variants). The output of the analysis performed for this 
study is available. (http://bit.ly/gvz-PMTCT-NGS). 
Online access to an open source service that performs quality control and trouble-shooting of next 
generation sequencing data would be highly valuable in providing increased access to this 
technology. The recent introduction of Seq2Res and RAMICS allows for relatively easy HIV drug 
resistance analysis from NGS data from multiple deep sequencing platforms (Wright & Travers 
2014). To our knowledge, this is one of the first widely accessible analysis pipelines for HIV-
specific NGS analyses, available online at hiv.sanbi.ac.za/tools#/seq. However, the bioinformatic 
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pipeline, used in the present study is available in the public domain at 
hyphy.org/w/index.php/Main_Page.  
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3.7 Appendix C: Supplemental figures  
 (An addendum to section 3.3.3 Nested and re-PCR)  
 
Figure 3.7.1 Concatenated nested PCR gels: The above figure depicts the results of two joined electrophoresis gel 
photographs with the excluded samples removed. This figure shows successful amplification of the 1 Kbp nested PCR 
amplicon from samples A214, A137, A144, and A157. All of these samples were positive in all seven nested PCRs, 
however, A144 shows inefficient amplification in two of its seven reactions. 
 
Figure 3.7.2 Concatenated nested PCR gels: The above figure depicts the results of three joined electrophoresis gel 
photographs with the excluded samples removed. This figure shows successful amplification of the 1 Kbp nested PCR 
amplicon from samples A158, A202 and A207. Two of these samples, A158 and A207 were positive for six of the seven 
nested PCRs while A202 shows inefficient amplification in all seven reactions. 
 
Figure 3.7.3 Concatenated nested PCR gels: The above figure depicts the results of three joined electrophoresis gel 
photographs with the excluded samples removed. This figure shows successful amplification of the 1 Kbp nested PCR 
amplicon from samples A302 and A364. Sample A302 showed inefficient amplification in three of its seven reactions 
while A364 was positive in all seven nested PCRs. 
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3.8 Published article  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The full article is available online at: 
http://www.sciencedirect.com/science/article/pii/S1386653214004223/pdfft?md5=052f63d8319134
2d7dca344443efd6b8&pid=1-s2.0-S1386653214004223-main.pdf 
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4 PCR sampling error associated with the use of fusion primers (“founder effect” 
resampling error)  
4.1 Background 
4.1.1 Founder effect on population diversity  
The founder effect described in population genetics is an evolutionary bottleneck that results in 
diminished population diversity. A typical example is when a group of migrants who are not a 
representative of their origin population, travel to a new geographical area where they settle and 
multiply (Wright 1942). The genetic diversity in the subsequent offspring population is limited 
compared to the population of origin. The same principle applies to molecular biology when a 
relative small fraction of a highly diverse sample is enriched through exponential amplification (e.g. 
PCR) and characterised in high resolution by next generation sequencing (NGS). This 
phenomenon is better known as PCR resampling error (Liu et al. 1996) and consists of biased 
priming of particular species and random sampling error of low frequency events (minor variants). 
Figure 4.1.1.1 below demonstrates the mechanics of the two PCR-enrichment associated errors 
when compared to representative sampling. 
Figure 4.1.1.1 Effect of bias on population diversity: In column one of the figure above, the starting population is 
diverse however, amplification with stringent primers diminishes the sampled diversity, post-enrichment. In column three, 
the starting population contains an equal distribution of two variants. The variant randomly selected during the first few 
enrichment cycles (yellow), is eventually over-represented in the post-amplification population.  
4.1.2 Biased priming and PCR amplification  
A fundamental principle of PCR is the ability of the designed primers to specifically amplify a 
particular target sequence. Ideally, once the forward and reverse binding sites are primed, 
exponential amplification of the DNA sequence flanked by the primers occurs, resulting in millions 
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of copies of the desired target after 35 PCR cycles. Since amplification is exponential, any early 
preference for a particular template would result in bias: In case of a good match between the 
primer and template a high proportion of primers would bind during the annealing phase and a high 
proportion of templates would be extended. In cases of mismatches a lower proportion of 
templates would be primed either due to a lower primer-template annealing temperature or due to 
inefficient extension in cases of mismatches in bases close to the primer 3’ end. Any such 
inefficient priming would result in poor efficiency of amplification during the first few cycles. Due to 
the nature of exponential amplification, any template-related difference in efficiency during early 
PCR cycles would result in a difference in template yield at the end of the PCR reaction. 
4.1.3 Random sampling error  
A second PCR enrichment-associated error resulting in misrepresentation of the original sample 
population is random. Primers randomly prime particular templates earlier than others and any 
random difference in time to initial priming and extension is amplified by exponential amplification: 
the so-called “primer resampling error” (Liu et al. 1996).  
4.1.4 Primer error and random error misrepresent the original population 
The unequal representation of particular templates is either due to biased priming or random 
resampling error is conceptually comparable to the “founder effect” described above. 
Consequentially, the proportion of minor variants at the end of a PCR reaction, as determined by 
deep sequencing, would not accurately represent the template distribution in the original sample. In 
the previous chapter (chapter 3), primer induced selection bias is partially avoided by using primers 
binding in conserved genomic areas, however, this cannot obviate bias in highly diverse viruses 
such as HIV.   
4.1.5 Fusion primers and the founder effect  
A particular scenario where this “founder effect” may be more pronounced is in the case of fusion 
primers being used to generate amplicons for NGS. Genome Sequencer (GS) Junior (454 Life 
Sciences, Connecticut, USA) amplicon sequencing requires the use of a sequencing adaptor, a 
sample-specific molecular identifier (MID) and a template-specific region. Incorporation of 
sequencing adaptors and MIDs in the primers obviates the need to ligate them after PCR, 
simplifies workflows and reduces costs. Amplicon sequencing using fusion primers is well-
established for HIV-1 drug resistance genotyping (Garcia-Diaz et al. 2013; Mohamed et al. 2014; 
Simen et al. 2014; Fisher et al. 2012). However, the primer requirements result in abnormally long 
primers with high melting temperatures (Tms).  
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During the first round of PCR amplification only the 3’ template-specific fusion primer domains bind 
to the template. After the first PCR cycle, fusion primers harbouring the 5’ MID and sequencing 
adaptor would have been incorporated into the template. Due to the higher Tm of these PCR-
generated templates, at temperatures close to the Tm of the specific primer, PCR derived 
templates from the first few rounds of amplification would be preferentially amplified compared to 
templates for which amplification initiates in subsequent cycles. Resampling is practically relevant 
as, due to the risk of primer dimer formation, high temperature cycling conditions are used for 
fusion primer PCR annealing. Any primer-template mismatches that delay amplification would 
therefore be more pronounced with fusion primers, resulting in a pronounced unequal enrichment 
or a “founder effect”. 
4.1.6 Identifying original templates with random tags before PCR enrichment  
Recently, two cDNA random primer ID approaches have enabled bioinformaticists to identify each 
sampled RNA species, compensating for PCR resampling. Both strategies reverse transcribe RNA 
with a gene-specific cDNA primer that contains a 5’ PCR primer-binding site, followed by eight to 
ten random bases that are used to identify individual cDNA species. This primer is seen in figure 
4.1.6.1 below along with the enrichment strategy. In the first strategy, an eight base random ID tag 
is used to identify a particular cDNA species. Then, PCR is used to add the sequence adaptors 
and molecular identifiers (MIDs) to the amplicon by priming the 3’ PCR primer-binding site and an 
upstream gene-specific region (Jabara et al. 2011). The second method uses a 10 random-base ID 
tag and 22-mer pre-nested PCR primers with 5’ uracils. These uracils are later digested to produce 
sticky-ends to which single-stranded sequence adaptors and MIDs are ligated. The single-stranded 
adaptor is complemented by a polymerase, forming a functional amplicon (Boltz et al. 2015). Once 
amplicons have been sequenced, sequences are condensed based on their individual IDs and a 
consensus is generated for each sampled RNA species. 
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Figure 4.1.6.1 Random base ID tag: In the Jabara method (left), cDNA synthesis uses a primer consisting of a gene-
specific region, an eight random-base ID and a PCR binding tag (3’ to 5’ direction). Each cDNA species has a unique 
tag. This primer is incorporated into the cDNA. The tagged cDNA is PCR amplified with primers complementary to the 3’ 
PCR tag and a 5’ genomic region. These PCR primers contain 5’ patient MIDs and the MiSeq adaptors. For the Boltz 
method (right), cDNA is generated with a gene-specific primer with a 10 random-base ID and a PCR binding tag (3’ to 
5’). cDNA is then amplified with 22-mer uracil-containing primers that bind to the incorporated PCR tag on the 3’ end and 
a 5’ genomic region. Uracil DNA glycosylase digests the uracil bases at the end of the incorporated primers and the 
single-stranded adaptors are ligated to the amplicon’s sticky-ends. Finally, the adaptor compliment is synthesised by a 
high fidelity polymerase.  
 
These primer ID methods allows bioinformatic correction resampling (as demonstrated in figure 
4.1.7.1 below), but have proven to be insensitive and only clinically applicable to patients 
presenting with high viral loads. Empirically, the older methods sample between 2 and 20% (Keys 
et al. 2015; Zhou et al. 2015; Brodin et al. 2015) and the newer method (Boltz et al. 2015), samples 
roughly 35% of the available RNA species. In addition, the primer ID approach induces biased 
resampling and does not always correct for PCR substitutions (Brodin et al. 2015). Curative 
alternatives, such as limiting dilution PCR (LD-PCR) and partitioned PCR (e.g.: nano-droplet 
partitioning as in digital droplet PCR (ddPCR)) as opposed to the corrective random primer ID 
sequence approach, would allow representational enrichment of the original template. 
4.1.7 Representational enrichment to overcome PCR resampling 
LD-PCR has been used for single genome amplification (Salazar-Gonzalez et al. 2008) and 
requires a predetermined cDNA copy number and cDNA dilution to a single-genome-per-PCR 
resolution. Essentially, selection bias is eliminated since there is no binding competition between 
PCR primers and numerous cDNA templates, as illustrated in figure 4.1.7.1 below. While this 
methodology efficiently eliminates the effects of PCR recombination, resampling and selection 
biasing, it proves laborious and expensive when considering the sheer number of reactions 
required.  
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Another viable alternative to LD-PCR is ddPCR. This technology diminishes the PCR founder 
effect through partitioning templates in individual nanolitre reactions which diffusion constrains 
templates and primers (as depicted in figure 4.1.7.1 below). These conditions may increase the 
efficiency of PCR in the presence of template-primer-mismatches. However, the limited nano-
reaction volumes result in early PCR plateau of templates that are primed first and amplified with 
high efficiency. Commercial ddPCR platforms offer the advantage of standardised reaction droplet 
volumes and are available from BioRad in the QX200 ddPCR system (California, USA) or the 
RainDance Technologies droplet PCR platform (Massachusetts, USA). 
Both platforms generate one nanolitre PCRs however, only the RainDance Technologies platform 
(Massachusetts, USA) accommodates a high fidelity PCR for upstream NGS sample preparations 
since the QX200 is dedicated for absolute quantification. Also common to both ddPCR platforms is 
the expensive, obligatory equipment (i.e.: RainDance Technologies RDT1000 droplet generator or 
the BioRad QX200 droplet generator) and the exorbitant cost of consumables, such as the 
disposable microfluidics cartridges. These factors limit the accessibility of the platforms in 
resource-limited settings. 
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* cDNA is indexed with a random ID tag during reverse transcription.  # em-PCR (emulsion PCR) is achievable with basic laboratory equipment 
Figure 4.1.7.1 Compensatory and curative approaches: The figure above compares conventional PCR to the compensatory and curative methods for obviating PCR 
sampling error. The random primer ID method, currently the only compensatory method, does not correct the sampling bias but post-hoc allows for sequences derived from the 
same template to be condensed into one consensus sequence. By generating a consensus, any PCR and sequencing errors can be corrected, based on the nucleotide 
prevalence at a given locus. Alternatively, a curative approach to enrichment error is nano-partitioning in minute individual reactions, each containing one template only. 
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4.1.8 Water-in-oil emulsion PCR (em-PCR) 
Partitioning PCRs into “nano-reactors” obviates not only biased priming and random sampling error 
but also PCR recombination. An inexpensive and robust means of generating minuscule, diffusion 
constrained reactions is by PCR emulsification in oil. Various methods of PCR emulsification have 
previously been published (Shao et al. 2011; Nakano et al. 2003; Hori et al. 2007), the easiest of 
which was described by Schütze and colleagues in 2011 (Schutze et al. 2011). Briefly, a 50 µl PCR is 
emulsified in three volumes of a pre-chilled oil and surfactant mixture, by vortexing the aqueous and 
oil faction for three minutes at 10 °C (achieved by placing an inexpensive Vortex-genie II (Scientific 
Industries, New York, USA) in a cold room). After enrichment, the emulsion was broken with an 
organic solvent and the DNA, recovered.  
Similar to the nano-reaction depletion phenomenon seen in ddPCR, the fento or atto-litre reactions 
generated by this emulsion PCR are also subject to depletion, possibly sooner than the larger nano-
reactions. Remedially, Nakano and colleagues proposed emulsion dissolution to replenish template-
containing droplets with empty droplets (Nakano et al. 2003). Presumably, the initial emulsified PCR 
cycles are sufficient to mutate the mismatched templates (selected and amplified as a consequence of 
partitioning) into templates that are perfectly matched to the same species of fusion primer, in 
subsequent PCR cycles. 
4.1.9 Study rationale 
While fusion primers remain a cost effective means of performing 454 NGS targeted resequencing, we 
set out to measure the founder effect induced when using these unusually long primers. We also 
applied the described em-PCR methodology to a high fidelity PCR, primed with the 454 fusion primers 
that are known to be highly selective. The em-PCR would allow us to “handicap” the best-matched 
variants (by being volume constrained and reaching PCR plateau early), while permitting the 
mismatched variants to “catch-up”. Once the template has been successfully PCR-mutated (probably 
after seven cycles), we replenish the droplets with negative droplets for efficient processivity. 
In short, we synthesised three plasmids with patient-derived HIV reverse transcriptase sequences, 
containing variable primer binding targets sequences. The plasmids were characterised by Sanger 
sequencing and each plasmid was quantified with a ddPCR. To assess the effect of early selection 
events on the relative proportion after PCR enrichment, three mixtures (of the three plasmid species) 
were made and consisted of 1%; 9% and 90% of each plasmid respectively. These mixtures were 
then PCR-amplified in triplicate, using three fusion primer sets (each including a different MID) for 
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each mixture. Thus, a total of nine primer sets with different MIDs was used. For each plasmid 
mixture, the same set of three fusion primers was used for both em-PCR and bulk or open-PCR (o-
PCR), resulting in a total of 18 reactions (nine em-PCRs and nine o-PCRs). The em-PCR and o-PCR 
products were then size selected and purified before being deep-sequenced in separate runs on the 
GS Junior platform (454 Life Sciences, Connecticut, USA). Post-sequencing, homopolymer 
sequencing error was corrected using a codon-aware sequence mapping software.      
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4.2 Methods 
The sampling strategy used in our study was to amplify three known plasmid mixtures, each with three 
fusion primer sets, through both open (o-PCR) and emulsion PCR (em-PCR). To achieve this goal, 
specific objectives had to be met. These objectives were as follows: 
 Synthesise, characterise and accurately quantify the three plasmid species that would form our 
three mixed populations. 
 Design and test GS Junior fusion primers through both o-PCR and em-PCR. 
 Optimize a high fidelity em-PCR to reduce the initial sampling bias and produce sufficient 
product to be sequenced. 
 Perform post-sequencing bioinformatic analysis to map all GS Junior reads to one of three 
plasmid-derived “reference” sequences.   
The methods that follow describe the plasmid synthesis, sequencing, quantification and the plasmid 
pooling strategy to form the three sample populations. Also described below are the fusion primer 
design, the o-PCR and em-PCR optimisation, the amplicon size selection and purification and the 
post-sequencing data analysis. 
4.2.1 Plasmids  
4.2.1.1 Ligation 
Amplicons sequenced in this study were derived from a mixture of three recombinant plasmid species. 
Each plasmid construct consisted of the pGEM®-T Easy Vector “back-bone” (Promega, Wisconsin, 
USA) and a ~930 bp, patient-derived HIV-1 subtype C, reverse transcriptase insert. These inserts 
were generated as part of another study and the associated methods can be seen in the previous 
chapter (chapter 3). Once generated, amplicons were separated in a 2% agarose gel before being 
excised and gel extracted. 150 to 250 ng of these gel purified inserts were ligated into 100 ng of the 
pGEM®-T Easy Vector (Promega, Wisconsin, USA) using in-house optimised reaction mixtures and 
conditions seen below. The ligation reaction was validated using the relevant reaction controls that 
included a ligation positive control insert and a background/no-insert control. Each reaction was 
prepared individually (i.e.: no mastermix was prepared) in a 200 µl thin-walled PCR tube and all 
thermal incubations were carried out in ABI 9700 thermocycler (Applied Biosystems, Massachusetts, 
USA), with the heat-lid activated at 105 °C. 
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Reagent       Final concentration (in 20 µl) 
1. 2 x Rapid ligation reaction buffer    1 x 
2. T4 DNA Ligase (3 U/µl) (Promega)   3 U/rxn  
3. Control DNA insert (4ng) or DNA amplicon  Various  
4. 10 µl Nuclease free water (N.F.H2O)   1 x 
5. pGEM T-Easy vector (50 ng/µl)   100 ng 
Ligation reactions were then incubated at 25 °C for 2 hrs, followed by 4 °C for 16 hrs, 75 °C for 5 min 
and an indefinite hold at 4 °C. On completion, recombinants were immediately transformed using an 
in-house optimised transformation protocol shown below. 
4.2.1.2 Culturing recombinant plasmids 
The recombinant plasmids were transformed using the following protocol, along with a transformation 
efficiency control plasmid:  
 Pre-chill 1.5 ml tubes and SOC media while thawing 250 µl JM109 chemically competent 
bacteria (Promega, Wisconsin, USA) on ice. 
 Add 5 µl of the ligation constructs to the pre-chilled tubes. 
 Add 50 µl JM109 (Promega, Wisconsin, USA) cells to each transformation tube. Mix once by 
slow up and down pipetting. 
 Incubate tubes on ice for 1 min and heat shock at exactly 42 °C for 50 sec. 
 Incubate reactions on ice for 2 min before adding 950 µl cold SOC media. 
 
The reaction was then incubated at 37 °C for 1.5 to 2 hrs with gentle shaking before being spread on 
semisolid ampicillin-selective LB media culture plates, for IPTG-X-Gal mediated blue/white colony 
selection. Single, white colonies were inoculated into 4 ml of sterile LB liquid media with 100 µg/ml 
ampicillin. After an overnight shaking incubation at 37 °C, plasmids were isolate using Promega’s 
PureYield™ Plasmid Miniprep system (Wisconsin, USA) and eluted in warm (50 °C) TE buffer. 
4.2.1.3 Quantification and genotyping recombinants 
The dsDNA BR assay kit (Life Technologies, California, USA) was used according to the 
manufacturers’ specifications to quantify the plasmid species in triplicate, on the Qubit Fluorometer 2.0 
(Life Technologies, California, USA). The Qubit (Life Technologies, California, USA) measures the 
florescence emanating from double-stranded DNA diluted in the assay buffer, which contains an 
intercalating fluorescent DNA dye. An intercalating dye assay allows for DNA quantification without 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
 126 
 
quantifying background, non-specific, co-purified agents (e.g.: salts and proteins). When using 
spectrophotometric quantification, the spectral overlap of these co-purified agents cause false, over-
quantification. The average of the three measured concentrations was used to add 150 to 250 ng of 
the purified pGEM® constructs to an in-house optimised BigDye® Direct Cycle (V3.1) sequencing 
reaction (Applied Biosystems, Massachusetts, USA), primed with standard M13 forward or reverse 
oligos.  
 Reagent      Final concentration (in 10 µl) 
1. 5 x Terminator sequencing reaction buffer  1.5 x 
2. BigDye® Terminator reaction mix   1 x 
3. M13 Fwd or Rev Primer     5 pMoles 
4. pGEM DNA construct     150 to 250 ng 
 
Sequencing PCRs were performed using the following in-house-optimised reaction conditions in a 
9700 thermocycler: 
95 °C for 10 sec 
95 °C for 5 sec 
25 x  72 °C for 4 min 
4 °C soak  
On completion, the sequencing PCR reaction was purified using an in-house-optimised BigDye® X-
terminator clean-up (Applied Biosystems, Massachusetts, USA), seen below. The SAM solution™ 
(Applied Biosystems, Massachusetts, USA) used in the purification reaction was heated to room 
temperature before use. 
 Reagent      Volume added to Mastermix  
1. SAM™ solution     49 µl 
2. X-terminator solution     11 µl 
Fifty-five microlitres of the above reaction mixture was added to each sequencing PCR in a 96 well 
plate, before the wells were sealed and the reaction, vortexed for 30 to 45 min. The purified 
sequencing PCR product was then centrifuged at 1 000 xg for 2 min to pellet the X-terminator nano-
particles and the sequencing reaction was read on an ABI Genetic Analyser 3130xL (Applied 
Biosystems, Massachusetts, USA). Chromatograms from the sequencing reactions were imported into 
Geneious (V6.0) (Biomatters, Auckland, New Zealand) and blasted against the National Centre for 
Bioinformatics Information (NCBI) nucleotide database to determine specificity (available online at: 
http://blast.ncbi.nlm.nih.gov/Blast.cgi). Three plasmid species were selected for further use (i.e.: 
P2.38, P3.32 and P4.38) based on their diversity between regions 2 559 to 2 931 (HXB2). The 
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3 015 bp plasmid copy numbers were estimated using a molecular weight calculator (available online 
at http://www.bioinformatics.org/sms2/dna_mw.html) and a copy number calculator (available online at 
http://cels.uri.edu/gsc/cndna.html). Plasmid stocks were then diluted to approximately 1 x 103 and 
1 x 102 c/µl before absolute quantification using BioRad’s QX200 (California, USA) digital droplet PCR 
system. 
4.2.1.4 Absolute quantification of recombinant plasmids 
At this stage in our study, we become aware of the Qubit’s (Life Technologies, California, USA) 
tendency to under-quantify DNA concentration due to differential intercalation of the assay dye. As we 
were already aware of the NanoDrop’s (Thermo Scientific, Massachusetts, USA) inclination to over 
quantification due to contaminant spectral overlap, we decided to quantified the plasmids using 
BioRad’s QX200 (California, USA) digital droplet real time PCR (ddPCR) system and the primers 
listed in table 4.2.1.4.1 below. Digital droplet PCR allows for accurate quantification of DNA without 
the necessity of DNA standards.  
Table 4.2.1.4.1 ddPCR absolute quantification primers  
Description Name Sequence (5’-3’) HXB2 binding  
Forward primer F3_F_RealT GGGCAACATAGAGCAAAAATAGARGA 3135 to 3160 
Reverse primer F3_R_RealT GGAGTTCATACCCCATCCAAAGAAATG 3226 to 3252 (RC) 
(RC) = Reverse complement 
The three selected plasmid species were quantified using BioRad’s EvaGreen Digital PCR SuperMix 
(California, USA) according to the manufacturer’s specifications as seen below. 
Reagent       Final concentration (in 25 µl) 
1. 2 x Bio-Rad EvaGreen SuperMix    1 x 
2. F3_F_RealT FWD Primer    100 nM 
3. F3_R_RealT REV Primer    100 nM 
4. 5 µl plasmid DNA (P2.38, P3.32 or P4.38)  Supposedly 50 and 500 copies   
5. 3 µl N.F.H2O      1x 
The mastermix of each plasmids species was made for four reactions, of which only three, technical 
replicates were quantified. A no-template control (NTC) was included with nuclease free water 
(N.F.H2O) supplementing the 20 µl reaction volume. Of each reaction mastermix, 20 µl was pipetted 
into the sample wells of the microfluidics DG8 droplet generator cartridge (figure 4.2.1.4.1). Seventy 
microliters of the EvaGreen droplet generator oil was added to each of the oil reservoirs in the DG8 
cartridge (figure 4.2.1.4.2) and the cartridge was loaded into the holder (figure 4.2.1.4.3). Once the 
droplet generator gasket was placed on the cartridge holder, the assembly was loaded into the droplet 
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generator (figure 4.2.1.4.4). (The images shown below are available online at http://www.bio-
rad.com/en-za/category/digital-pcr) 
Figure 4.2.1.4.1 Sample loading: 20 µl sample mastermix is loaded into sample 
wells of the DG8 cartridge using a multichannel pipette. Extra care is taken to 
prevent air bubbles from forming at the bottom of the loading well as this would 
hinder the embedded microfluidics from forming the emulsion droplets.  
 
 
Figure 4.2.1.4.2 Oil loading (right): 70 µl emulsion oil is loaded into 
the oil reservoir. Once again, the operator must be cautious to prevent 
air bubbles from collecting at the bottom of the wells.  
 
Figure 4.2.1.4.3 Cartridge holder assembly (left): The DG8 cartridge is 
loaded into the holder which clips closed to secure the cartridge in place before 
the rubber gasket is hooked over the edges of the cartridge holder and the 
assembly is loaded into the droplet generator (as seen in figure 4 below). 
 
Figure 4.2.1.4.4 Assembly loading (right): The assembly is loaded 
into the droplet generator and once the assembly is correctly in 
place, the green “sample loaded” light is engaged. The droplet 
generator is closed and the microfluidics are engaged.  
 
 
Figure 4.2.1.4.5 Droplet generation (left): By pressurising the air in 
the oil and sample wells, the droplet generator creates 20 000 one 
nanolitre PCR reaction, as depicted in figure 5.  
 
The droplet generator then uses the microfluidics embedded in the DG8 cartridge to generate ~20 000 
droplet reactions (figure 4.2.1.4.5) which are then carefully loaded into an Eppendorf (Hamburg, 
Germany), twin-tech, semi-skirted, 96 well plate. Once heat sealed with pierceable foil, these samples 
are amplified through 40 cycles of PCR and a final signal stabilisation step of 90 °C for 5 min. 
Thermocycling conditions were as follows: 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
 129 
 
95 °C for 5 min    
95 °C for 30 sec 
  60 °C for 30 sec 
4 °C for 5 min 
90 °C for 5 min (signal stabilisation) 
4 °C soak                      
On completion, the twin-tech plate was loaded into the droplet reader machine, making sure to clamp 
the plate down correctly with the plate holder lid (figure 4.2.1.4.6 above). Data acquisition on the 
droplet reader (BioRad, California, USA) requires that the wells are defined with respect to the 
expected florescence (i.e.: EvaGreen, VIC or FAM probe based detection) in the graphical user 
interface software, QuantaSoft (BioRad, California, USA). The software also allows the user to define 
the contents of the experiment in each well.  
The droplet reader reads as many droplets as possible in a similar manner to a flowcytometer. 
Positive discrimination is based on the difference in the amount of observed florescence between 
droplets with or without an amplified PCR target. As is the case with EvaGreen reactions, “negative 
droplet” exhibit baseline florescence, comparable to that observed in no-template controls (NTCs), 
while “positive droplets” display an approximate three to four-fold increased florescence.  
When the samples are analysed or “read” on the droplet reader, two distinct populations are visible, 
provided that the reaction was not over saturated with amplifiable template (i.e.: all droplets would be 
positive). In the resultant 1 dimensional data plot, positive droplets display high florescence amplitude 
readings and negative droplets show base-line florescent. QuantaSoft (BioRad, California, USA) 
analysis software employs Poisson probability statistics to estimate the number of target copies in the 
starting 20µl reaction, using the ratio of positive to negative droplets and the total number of droplets 
sampled.  
The results of the absolute quantification experiments and the employed dilution factors were used to 
calculate and correct the concentrations of the three plasmid species stocks. These three plasmid 
species were reconstituted at a corrected 2x 104 c/µl in elution buffer before being pooled into three 
plasmid mixtures each consisting of different proportions of the individual plasmids.  
 
40 x 
Figure 4.2.1.4.6 Sample reading: After 
amplification, the plate is loaded into the 
droplet reader and the probe-guide cover-
plate is secured in place.  
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4.2.1.5 Plasmid pooling  
Employing the absolute quantification results, the three plasmid species stocks were diluted 
appropriately and combined in the mixtures tabulated in the results section below (table 4.3.6.1). 
These plasmid mixtures were constituted at 10-fold the required concentration and formed the 
synthetic mixture which would be PCR amplified using the fusion primers which include molecular 
identifiers (MIDs) and GS Junior sequencing adaptors. 
4.2.2 Fusion primers 
GS fusion primers were based on the previously published Varghese et al. (2010) primer sets, to 
amplify a 417 bp region of HIV-1 (Varghese et al. 2010). These Varghese primers were subtype C-
specific with sequencing adaptors and MIDs for the FLX Titanium 454 platform (454 Life Sciences, 
Connecticut, USA), while ours contained adaptors and MIDs for the GS Junior sequencing platform 
(454 Life Sciences, Connecticut, USA), and the target-specific regions were chosen based on the 
South African subtype C consensus sequence. The fusion primer gene-specific regions were a perfect 
match for plasmid 2.38; had one forward and one reverse mismatch to plasmid 3.32; and three 
forward mismatches to plasmid 4.38 (the most fatal of which was in position -3). The primer specifics 
can be seen in table 4.2.2.1 below, while the primer schematics are listed in section 4.3.8 of the 
results section.  
Table 4.2.2.1 Modified GS Junior fusion primer specifics: Underlined text notates a primer to template mismatch and 
bolded text indicates a lethal mismatch. The * notates an annealing temperature calculated using the neighbour joining 
method available online at https://www.exiqon.com/ls/Pages/ExiqonTMPredictionTool.aspx. 
4.2.3 Fusion primer PCR optimisation 
The fusion primer PCR was initially tested in the presence of Epicentre’s MasterAmp PCR enhancer 
containing Betaine (Wisconsin, USA) which reduced the occurrence of primer dimers, when compared 
to the native high fidelity PCR, with and without added dimethyl sulfoxide (DMSO). The assay was 
further optimised with respect to primer and magnesium chloride (MgCl2) concentration, and finally, 
annealing temperature. These steps dictated an optimised reaction using 1x MasterAmp PCR 
enhancer (Epicentre, Wisconsin, USA), a final MgCl2 and fusion primer concentration of 2.25 mM and 
MID to plasmid mix matching 
Primer to template matching 
Origin FWD Sequence (Tm* 56-58°C) REV Sequence (Tm* 59°C) 
MIDs Plasmid mix Primer TGCACAYTAAATTTTCCAATTAG ACTAGGTATGGTGAATGCAG 
13, 14, 60 90%P2, 9%P3, 1%P4 (MIX1) Plasmid 2 TGCACAYTAAATTTTCCAATTAG ACTAGGTATGGTGAATGCAS 
5, 7, 20 90%P3, 9%P4, 1%P2 (MIX2) Plasmid 3 TGCACAYTGAATTTTCCAATTAG ACTAGGTATGCTGAATGCAG 
10, 17, 24 90%P4, 9%P2, 1%P3 (MIX3) Plasmid 4 TGCACAYTGAATTTCCCAATAAG ACTAGGTATGGTGAATGCAG 
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100 nM respectively, and an annealing temperature of 55 °C. The following gel figures were used as 
end-point evaluation of the efficacy of the optimisation steps implemented. As described in the 
methods, the fusion primer PCR was optimised with regards to PCR additives, MgCl2 and primer 
concentration and annealing temperature.  
4.2.3.1 PCR additives 
The three primer species were chosen as optimisation candidates as they represent the three fusion 
primer PCR outcomes observed in the standard reaction:  
 MID 3 fusion primers produced a specific amplicon without any dimer. 
 MID 13 efficiently produced both a specific product and a primer dimer. 
 MID 20 efficiently produced a sequence amplicon but less efficiently produces a primer dimer. 
Figure 4.2.3.1.1 below depicts the effect of various PCR additives on the fusion-primer-initiated 
amplicon production. 
 
 
 
 
 
Figure 4.2.3.1.1 PCR additives DMSO and betaine: In the gel figure above, the first row shows MID fusion primer set used 
in the reaction while the second, the reaction additives: STD notates the native reaction; DMSO notates a reaction with 1 mM 
DMSO (final conc.); Beta labels a reaction with added MasterAmp betaine-containing PCR enhancer; and D+B labels 
reactions with both MasterAmp and DMSO. The addition of DMSO biased the reaction towards primer dimerization, evident 
by the brighter bands visible at ~120 bp, when compared to the standard reaction. 
 
Conversely, the addition of the Betaine-containing PCR enhancer biased the reactions towards the 
sequence amplicon in reactions with both dimers and amplicons (MID 20 and MID 3) and improved 
amplicon production in reactions without dimer (MID 3). The addition of both the PCR enhancer and 
DMSO reduced the occurrences of primer dimers at the expense of specific amplicon production. 
These results warranted the use of the PCR enhancer without the addition of DMSO. 
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4.2.3.2 MgCl2 concentration optimisation  
MID 13 was selected for MgCl2 optimisation as it gave the best indication as to the reactions tendency 
towards dimerization. Figure 4.2.3.2.1 below displays the results of the MgCl2 titration reactions. While 
the higher concentrations of MgCl2 resulted in efficient amplicon production (lanes eight to 10), it also 
favoured the production of non-specific products, such as primer dimers, seen at aproximately 120 bp. 
For this purpose, a final MgCl2 concentration of 2.25 mM was employed dispite the possible bias 
towards non-specific products, which we would exclude through amplicon size selection. 
 
 
 
 
 
Figure 4.2.3.2.1 MgCl2 optimisation with MID 13: MgCl2 was titrated at 1.75 mM (lanes one to three), 2.0 mM (lanes four to 
six) and 2.5 mM (lanes eight to 10) in both o-PCR and em-PCR as depicted above. At the time of optimisation, we refered to 
open PCRs as “bulk PCR” and labled these reactions as “B+” while “E+”and “E-“ notated positive and NTC emulsion 
reactions, respectively. 
4.2.3.3 Fusion primer concentration optimisation 
The manufacturer-specified primer concentration for the Expand High FidelityPLUS PCR system ranges 
from 200 to 400 nM (Roche Diagnostics, Basel, Switzerland). We attempted to reduce primer dimer 
formations by titrating fusion primers to lower concentrations, as seen in figure 4.2.3.3.1 below. The 
gel figure below depicts the results of a range of NTC reactions amplified with 200, 100 and 50 nM 
primer concentrations. 
 
 
 
 
 
 
Figure 4.2.3.3.1 Fusion primer titration: MIDs 20 and 21 were used to test the effect of primer concentration on dimer 
formation. Since the fusion primers were ~65 bases in length, faint band visible at almost twice this size were presumed to be 
a dimer. In the 200 nM fusion primer concentration reaction (MID 20), a primer dimer is seen at ~130 bp (lane two from the 
left), but is absent in the 100 nM reaction. 
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For our assay, a final primer concentration of 100 nM was used since it was the highest tested 
concentration that did not produce a dimer in the absence of amplifiable template. While MID 21 
showed no dimerization at all primer concentrations, it was not used for further experiments as it failed 
to amplify plasmid template in both open and emulsion PCRs. MID 20 dimerized at 200 nM but not at 
100 nM and was used for further experiments. 
4.2.3.4 Fusion primer annealing temperature optimisation 
The nearest-neighbour Tm prediction method was used to calculate the appropriate annealing 
temperature for the template-specific region of the fusion primers. The optimum annealing 
temperature however, had to be empirically determined. Gel figure 4.2.3.4.1 below depicts a sample of 
the optimisation assay wherein primers were annealed at five and ten degrees below their 65 °C 
melting temperature however, the full range of fusion primers were tested. 
 
 
 
 
 
 
Figure 4.2.3.4.1 Fusion primer Tm optimisation: Using MIDs 5, 7, 8 and 13, the assay annealing temperature was broadly 
optimised at five and ten degrees below the calculated melting temperature of the fusion primer. Brighter bands are observed 
when using the 55 °C annealing temperature which suggests better efficiency with the less stringent annealing parameters.  
The figure above demonstrated more efficient amplification using an annealing temperature 10 °C 
below the primer melting temperature. A lower annealing temperature is associated with less stringent 
primer binding, a higher primer to template mismatch tolerance and thus a lower selection bias. To this 
end, an annealing temperature of 55 °C was used for further experiments as it displays more efficient 
amplification and a better mismatch tolerance.  
4.2.3.5 Additional em-PCR optimisation 
In preliminary experiments using the em-PCR as described by Schütze (Schutze et al. 2011), 
amplification for the full reaction duration resulted in poor product yield due to reagent depletion in 
droplets that contain both primers and amplifiable template, as is visible in the figure 4.2.3.5.1 below. 
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Both o-PCRs and em-PCRs were allowed to complete 50 cycles, and on completion, the emulsion 
reaction was broken through centrifugation and separated in a 2% agarose gel, alongside the o-PCR. 
Remedially, emulsification was limited to the first seven cycles, as PCR sampling bias is probably 
most affected by early PCR events, before PCR mediated template mutagenesis (PCR template is 
predominantly primer derived after a few cycles). After these emulsified cycles, the emulsion was 
broken through centrifugation, to replenish substrate-depleted, template-containing droplets with 
unamplified, negative droplet substrates. In a study conducted by Nakano in 2003, 13 emulsified 
cycles were used to saturate larger emulsion droplets before the emulsion was broken to replenish 
PCR substrates (Nakano et al. 2003).  
Figure 4.2.3.5.1 Inefficient emulsified amplification: The gel figure 
to the left displays the o-PCR NTC in lane one on the left, followed by 
triplicate positive reactions, displaying a 465 bp amplicon in lanes two 
to four. The em-PCR products can be seen to the right of the o-PCRs 
(after the 100 bp marker) and loaded in the same format. In lanes 
seven to nine, the em-PCRs display faint amplicons and poor 
amplification efficiency. 
 
Our final em-PCR reaction consisted of an initial seven cycles of emulsified PCR, allowing initial 
partitioned amplification (to prevent competition with other templates) in diffusion constrained droplets 
(to enhance the efficiency of amplification). These initial cycles were expected to facilitate PCR-
mediated mutagenesis of the template to match the fusion primer. After seven cycles, the large 
majority of PCR product would be expected to be primer derived, and after this, to counteract the 
reaction depletion in the minute vesicles, the emulsion was broken through centrifugation and the PCR 
cycling then continued for an additional 43 PCR cycles. Gel figure 4.2.3.5.2 below depicts the fully 
optimised fusion primer PCR executed on the three, previously-described plasmid mixtures, 
implementing the replenished em-PCR methods. 
 
Figure 4.2.3.5.2 Optimised fusion primer open and em-PCR: Successful amplification of the three plasmid mixtures is 
seen above. Both the em-PCRs and the o-PCRs generated the approximately 465 bp sequence amplicon while faint, primer 
dimers (roughly 120 bp) are seen in the NTCs and the em-PCR for plasmid mixture 3. 
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4.2.4  Amplicon generation 
4.2.4.1 Reaction mixture 
Each of the plasmid mixtures was amplified in triplicate through both em-PCR and o-PCR, using 
fusion primers with a different MID for each of the replicates. Prior to each experiment, emulsion oil 
was prepared, vortexed and stored on ice until required. The emulsion oil consisted of 73% Tegosoft 
DEC (Evonik Industries, Essen, Germany), 23% mineral oil (Sigma Aldrich, Missouri, USA) and 7% 
Abil WE09 (Evonik Industries, Essen, Germany) in a final volume of 200 µl, of which 150 µl was used 
per reaction. The PCR mastermix was prepared using the Roche Diagnostics’ Expand High 
FidelityPLUS (Basel, Switzerland) reagents at the concentration indicated below: 
 Reagent       Final concentration (in 50 µl) 
1. 5 x Reaction buffer     1x 
2. dNTP Mix (10 mM of each)    200 µM 
3. MgCl2       2.25 mM 
4. Expand HiFi Plus Polymerase     2.625 U/rxn 
5. 5 µl Plasmid mixture     2 000 c/rxn 
6. 22 µl Buffer EB (Qiagen, Netherlands)  1 x 
 
To reduce the occurrence of primer dimers, forward and reverse fusion primers were pipetted into 
separate areas of the reaction tubes and were only combined when the reaction mastermix was 
added. In addition, fusion primers were titrated to 100 nM as opposed to the manufacturer prescribed 
200 nM final concentration. As indicated by the reaction recipe above, each plasmid mixture was 
added to its respective mastermix in the DNA loading area however, this only occurred once the o-
PCR and em-PCR no-template controls (NTCs) had been removed. Elution buffer was added to the 
NTC reactions in the DNA loading area, before the plasmid mixtures were opened, to control for 
possible environmental contamination.  
4.2.4.2 o-PCR preparation 
Once the plasmid mixture had been added to the reaction mix, the “spiked” mastermix was added to 
the already aliquotted MIDs fusion primers to result in a 50 µl reaction volume. For the o-PCRs, 
reactions were prepared in 200 µl, thin walled PCR tubes while em-PCRs were first prepared in 
1.5 ml, low DNA-binding Eppendorf (Hamburg, Germany) tubes which were later aliquotted into two 
100 µl PCRs, once emulsified. 
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4.2.4.3 em-PCR preparation  
For emulsification, 150 µl of the chilled emulsion oil was layered above the now 50 µl PCR, resulting in 
a 3:1 oil to aqueous-PCR ratio. These 1.5 ml tubes were then pulse vortexed five times using a 
Heidolph REAX top vortex mixer (Schwabach, Germany) at maximum speed, to generate an opaque 
emulsion. The emulsified reaction was distributed into two 100 µl reactions in single 200 µl, thin walled 
PCR tubes. All the prepared reactions were placed into a Veriti thermocycler (Applied Biosystems, 
Massachusetts, USA) and thermo-cycled using the following conditions:  
94 °C for 2 min 
94 °C for 30 sec 
7 x  55 °C for 30 sec 
72 °C for 30 sec 
72 °C for 10 min 
At the completion of the first seven cycles, the temperature is maintained at 72 °C for 10 min, allowing 
sufficient time for all reactions to be taken out of the cycler and placed on ice, while the em-PCRs are 
centrifuged for 2 min at 16300 xg. This centrifugation step breaks the emulsions droplets, replenishing 
the depleted template-containing droplets with the reaction mixture contained in droplets that 
contained no amplifiable template. The reactions were then returned to the thermocycler and the 
remainder of the 72 °C incubation was skipped. The following conditions were used for the remaining 
cycling: 
94 °C for 30 sec 
43 x  55 °C for 30 sec 
72 °C for 30 sec 
72 °C for 7 min 
4 °C soak  
Open-PCRs were stored at 4 °C until post-amplification clean-up while the em-PCRs were cleaned 
using isobutanol (Sigma Aldrich, Missouri, USA) and the following amplicon recovery protocol: 100 µl 
isobutanol was added to each of the 100 µl emulsion reactions before vortexing. Once homogenous, 
reactions were centrifuged at 10 000 xg for 1min to separate the aqueous and oil factions. In a well-lit 
post-amplification area, the aqueous faction was pipette out from underneath the oil faction using an 
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extra length, 10 µl filter pipette tips (QSP, California, USA) and the appropriate pipette. Great care was 
taken not to aspirate the emulsion oil during the amplicon recovery process wherein the two em-PCR 
aliquots were combined to form an approximately 38 µl aqueous faction.   
4.2.4.4 Gel electrophoresis  
Once cleaned, 1 µl of both the em-PCR amplicons and the un-cleaned o-PCR amplicons were 
separated on a 2% agarose gel stained with 1x GR Green nucleic acid stain (Labgene, Châtel-Saint-
Denis, Switzerland), along with a 100 bp DNA ladder (Lonza, Basel, Switzerland). These gels were 
electrophoresis at 80 V for 50 min and were photographed on completion.  
4.2.4.5 Additional precautions taken  
 Surfaces and pipettes were flushed with 20% household bleach (0.7% Sodium Hypochlorite) and 
70% ethanol before and after each reaction run. 
 Once PCRs were completed, reaction NTCs were separated from positive reaction to avoid any 
possible post-amplification contamination. These NTCs were only used later for the reaction 
validation through nested PCR. 
 Each plasmid mixture was processed on a different day and each batch of em-PCR amplicons 
were recovered in a different post-amplification area to prevent reaction cross contamination.  
 A different set of tips and pipettes were used in every post-amplification clean-up areas.  
 PCR efficiency is influenced not only by the template-specific sequence but by the whole fusion 
primer (based on our own empiric data and published literature). Therefore for comparison, the 
same primer set – identical primers with identical MIDs were used for the em-PCR and o-PCR 
reactions to amplify the same plasmid mixtures. Hence em-PCR and o-PCR sequencing were 
performed in separate 454 sequencing runs.  
 Post-amplification em-PCR and o-PCRs were never opened in the same area since cross 
contamination between these amplicon batches would invalidate the entire experiment. 
 A fourth (additional) MID fusion primer set was included in every run to substitute any failed 
reactions in a specific run. 
4.2.5  Amplicon and reaction validation 
While NTCs yielding no specific band would be considered uncontaminated, for our purposes, very 
low copy number contamination would resemble a minor variant in downstream GS Junior 
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sequencing. For this purpose, in our experiment, a reaction was only considered valid if the NTCs 
remained un-amplified following a nested PCR. In addition, 454’s sequence-by-synthesis technology 
dictates that amplicons are only considered viable for sequencing if they are amplifiable. Considering 
the above criteria, amplicons and NTCs were validated using a nested PCR amplifying a 165 bp 
region within the proposed pre-nested sequence amplicon. Nested or validation PCRs were prepared 
using Promega’s GoTaq® HotSart PCR system (Wisconsin, USA) with the primers listed in the table 
4.2.5.1 below and the reaction protocol that follows. 
Table 4.2.5.1 Validation PCR primers 
 Description Name Sequence (5’-3’) HXB2 binding  
Forward primer AK11 GTACCAGTAAAATTAAARCCAG 2571 to 2592 
Reverse primer 30.PROT.1 GCAAATACTGGAGTATTGTATGGATTTTCAGG 2734 to 2706 (RC) 
                (RC) = Reverse complement 
 
GoTaq® HotSart (Promega, Wisconsin, USA) validation PCRs were prepared using the listed reagents 
at their described concentration in a final reaction volume of 50 µl. 
Reagent        Final concentration (in 50 µl) 
1. 5 x Reaction buffer     1 x 
2. AK11 FWD Primer     200 nM 
3. 30.PROT.1 REV Primer    200 nM 
4. dNTP Mix (10mM of each)    200 µM 
5. MgCl2       2.5 mM 
6. GoTaq® HotStart DNA Polymerase   0.625 U/rxn 
7. 0.5 µl Pre-nested amplicon / NTC   Unknown 
8. 31.25 µl N.F.H2O     1 x 
The following thermocycling conditions were used on an Applied Biosystems 9700 thermocycler 
(Massachusetts, USA). On completion, products were once again separated on a 2% agarose gel as 
previously described. 
95 °C for 2 min    
95 °C for 30 sec 
35 x  50 °C for 30 sec 
72 °C for 30 sec 
72 °C for 5 min 
4 °C soak 
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4.2.6 Amplicon size selection and purification 
Once individual runs were validated, amplicons were size selected using Invitrogen’s E-Gels 
SizeSelect 2% system (California, USA) and recovered in nuclease-free water. Due to the large 
volumes required to effectively recover the amplicons from the E-Gel, size selected products were 
concentrated through in-house optimised ethanol precipitation described below. To prevent cross 
contamination, em-PCRs and o-PCRs were size selected and precipitated on separate days and in 
separate laboratory areas. Precipitated amplicons were resuspended in 25 µl elution buffer before 
being spectrophotometrically quantified and sent to the Institute for Microbial Biotechnology and 
Metagenomics (IMBM) at the University of the Western Cape (UWC) where they were prepared for 
GS Junior (454 Life Sciences, Connecticut, USA) sequencing.  
4.2.6.1 Ethanol precipitation of size selected amplicons 
Freshly prepared pH 5.5 sodium acetate was added to each sample to a 0.3 molarity, along with 20 µg 
molecular grade glycogen (Roche Diagnostics, Basel, Switzerland). Samples were briefly vortexed 
and maintained on wet ice before the addition of two to three volumes of ice cold 95% GR grade 
ethanol (Sigma Aldrich, Missouri, USA). After mixing by inversion, the DNA was pelleted at 23 100 xg 
for 20 min in a 4 °C centrifuge. Once completed, the supernatant was discarded revealing a clear, 
glossy DNA pellet that was then washed with ice cold 80% GR grade ethanol. The DNA was again 
pelleted at 20 000xg for 15 minutes before the supernatant was discarded and the pellet, resuspended 
in 25 µl warm elution buffer.  
4.2.7 GS Junior library preparation 
Once purified, amplicons sets were sent to the Institute for Molecular Biology and Metagenomics for 
GS Junior (454 Life Sciences, Connecticut, USA) library preparation and sequencing. Briefly, 
amplicons were quantified using the PicoGreen intercalating dye assay according to the 
manufacturer’s specifications, before equimolar pooling. For enrichment and deep sequencing, the GS 
Junior Titanium emPCR Lib-A version two kit was used according to the manufacturers’ specifications 
(Roche Diagnostics, Basel, Switzerland).   
4.2.8 Bioinformatic analysis 
When sequencing was completed, the GS junior data was available in standard flowgram format (.sff) 
which was sent to our collaborators at the South African National Bioinformatics Institute (SANBI) for 
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analysis. Also provided to the bioinformaticist was the M13 sequencing results of the three plasmid 
species comprising the various plasmid mixtures. Once de-multiplexed by MID barcodes, our 
collaborators (doctors Simon Travers and Imogen Wright) mapped the GS Junior reads using 
RAMICS, a codon-aware sequence mapping tool (available online at: 
http://hiv.sanbi.ac.za/tools#/ramics). For each plasmid mixture, the MID reads were summed together 
and the number of reads mapping to the each of the three species contained in the mixture, was 
tabulated.     
4.2.9 Statistical analysis  
To gauge significant differences in sampling error, a binomial probability test was conducted using R. 
(version 3.1.0.), available online at: http://www.R-project.org (Gentleman & Ihaka 1997).   
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4.3 Results  
4.3.1 Recombinant plasmid synthesis 
Successful recombination and transformation was validated by the presence of white and blue 
colonies on the LB agar plates post overnight 37 °C incubation and by the expected outcomes of the 
ligation and transformation controls. The successful growth of cultures inoculated with single colonies 
again validated effective transformation through by observing ampicillin resistance.  
4.3.2 Recombinant sequencing  
Pair-wise-aligned forward and reverse M13 sequences confirmed the presence of the ligated 
amplicons in the three recombinants, previously validated by the observed white colonies on culture 
plates. The contiguous sequences can be seen in Appendix D.  
4.3.3 Absolute quantification of plasmid 2.38 
Figures 4.3.3.1 and 4.3.3.2 below depict the results of the ddPCR quantification of the plasmid 2.38 
using the F3 primers and the QuantaSoft (BioRad, California, USA) analysis software. The scatter plot 
seen below (figure 4.3.3.1) is referred to as a one dimensional data plot (or a 1D plot) and depicts the 
observed fluorescence amplitude in relation to the number of ddPCR droplets read. QuantaSoft 
(BioRad, California, USA) automatically distinguishes between positive and negative droplets based 
on the varied fluorescence amplitude units (FAU) seen between these two populations. For the 
purpose of this experiment, a user-defined threshold of 7 107 FAU was used to distinguish positivity in 
all samples.  
 
 
Figure 4.3.3.1 Plasmid 2.38 1D data plot: The 1D plot to 
the left displays the positive droplets population (blue dots) 
at approximately 18 000 FAU and the negative droplets 
population (black dots) at 5 000 FAU, separated by the 
7 107 FAU user-define threshold. The first three columns 
correspond to the 500 copies input and the last three, the 50 
copies input reactions.  
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In figure 4.3.3.1 above, the greatly diminished negative population seen in the 500 copies input 
reactions is indicative of an oversaturated ddPCR. Similar to conventional quantitative PCR (qPCR), 
oversaturation results in an inaccurate starting copy number estimation. The bar graph in figure 
4.3.3.2 below displays the absolute count of positive and negative droplets in relation to the total 
number droplets, as sampled in the replicates of the plasmid 2.38 ddPCR experiments.  
 
 
 
 
 
 
Figure 4.3.3.2 Plasmid 2.38 positivity count: The figure above displays the absolute number of positive and negative 
droplets in relation to the total number of droplets sampled for each reaction. Reactions containing an estimated 500 copies 
displayed a high ratio of positive to negative droplets while the 50 copy input reactions showed a 1:2.6 ratio. Also, 50 copy 
input reactions triplicates show good agreement. 
In figure 4.3.3.2 above, the first nine bars on the left indicate the oversaturated 500 copies input, 
ddPCR triplicates with a high positive to negative ratio. The nine bars on the left correspond to the 50 
copies input reaction triplicates and depict an approximate 2.6:1 ratio of negative to positive reaction 
droplets. For accurate Poisson statistics a lower ratio of positive to negative droplets is favourable 
since, in oversaturated reaction with high population rations, one droplet may contain more than one 
template plasmid copy. 
4.3.4 Absolute quantification of plasmid 3.32 
The following figures (4.3.4.1 and 4.3.4.2) depict the results of the ddPCR quantification of the plasmid 
3.32 using the F3 primers and the QuantaSoft analysis software (BioRad, California, USA). The 1D 
plot below (figure 4.3.4.1) indicates a similar trend as observed in the plasmid 2.32 ddPCR, above. 
Oversaturation is once again depicted in the 500 copies input reactions (columns C01, C02 and C03), 
displaying a dense positive droplet population at approximately 18 000 FAU and a sparse negative 
population at 5 000 FAU.  
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Figure 4.3.4.1 Plasmid 3.32 1D data plot: Figure 4.3.4.1 
displays the 1D data plot for plasmid 3.32 ddPCR triplicates. 
500 copies input reactions are in columns C01 to C03 and 50 
copies input reactions, in columns D01 to D03. Both sets of 
triplicates display both positive (blue dots at ~18 000 FAU) and 
negative droplet (black dots at 5 000 FAU) populations, 
separated by the user-defined positivity threshold (pink line at 
7 107 FAU). 
 
 
Similarly to plasmid 2.38 ddPCR, plasmid 3.32’s bar graph in figure 4.3.4.2 below depicts the number 
of positive and negative droplets in both sets of triplicate reactions (i.e.: 500 and 50 copies input), in 
relation to the total number of droplets sampled.  
 
 
 
 
 
 
Figure 4.3.4.2 Plasmid 3.32 positivity count: Figure 4.3.4.2 displays the total number of positive, negative and the total 
number of droplets sampled for each reaction. Reactions containing an estimated 500 copies displayed a high ratio of 
positive to negative droplets while the 50 copy input reactions showed a 1:3.8 ratio. Once again, the reactions triplicates 
show good agreement. 
In figure 4.3.4.2 above, the nine bars on the left correspond to the three oversaturated 500 copies 
input ddPCRs, the nine bars on the right display an approximate 3.8:1 negative to positive reaction 
droplet ratio for the 50 copies input reactions. 
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4.3.5 Absolute quantification of plasmid 3.32 
The following figures (4.3.5.1 and 4.3.5.2) depict the results of the ddPCR quantification of plasmid 
4.38 using the F3 primers and the QuantaSoft analysis software (BioRad, California, USA). A similar 
trend was observed in plasmid 4.38 reactions as in the other two ddPCRs.  
 
Figure 4.3.5.1 Plasmid 4.38 1D data plot: The 1D plot 
depicts a large positive population (blue dots) in relation to the 
negative droplet population (black dots) in the 500 copies input 
reactions (columns E01 to E03) and the converse in the 50 
copies input reaction (F01 to F03). The 500 copies input 
reactions are however not oversaturated, as a sizable negative 
population is clearly visible at 5 000 FAU, while positive 
droplets are seen at roughly 18 000 FAU, and are separated 
by the user defined threshold at 7 107 FAU.  
 
 
The “raining effect” observed in ddPCR indicates the presence of weakly positive droplets, resulting 
from an inefficient PCR. This inefficiency is possibly due to poor primer-to-template matching or, as in 
SYBR green based ddPCRs such as this one, primer dimers. This raining effect is more evident in the 
case of plasmid 4.38 ddPCRs than in the previous assays since the forward primer used in this 
reaction has a -2 mismatch to the plasmid, at the primer’s 5’ end. In this instance, poorly amplified 
droplets may result in a false copy number estimation since positivity is determined by a droplet’s FAU 
in relation to the threshold and not by the detection of an unquenched fluorophore. Nevertheless, 
using the arbitrary 7 107 FAU threshold, the figure 4.3.5.2 below depicts the number of positive and 
negative droplets in both batches of triplicates (i.e.: 500 and 50 copies input), in relation to the total 
number of droplets sampled. 
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Figure 4.3.5.2 Plasmid 4.38 positivity count: Figure 4.3.5.2 above displays the number of positive, negative and the total 
number of droplets sampled for each of the triplicate ddPCRs. Reactions containing an estimated 500 copies displayed a 
high ratio of positive to negative droplets (approximately 1:0.105) while the 50 copy input reactions showed a 1:7.56 ratio. 
The reactions triplicates show good agreement. 
Considering the absolute quantification of plasmid species 4.38 represented in figure 4.3.5.2: the nine 
bars on the left are indicative of nearly saturated ddPCRs while the nine on the right display a 7.6:1 
negative to positive droplet ration.  
4.3.6 Summation of ddPCR data 
The ratio of positive to negative droplets derived from the above assays, along with the total number of 
droplets sampled, were used to calculate the probable starting reaction copy number displayed in 
table 4.3.6.1 below. The Poisson probability model is capable of estimating the initial concentration 
when considering a high ratio of positive to negative events. The inference is however more accurate 
with middle to low ratios, as there is a lower probability of two positive events occurring at one unit of 
measurement (e.g.: two plasmids in one droplet). Aware of the limitations of copy number estimating 
when over saturated, the higher dilutions data (50 copies input) was used to calculate the inferred 
plasmid stock concentration.  
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Table 4.3.6.1 Absolute quantification of plasmid species: Table 4.3.6.1 below displays the expected reaction 
concentrations (column two) derived by dividing the input copy number by the total ddPCR volume (rounded to the second 
decimal). The Poisson probability statistics results in column six shows the calculated reaction concentration. The average 
copy number of the 50 copies input (2.5 c/µl) reaction triplicates was used to redefine the concentration of the plasmid 
stocks. 
Plasmid 
species 
Expected Conc. 
(copies/µl) 
Replicate 
Positive 
droplets 
Negative 
droplets  
Calculated 
Conc. 
(copies/µl) 
P2.38 
25 
1 13766 73 6107 
2 15550 100 5940 
3 16694 106 5960 
Averages 15337 93 6002.33 
2.5 
1 3970 10512 377 
2 4229 11083 380 
3 4200 10795 387 
Averages 4133 10797 381.33 
P3.32 
25 
1 14716 32 7220 
2 14834 32 7220 
3 14783 35 7120 
Averages 14778 33 7186.67 
25 
1 3153 11791 279 
2 3186 12038 276 
3 2864 11275 266 
Averages 3068 11701 273.67 
P4.38 
25 
1 13577 1460 2740 
2 14096 1436 2800 
3 13381 1393 2780 
Averages 13685 1430 2773.33 
2.5 
1 1809 13356 149 
2 1737 13421 143 
3 1785 13500 146 
Averages 1777 13426 146.00 
 
By substituting the assayed concentrations, the sample volume (5 µl) and the reaction volume (20 µl) 
into the formula: Conc. stock = [(Conc. assayed) x (Vol. assayed)] ÷ (Vol. stock), we were able to determine the 
correct 1x 101 plasmid stock concentration as shown below. 
For plasmid 2.38: Conc. stock = [(381.33 c/µl) x (20 µl)] ÷ (5 µl); ∴ Conc. stock = 1525.32 c/µl 
For plasmid 3.32: Conc. stock = [(273.67 c/µl) x (20 µl)] ÷ (5 µl); ∴ Conc. stock = 1094.68 c/µl 
For plasmid 4.38: Conc. stock = [(146 c/µl) x (20 µl)] ÷ (5 µl); ∴ Conc. stock = 584 c/µl 
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Multiplying the corrected concentration by 100 allowed us to extrapolate the concentration of the 1x103 
plasmid stocks, which were diluted to a concentration of 2x104c/µl in a 100µl final volume as indicated 
in table 4.3.6.2 below.  
Table 4.3.6.2 Copy number correction by dilution: Table 4.3.6.2 below shows the estimated copy number of each of the 
plasmid stocks and the dilutions employed to correct the stock copy numbers. 
 
  
        
c/µl=copies/microlitre  
The corrected plasmid stocks were used to construct three, synthetic plasmid populations as 
described below. These plasmid species were later amplified using an in-house optimised fusion 
primer PCR. 
4.3.7 Synthetic populations 
The plasmid stocks were recombined to prepare the three plasmid mixtures as described in the 
method. The pooling strategy resulted in three synthetic populations listed in table 4.3.7.1 below. 
Table 4.3.7.1 Synthetic populations   
Mixture 
Plasmid 2.38 Plasmid 3.32 Plasmid 4.38 Total  
Contribution Copy No Contribution Copy No Contribution Copy No Copy No 
1 90% 18 000 9% 1 800 1% 200 20 000 
2 1% 200 90% 18 000 9% 1 800 20 000 
3 9% 1 800 1% 200 90% 18 000 20 000 
 
4.3.8 Fusion primers  
The modified fusion primers contained all the necessities for GS Junior sequencing. The forward 
primers consisted of an “Adaptor A” sequence, a “key” sequence, a ten-base-long MID and finally, the 
target gene-specific sequence. Similarly, reverse primers contained an “Adaptor B” sequence, a “key” 
sequence, an MID and a target gene-specific sequence, reverse complimented to the 3’ end of our 
target amplicon. These primers schematics can be seen in table 4.3.8.1 and 4.3.8.2 below. 
 
 p2.38 10
3
 c/µl p3.32 10
3
 c/µl p4.38 10
3
 c/µl 
Current Conc. 152 532 c/µl 109 468 c/µl 58400 c/µl 
Sample  13.11µl 18.27µl 34.25µl 
Elution Buffer 86.89µl 81.73µl 65.75µl 
Final Conc. 20 000 c/µl 20 000 c/µl 20 000 c/µl 
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Table 4.3.8.1 Forward fusion primers: In table 4.3.8.1 below, the “Adaptor A” sequence is italicised, the “Key” sequence is 
underlined and the MID is in bold, while the template-specific sequence is seen on the 3’ end. The third column (P. mix) 
numerates the plasmid mixture sampled by that specific fusion primer. 
Primer name Sequence (5'-3') Adaptor A – Key – MID – Gene-specific sequence  P. mix 
RTA-F-MID-13 CGTATCGCCTCCCTCGCGCCA-TCAG-CATAGTAGTG-TGCACAYTAAATTTTCCAATTAG 1 
RTA-F-MID-14 CGTATCGCCTCCCTCGCGCCA-TCAG-CGAGAGATAC-TGCACAYTAAATTTTCCAATTAG 1 
RTA-F-MID-60 CGTATCGCCTCCCTCGCGCCA-TCAG-CTACGCTCTA-TGCACAYTAAATTTTCCAATTAG 1 
RTA-F-MID-5 CGTATCGCCTCCCTCGCGCCA-TCAG-ATCAGACACG-TGCACAYTAAATTTTCCAATTAG 2 
RTA-F-MID-7 CGTATCGCCTCCCTCGCGCCA-TCAG-CGTGTCTCTA-TGCACAYTAAATTTTCCAATTAG 2 
RTA-F-MID-20 CGTATCGCCTCCCTCGCGCCA-TCAG-ACGACTACAG-TGCACAYTAAATTTTCCAATTAG 2 
RTA-F-MID-10 CGTATCGCCTCCCTCGCGCCA-TCAG-TCTCTATGCG-TGCACAYTAAATTTTCCAATTAG 3 
RTA-F-MID-17 CGTATCGCCTCCCTCGCGCCA-TCAG-CGTCTAGTAC-TGCACAYTAAATTTTCCAATTAG 3 
RTA-F-MID-24 CGTATCGCCTCCCTCGCGCCA-TCAG-TAGAGACGAG-TGCACAYTAAATTTTCCAATTAG 3 
 
Table 4.3.8.2 Reverse fusion primers: In table 4.3.8.2, the “Adaptor B” sequence is italicised, the “Key” sequence is 
underlined and the MID is in bold, while the reverse-complemented template-specific sequence is seen on the 3’ end. The 
third column (P.mix) once again numerates the plasmid mixture sampled by that specific fusion primer. 
Primer name Sequence (5'-3') Adaptor B – Key – MID – Gene-specific sequence (RC) P. mix 
RT-A-R-MID-13 CTATGCGCCTTGCCAGCCCGC-TCAG-CATAGTAGTG-ACTAGGTATGGTGAATGCAG 1 
RT-A-R-MID-14 CTATGCGCCTTGCCAGCCCGC-TCAG-CGAGAGATAC-ACTAGGTATGGTGAATGCAG 1 
RT-A-R-MID-60 CTATGCGCCTTGCCAGCCCGC-TCAG-CTACGCTCTA-ACTAGGTATGGTGAATGCAG 1 
RT-A-R-MID-5 CTATGCGCCTTGCCAGCCCGC-TCAG-ATCAGACACG-ACTAGGTATGGTGAATGCAG 2 
RT-A-R-MID-7 CTATGCGCCTTGCCAGCCCGC-TCAG-CGTGTCTCTA-ACTAGGTATGGTGAATGCAG 2 
RT-A-R-MID-20 CTATGCGCCTTGCCAGCCCGC-TCAG-ACGACTACAG-ACTAGGTATGGTGAATGCAG 2 
RT-A-R-MID-10 CTATGCGCCTTGCCAGCCCGC-TCAG-TCTCTATGCG-ACTAGGTATGGTGAATGCAG 3 
RT-A-R-MID-17 CTATGCGCCTTGCCAGCCCGC-TCAG-CGTCTAGTAC-ACTAGGTATGGTGAATGCAG 3 
RT-A-R-MID-24 CTATGCGCCTTGCCAGCCCGC-TCAG-TAGAGACGAG-ACTAGGTATGGTGAATGCAG 3 
4.3.9 Sequencing amplicon generation  
Once the open and em-PCRs had concluded, em-PCRs were cleaned using isobutanol and the 
previously described. A 1 µl aliquot of each reaction was diluted in 1.2x concentrated DNA loading 
dye. This mixture was then separated in a 2% agarose gel stained with 1x GR Green nucleic acid 
stain, at a constant 90 V for 50 min, along with a 100 bp DNA ladder. The resultant gel figures are 
shown below. 
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Figure 4.3.9.1 Plasmid mix 1 amplified: Plasmid mix 1 was amplified through both open and emulsion PCR. The figure 
above displays 1 µl of the separated PCR product showing the characteristic sequence amplicon (approximately 465 bp) 
while faint primer dimers are also visible at roughly 130 bp. The faint band sequence amplicon seen in the MID2 o-PCR 
indicates poor reaction efficiency.  
Figure 4.3.9.1 above depicts the successful production of the ~465 bp amplicon from plasmid mixture 
1, using fusion primer sets 2, 13, 14 and 60 through both o-PCR and em-PCR. Despite all the efforts, 
a primer dimer is visible in most em-PCRs at approximately 130 bp. Dimerisation is however, to be 
expected, since the diffusion- constrained reaction in a minute droplet is expected to improve both the 
efficiency of the specific PCR as well as non-specific primer dimerization in droplets without template. 
While the NTC reactions appear negative by the absence of a specific band at approximately 465 bp, 
they were later screened with a nested PCR as confirmation.  
Similarly to mixture 1 amplicons, amplicons generated from plasmid mixtures 2 and 3 can be seen in 
figures 4.3.9.2 and 4.3.9.3 below. While mixture 2 was sampled with fusion primer sets 5, 7, 20 and 
24, plasmid mixture 3 was amplified with fusion primer sets 4, 10, 17, and 24.  
 
Figure 4.3.9.2 Plasmid mix 2 amplified: Plasmid mix 2 was amplified through both open and emulsion PCR. The figure 
above displays 1 µl of the separated PCR product showing the characteristic sequence amplicon (approximately 465 bp). 
Faint primer dimers are also visible at roughly 130 bp despite our best efforts to bias the reaction towards the specific 
amplicon. The faint band sequence amplicon seen in the MID 24 o-PCR indicates poor reaction efficiency. 
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Figure 4.3.9.3 Plasmid mix 3 amplified: Plasmid mix 3 was amplified through both open and emulsion PCR. The figure 
above displays 1 µl of the separated PCR product showing the sequence amplicon (approximately 465 bp). Again, faint 
primer dimers are seen at roughly 130 bp despite our best efforts. The faint band sequence amplicon seen in the MID 4 em-
PCR indicates poor reaction efficiency. 
The inclusion of a fourth fusion primer set in every open and em-PCR was precautionary to 
compensate for any failed reaction or failed amplicon recovery, post amplicon size selection.  
4.3.10 Post amplicon generation – reaction validation 
A nested PCR was used to confirm the viability or ‘amplifiability’ of the generated amplicons for 
sequencing-by-synthesis. The gel figure below depicts the 165 bp nest amplicon, generated from the 
amplicons prepared for deep sequencing from the three plasmid mixtures.  
 
Figure 4.3.10.1 Sequence amplicon validation: Similar to the positive control (lane 11 from the right), all amplicon 
validation reactions generated the specific 165 bp nested amplicon. Also visible in nested wells are faint bands containing 
products from the pre-nested reaction (e.g.: the sequence amplicon at roughly 465 bp). The amplification of the specific 
product validates the amplifiability of these sequence amplicons. 
Also visible in figure 4.3.10.1 are the sequence amplicons carried over from the pre-nested reaction at 
approximately 465 bp. This band is however, not indicative of reaction contamination since the pre-
nested amplicon is not present in the positive control and are easily distinguishable from a specific 
product as seen in the positive control well 11 (from the right) above.  
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The controls validation reactions gel can be seen in figure 4.3.10.2 below. The negative nested NTC 
reactions validate the amplicon generation reaction as being free of contaminants while the positive 
nested reaction bands at 165 bp, validate the screening reaction. While faint, non-specific bands are 
visible in the pre-nested reactions, these are not considered contaminants since they were not 
amplified in the validation reaction.  
 
Figure 4.3.10.2 Reaction control validation: Figure 4.3.10.2 displays the successful validation of the sequence amplicon 
PCR, as none of the NTC were amplifiable using the short fragment, nested PCR (NST). Primer dimers are visible in most of 
the pre-nested (PN) o-PCR and em-PCR NTCs (ladled O and EM above) at roughly 130 bp. All validation experiments were 
deemed viable by the correct functioning of the reaction positive and NTC controls. 
4.3.11 Amplicon quantification post ethanol precipitation 
On completion of the ethanol precipitation assay, 2 µl of the purified amplicons were quantified using a 
NanoDrop ND1000 (Thermo Scientific, Massachusetts, USA) according to the manufacturer’s 
specifications. The reconstruction of the absorbance data for the o-PCR ethanol precipitation is seen 
on the line graph in figure 4.3.11.1 below.  
Figure 4.3.11.1 Absorbance at 230, 260 280 nm of o-PCR amplicons: The peak observed at 260 nm represents the 
presence of precipitated DNA in the quantified sample while the absorbance at 280 nm indicates the presence of the nucleic 
acid carrier, glycogen, which was added to the precipitation reaction. The absorbance observed 230 nm suggests the co-
precipitation of the chaotropic agent, sodium acetate, also added to the precipitation experiment. 
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The line graph below (figure 4.3.11.2) displays the illustrated absorbance data of the em-PCR 
amplicons as measured on the NanoDrop (Thermo Scientific, Massachusetts, USA). A similar trend as 
in the o-PCR data is visible at absorbance wavelengths 230, 260 and 280 nm.   
Figure 4.3.11.2 Absorbance at 230, 260 280 nm of em-PCR amplicons: As described above, the peak seen at 260 nm 
represents the presence of precipitated DNA, while the absorbance at 280 nm indicates the presence of glycogen and the 
absorbance at 230 nm displays the co-precipitation of sodium acetate. 
The NanoDrop (Thermo Scientific, Massachusetts, USA) uses the absorbance values displayed above 
to generate the tabulated concentration and purity values seen in table 4.3.11.1 below. 
Table 4.3.11.1 Quantification of size-selected sequence amplicons: The table above shows the absorbance values for 
the size-selected and purified o-PCR and em-PCR sequence amplicons. In column one (left) are the three plasmid mixtures 
that were amplified using the corresponding MID fusion primers, adjacently listed in column two. 
  
MID 
Open PCR Emulsion PCR 
 ng/µl   260/280   260/230   ng/µl   260/280   260/230  
Plasmid 
Mixture 
1 
2 13.18 1.58 0.78 21.4 1.54 0.96 
13 13.88 1.56 0.75 31.61 1.62 0.68 
14 13.36 2.02 0.8 12.5 1.73 1.04 
60 21.02 1.78 0.86 26.24 1.77 1.03 
Plasmid 
Mixture 
2 
5 16.3 1.95 1.04 12.04 1.49 0.83 
7 28.07 1.72 1.17 34.89 1.76 1.08 
20 16.55 1.78 0.96 6.44 2.13 0.78 
24 8.31 1.49 0.58 19.14 1.6 1.03 
Plasmid 
Mixture 
3 
4 14.11 1.94 0.93 19 1.87 1.16 
10 17.75 1.94 0.89 46.5 1.83 1.11 
17 32.72 1.82 1.22 29.8 1.8 1.01 
24 17.39 1.92 0.97 17.66 1.69 1.04 
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Preferable 260/280 and 260/230 ratios are 1.8 and 2 respectively, and are achievable when 
precipitating larger volumes of DNA. The addition of the chaotropic salts to the precipitation reaction is 
essential in providing a hydrophobic environment required for DNA to migrate out of solution (Green & 
Sambrook 2012), and contributes to the optical density seen at 230 nm. Glycogen, a non-essential 
additive, acts as a nucleic acid carrier molecule by binding and concentrating multiple free DNA 
strands. While glycogen improves DNA recover in precipitation reactions, it contributes to the 280 nm 
absorbance. The spectrophotometric sample purity is thus obscured by the addition of these 
necessary agents.  
On the basis of purity and concentration, amplicons with MIDs 13, 14 and 60 were selected to 
represent plasmid mixture 1, MIDs 5, 7 and 20 were chosen for plasmid mix 2, and MIDs 10, 17 and 
24 were chosen for plasmid mixture 3.  
4.3.12 Bioinformatic data analysis 
Since the same MIDs were used in both the o-PCR and em-PCR, o-PCR amplicons were sequenced 
in one GS Junior (454 Life Sciences, Connecticut, USA) run and em-PCR amplicons, another. Reads 
were trimmed based on their quality scores and de-multiplexed by MID. Each read was mapped to 
one of the three plasmid sequences and the mapping counts from the three MIDs used to sample 
each plasmid mixture, were summed in tables 4.3.12.1 below. 
Table 4.3.12.1 Mapped GS Junior reads: The table above displays the summarised results of the number of o-PCR and 
em-PCR GS Junior reads that mapped to a particular plasmid species. The three plasmid species are listed in column one 
while the plasmid mixtures are numerated in row one. Adjacent to the o-PCR mapping totals is the prevalence percentage 
(Prev) of the plasmid species (listed in column one) in the plasmid mixture listed in row one, above. Also under the 
numerated plasmid mixture and adjacent to the o-PCR mapping totals is the em-PCR mapping totals. Below each mapping 
total is the variant prevalence percentage in relation to the total number of reads. 
 
 
Plasmid mix 1 Plasmid mix 2 Plasmid mix 3 
Prev o-PCR 
(Prev) 
em-PCR 
(Prev) 
Prev o-PCR 
(Prev) 
em-PCR 
(Prev) 
Prev o-PCR 
(Prev) 
em-PCR 
(Prev) 
P2.32 
90% 21036 
(99.97%) 
30786 
(99.94%) 
1% 1641 
(11.41%) 
1155  
(5.42%) 
9% 16070  
(99.82%) 
13768 
(63.39%) 
P3.38 
9% 4  
(0.02%) 
17  
(0.06%)* 
90% 12742 
(88.59%) 
20051 
(94.02%)* 
1% 24  
(0.15%) 
7930  
(36.51%)* 
P4.32 
1% 
3  
(0.01%) 
3  
(0.01%) 9% 
0  
(0.00%) 
120 
 (0.56%)* 90% 
5  
(0.03%) 
21  
(0.10%)* 
* indicates a binomial probability p value <0.01 
From the table above, there is a clear sampling bias towards the plasmid 2.32, the species that is 
perfectly matched to the fusion primers. Even when the poorly matched template constitutes 9 or 10-
fold more of the sampled population, as in plasmid mixtures 2 and 3 respectively, plasmid 4.28 
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remains vastly under-represented. Emulsification improved the sampling accuracy of mismatched 
templates except where plasmid 4.32 was at 1%, however, seven cycles of emulsion PCR was 
insufficient to correct for sampling bias. The improved sampling of plasmid 3.38 in the emulsion 
reaction with plasmid mixture 3 result from MID 24’s inexplicable affinity for plasmid 3.38, and 
highlights the unpredictable nature of fusion primers. Samples in which em-PCR significantly favoured 
a variant relative to o-PCR are indicated with * (binomial probability p value < 0.01). 
 
 
  
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
 155 
 
4.4 Discussion 
In this study, we aimed to accurately quantify PCR associated random resampling error and bias 
induced by the use of fusion primers to enrich a sample for next generation sequencing. By modifying 
a previously published em-PCR method (Schutze et al. 2011), we tested a means of circumventing 
this bias using a high fidelity, emulsion PCR. The deep sequencing results obtained from the open 
PCR suggest that differential amplification in favour of perfectly primer-to-template matched variants 
greatly skews variant prevalence after PCR enrichment. Deliberately mismatched-to-template variants 
were vastly under-represented, despite contributing 90% of the starting population.   
We attempted to reduce PCR sampling error by using seven cycles of em-PCR. As these tiny droplets 
soon expend the available PCR reagents, amplification within the droplet would plateau. These 
reagent-depleted PCR droplets were replenished with reagents from negative droplets (lacking 
amplifiable template), by breaking the emulsion through centrifugation. A previous study conducted by 
Nakano (Nakano et al. 2003), produced larger PCR droplets (two to 10 µm); this method made use of 
13 cycles of emulsion PCR before the PCR substrates in template-containing droplets, were depleted, 
resulting in PCR plateau. Nakano then replenished the positive reactions by breaking the emulsion 
and continued to enrich specific template through an additional 30 PCR cycles. We did not know the 
optimal emulsified cycle number but chose seven cycles based on the much smaller droplet size in our 
reaction which would result in an earlier PCR plateau. The seven cycles we used were evidently 
insufficient to fully overcome the lower yield of mismatched compared to perfectly-matched templates. 
Templates with a good match to the primers still largely out-competed the poorly matched template 
4.32.  
Our original hypothesis was that droplet partitioned PCR would overcome mismatches through 
improving efficiency despite mismatches. However, our data suggest that the benefit of droplet PCR 
with reference to poorly matched templates is largely an effect of constraining efficient reactions 
through the small droplet size (and early PCR plateau) relative to the inefficient non-specific reaction. 
It is not clear what number of cycles would be optimal, moreover the previous ddPCR experiment and 
raining effect with mixture 4.32 suggests that even a full complement of 40 PCR cycles would not fully 
overcome inefficient PCR due to many mismatches. Although the difference in PCR yield for the 
poorly matched template was small, it was significantly improved and seemed to have a big effect on 
the yield of the plasmid 3.38 amplicons (with only two mismatches) when the perfectly matched 
template was not the most abundant. Overall, sampling of mismatched templates was marginally 
improved. 
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A standard polymerase chain reaction (PCR) relies on primer sequences that bind to complementary 
sequences in the target sequence, allowing the polymerase to extend the primed genomic regions. 
Template-specific primers, by nature, are a great source of selection bias as they are designed to 
discriminate specific genomic region. As described by Kanagawa in 2003, amplification of genomic 
variants with mismatches to the primer species is largely inefficient. Remedially, they recommend the 
use of degenerate bases to compensate for diversity (Kanagawa 2003). In the case of highly diverse 
viruses, degeneracy may nevertheless not yield any primer species with a perfect match to the 
template. Moreover, it decreases the ratio of primers that are perfect template complements.  
Degenerate primers may also increase the risk of non-specific binding to other than the desired 
targets resulting in non-specific amplification. 
In a letter to the editor, Shan-Lu Liu of the University of Washington highlights the dilemma of random 
sampling error through resampling that occurs when using PCR enrichment to sample minority 
variants. Liu describes how PCR could randomly amplify particular species in the population and 
concludes that this can be avoided by PCR amplification of individual species. Single-template 
amplification is however costly as limiting dilutions and multiple PCRs are required (Liu et al. 1996).  
A recent study however, found similar bias with single genome amplification and sequencing to PCR 
followed by cloning (Jordan et al. 2010). Nevertheless the high accuracy of these methods has 
allowed the robust characterization of HIV evolution in various compartments (Salazar-Gonzalez et al. 
2011), the study of transmitted populations (Danaviah et al. 2015) and intra patient virus evolution in 
individuals on long-term suppressive cART (Kearney et al. 2014). NGS potentially offers a more 
efficient process to sequence minor variants. The high loci coverage of NGS potentially allows for a 
high resolution. This depth of sampling enables the quantification of minor variants at very low 
frequencies provided that the PCR mediated enrichment process resulted in an accurate 
representation of these variants at the end of the enrichment process.  
A real world example of the mentioned situation is when using deep sequencing for HIV drug-resistant 
variant detection. High fidelity PCR is required and is the most cost effective means of enriching 
resistance-associated genes. As previously publicised, sampling bias is induced when using specific 
primers to sample a diverse population (Kanagawa 2003; Polz & Cavanaugh 1998). NGS at high 
template coverage (deep sequencing) has been used to detect minor variant drug-resistant 
populations before commencement of therapy (Simen et al. 2009). When non-nucleoside reverse 
transcriptase inhibitor (NNRTI)-resistant, minority populations are detected before therapy (using by 
AS-PCR), their presence is predictive of NNRTI regimen failure (Li et al. 2013; Li et al. 2011; Halvas et 
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al. 2010). Using NGS to identify minority, drug- resistant populations could thus inform therapy choices 
however, its value in many other clinical settings is still not established.   
The limited application of deep sequencing is probably largely due to technical limitations. When 
sampling low frequency variants, resampling error could contribute to random inaccurate 
representation of these variants in the sequenced population, whereas in case of a poor primer 
template match a particular PCR may result in a biased underrepresentation of these variants. Lastly 
sequencing induced errors due to homopolymer read error affects NGS platforms such as 454 (454 
Life Sciences, Connecticut, USA) or Ion Torrent (Life Technologies, California, USA), whereas Illumina 
platforms (California, USA) are been prone to biased sequencing dependent on AT:GC ratio (Loman 
et al. 2012). Partitioning of PCR in a myriad of fento or atto-litre individual reactions such as an 
emulsified PCR could potentially overcome both the random resampling error and biased 
amplification. 
In 2011, Cassandra Jabara of the University of North Carolina published a study that addressed PCR 
resampling and presented RNA random primer ID tagging as a solution (Jabara et al. 2011). In their 
study, Jabara synthesized cDNA during a reverse transcription step using an HIV-specific primer that 
consists of a reverse complemented genome-specific region, an eight random-base RNA ID tag, and a 
PCR tag. After cDNA synthesis, a primer complimentary to the PCR tag and a 90-base-long forward 
fusion primer were used to enrich sequenceable amplicons, each containing a unique eight-base 
random ID sequence. Post-sequencing and filtering, template sequences with identical IDs are 
condensed into one consensus (representing an original template), allowing one to determine the 
exact number of original RNA variants sampled. However, although this method allows accurate 
quantification of variants that are sequenced, it requires a high concentration of template, it is 
associated with PCR bias and results in a large loss of cDNA species that produce sequences; which 
limits the usefulness for detection of low frequency variants (Brodin et al. 2015).   
In response to these problems, researchers from the National Cancer Institute (Boltz et al. 2015) 
improved the RNA ID tagging protocol. Briefly, RNA is reverse transcribed using cDNA primer with a 
10-random-base tagging approach, similar to Jabara’s method. However, instead of 90-mer fusion 
primers with 5’ adaptor, 22-mer primers containing uracils at the 5’ end are used for PCR 
amplification. Subsequently, 14 base adenine overhangs are generated by digesting uracils with uracil 
N-Glycosylase. This allows highly efficient adaptor and barcode ligation. Similar to the Jabara method, 
reads with the same randomly generated IDs (10 bases in this case) are consolidated into a 
consensus sequence as representing a single cDNA species. This modified assay obviates the need 
to use large fusion primers and has been shown to reduce bias and increase the number of cDNA 
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templates sampled (Boltz et al. 2015). While this modified random tagging approach improves one’s 
ability to correct the sampling error post-sequencing, few other methods, except the cumbersome 
single genome sequencing approach, have the potential of correcting sampling error at the source.  
The alternative approach to template tagging, which could overcome PCR enrichment error, is 
partitioning PCR into minute reactions. Emulsion PCR is commercially available from RainDance 
Technologies (Massachusetts, USA) and BioRad (California, USA) and addresses both random 
sampling error and primer biased sampling through efficiency constraint reactions. Both digital droplet 
PCR platforms offer the advantage of standardised droplet volumes with identical intra-droplet 
selection bias, since varied droplet volumes may also induce biased amplification as seen in figure 
4.4.1. The QX200 ddPCR system (BioRad, California, USA) was used in our study to accurately 
quantify the three plasmid species used for our assay and shows great repeatability within triplicates, 
as it was designed for quantification. The BioRad droplet generator (California, USA) uses proprietary 
emulsion oil and reaction mixtures produces 1 nanolitre reactions by the use of embedded 
microfluidics and differential air pressure.  
  
 
 
 
 
 
 
Figure 4.4.1 Biased enrichment in un-equilibrated droplets: The figure above demonstrates the biased enrichment of 
variant C as a result of the starting template being randomly assigned a larger droplet than variants A and B, at the start of 
the em-PCR. Before em-PCR enrichment (on the left), all variants had equal prevalence however, since variant A was in a 
tiny emulsion droplet, it was only enriched two-fold while Variants B and C are resampled more often before their droplets are 
reagent depleted (on the right).  
QX200 technology (BioRad, California, USA) is however, not expandable to next generation library 
preparation because of its limited sample input volumes and low fidelity. In contrast, RainDance 
technologies (Massachusetts, USA) offer ddPCR platform that is expandable to next generation 
sequencing amplicon library preparation by means of an adaptor ligation protocol. The RainDance 
system (Massachusetts, USA) generates as many as five million reaction droplets from a 50 µl PCR 
and boasts the highest ddPCR sensitivity, owing to its high droplet count. However, as with the 
BioRad’s QX200 (California, USA), generating these 10 picoliter reactions requires expensive, single-
use consumables and an expensive droplet generator.  
Emulsification 
7 cycles of enrichment 
         Variant A – 4 copies 
 
         Variant B – 8 copies 
 
         Variant C – 32 copies 
   Variant A – 2 copies 
Variant B– 2 copies 
Variant C– 2 copies 
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The methods we present here are widely implementable in any resource limited laboratory with three 
basic pieces of equipment (i.e.: a vortex, a micro-centrifuge and a thermocycler). The use of diffusion 
constraint reactions could abrogate the decreased efficiency associated with primer-mismatched 
variants, but it is not clear if it could overcome poor yield due to primers with multiple mismatches. It 
may however require multiple experiments and NGS runs to find optimal conditions which may would 
result in a PCR enriched population that represent the original variant proportions.  
Our method modified that of Schütze (Schutze et al. 2011) by using a high fidelity polymerase to allow 
deep sequencing and by including a depleted droplet replenishing step, adapted from Kanagawa 
(Kanagawa 2003). It should be noted though, that Schütze’s methods were a simplification of a 
BEAMing protocol (so named on the basis of the four principal components: beads, emulsion, 
amplification, and magnetics), which was used to enrich magnetic-bead-bound amplicons through em-
PCR (Diehl et al. 2006). BEAMing mediates enrichment of amplicons with the required 3’ or 5’ adaptor 
sequences and forms the foundation of bead-based enrichment in most next generation library 
preparation protocols. 
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4.5 Conclusion 
In the interests of simplicity and cost, we used an approach that could not control droplet volumes. 
The variation in droplet size would result in different droplets reaching PCR plateau after a varying 
number of cycles which complicates assay optimization. Other aspects of our em-PCR requiring 
further optimisation include: 
 The number of cycles used to saturate the droplets – Provided that the droplet volumes are 
equilibrated, saturation of positive droplets is advantageous as it would result in equal 
representation of all the PCR mutated variants, after the emulsion is broken. As was evident 
from the em-PCR mapped GS Junior analysis, seven emulsified cycles were insufficient to 
handicap the perfectly matched templates and allow the poorly matched templates to catch up.  
 The addition of bovine serum albumin (BSA) – To further improve processivity, BSA addition is 
advised as it prevents the polymerase from getting trapped and denatured in the water-oil 
interface (Williams et al. 2006) 
 Increased polymerase concentration to increase productivity – Shao (2011) demonstrated a 
2.5-fold increase in em-PCR efficiency when using 2.5-fold the polymerase concentration 
recommended for the open PCR (Shao et al. 2011).  
Despite the limitations of our method, it clearly demonstrated that PCR enrichment could misrepresent 
the relative abundance of the variants in the sampled population, when using next generation 
sequencing. Although our emulsified reactions resulted in a statistically significant increase in 
mismatched variant representation in most reactions, except when sampling 1% of the template with 
three mismatches, it only marginally improved sampling error. Once further developed, emulsified 
PCR could be a possible solution the observed “founder effect” quantified in this study. While 
conventional PCR with shorter primers might not induce as radical a bias as is the case of fusion 
primers, the effect of terminal mismatches is possibly similar when sampling highly diverse sample 
populations, such as HIV.  
Once fully optimised, emulsification as a means of partitioning templates during PCR enrichment may 
offer an affordable solution to PCR resampling error which is less cumbersome than the primer ID 
approach and less costly than commercial digital droplet PCR for NGS experiments. A simple PCR 
enrichment process without significant sampling error would expand the application of NGS in the 
fields of intra patient evolution, molecular epidemiology of diverse infectious agents in host 
populations, virus discovery or any other application where a highly diverse population is sampled with 
specific primers.   
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4.7 Appendix D 
(Additional information for section 4.3.2 Recombinant sequencing) 
Below are the contiguous Sanger sequences for the three plasmid species used in this study. Forward 
and reverse primer binding regions are in bold while mismatches to the fusion primers are underlined.  
Plasmid 2.38 
CAGATGATACAGTATTAGAAGATATAAATTTGCCAGGAAAATGGAAACCAAAAATGATAGGAGGAA
TTGGAGGATTTATCAAAGTAAGACAGTATGATCAAATACCTATAGAAATTTGTGGAAAGAAGACTA
TAGGTACAGTATTAATAGGACCTACACCGGTCAACATAATTGGAAGAAATATGTTGACTCAGCTTG
GA>TGCACACTAAATTTTCCAATTAG>TCCTATTAAAACTGTACCAGTAAAATTAAAGCCAGGAAT
GGATGGCCCAAAGGTCAAACAATGGCCATTGACAGAAGAAAAAATAAAAGCATTAACAGCTATTT
GTGATGAAATGGAAAAGGAAGGGAAAATTACAAAAATTGGGCCTGAAAATCCATACAACACTCCA
GTATTTGCTATAAAAAAGAAGGACAGTACTAAGTGGAGAAAATTAGTAGATTTCAGGGAACTCAAT
AAAAGAACTCAAGACTTTTGGGAAGTTCAACTAGGAATACCACACCCAGCAGGGTTAAAAAAGAA
AAAATCAGTGACAGTGCTGGATGTAGGGGATGCATATTTTTCAGTTCCTTTAGATGAAAACTTCAG
GAAATATA<STGCATTCACCATACCTAGT<ATAAATAATAAAACACCRGGGATTAGGTATCAATAT
AATGTGCTGCCACAGGGATGGAAAGGATCACCAGCAATATTCCAGAGTAGCATGACAAGAATTTT
AGAGCCTTTTAGGGCACAGAATCCAGACATAGTTATCATTCAATATATGGATGACTTGTATGTAGG
ATCTGACTTAGAAATAGGGCAGCATAGAGCAAAAATAGAGGAGTTAAGGGAACATTTATTGAAAT
GGGGATTTACCACACCAGACAAAAAGCATCAAAAAGAACCCCCATTTCTTKGGATGGGGTWTGAA
CTCCATCSTGACAAATGG 
 
Plasmid 3.32 
CAGATGATACAGTATTAGAAGAAATAAATTTGCCAGGAAGATGGAAACCAAAAATGATAGGAGGA
ATTGGAGGTTTTATCAAAGTAAGACAATATGAACAAATAGTTATAGAAATTTGTGGAAAAAAGGCT
ATAGGTTCAGTATTAGTAGGACCTACACCTGTCAACATAATTGGAAGAAATATGTTGACTCAGCTT
GGA>TGCACATTGAATTTTCCAATTAG>TCCTATTGAAACTATACCAGTAAAATTAAAGCCAGGAA
TGGATGGCCCAAAAGTTAAACAATGGCCATTGACAGAAGAAAAAATAAAAGCACTAACAGCGATT
TGTGAAGAGATGGAAAAGGAAGGAAAAATTACAAAAATTGGGCCCGAAAATCCATACAACACTCC
AGTATTTGCCATAAAAAAGAAGGACAGTACTAAATGGAGAAAATTAGTAGATTTCAGGGAACTCAA
TAAAAGAACTCGAGACTTTTGGGAAGTTCAATTAGGGATACCACATCCAGCAGGATTAAAAAAGA
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AAAAATCAGTGACAGTGCTGGATGTGGGGGATGCATATTTTTCAGTTCCTTTAGATGAAGGCTTTA
GGAAATATA<CTGCATTCACAATACCTAGT<ATAAACAATGAAACACCAGGAATTAGATATCAATA
CAATGTACTTCCACAGGGATGGAAAGGATCACCAGCAATATTCCAGAGTAGCATGACAAAAATCT
TAGAACCCTTTAGGACACAAAATCCAGACATAGTTATCTATCAATATATGGATGACTTGTATGTAG
GATCTGACTTAGAAATAGGGCAACATAGAGCAAAAATAGAGGAGTTAAGAGAACATTTATTGAGAT
GGGGATTTACCACACCAGACAAGAAGCATCAGAAAGAACCCCCATTTCTGTGGATGGGGTATGA
ACTCCATCCTGACAAATGG 
 
Plasmid 4.38 
CAGATGATACAGTATTAGAGGATATAAATTTGCCAGGAAAATGGAAACCAAAAATGATAGGAGGA
ATTGGAGGTTTTATCAAAGTAAGACAGTATGATCAAGTACATATAGAAATTTGTGGAAAAAAGGCT
ATAGGTACAGTATTAGTGGGACCTACACCCGTCAACATAATTGGAAGAAATATGTTGACTCAGATT
GGA>TGCACATTGAATTTCCCAATAAG>TTCCATTGAAACTGTACCAGTAAAATTAAAGCCAGGAA
TGGATGGCCCAAAGGTTAAACAATGGCCATTGACAGAAGAGAAAATAAAAGCATTAACAGCAATT
TGTGAAGAAATGGAAAAGGAAGGAAAAATTACAAAAATTGGGCCTGAAAATCCATATAACACTCCA
GTATTTGCCATAAAAAAGAAGGATAGTACTAAGTGGAGAAAATTAGTAGATTTCAGGGAACTCAAT
AAGAGAACTCAAGACTTTTGGGAAGTTCAATTAGGAATACCACACCCAGCAGGGTTAAAAAAGAA
AAAATCAGTAACAGTACTGGATGTGGGGGATGCATACTTCCCAGTTCCTTTAGATGAAAACTTCA
GGAAATATA<CTGCATTCACCATACCTAGT<ATAAACAATGAAACACCAGGGATTAGATATTAATA
TAATGTGCTGCCACAGGGATGGAAAGGATCACCAGCCATATTCCAGTGTAGCATGACAAAAATCT
TAGAGCCCTTTAGAACACAAAATCCAGAAATGGTCATCTATCAATATATGGATGACTTGTATGTAG
GGTCTGACTTAGAAATAGGGCAACACAGAGCAAAAATAGAGAAGTTAAGAGACCATCTATTAAGG
TGGGGATTTACCACACCAGATAAGAAACATCAGAAAGAACCCCCATTTCTTTGGATGGGGTATGA
ACTCCATCCTGACAAATGG 
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5 Conclusion  
5.1 Study summary 
Next generation sequencing (NGS) is a useful tool for identifying minor HIV variants with drug 
resistant mutations however, more in depth studies are needed to determine the clinical implications of 
the presence of these populations (Li 2013). We set out to test the utility of various NGS platforms as 
alternatives to our in-house human immunodeficiency virus (HIV) drug resistance testing (DRT), which 
employs PCR and Sanger sequencing (referred to here as bulk sequencing). We selected NGS rather 
than allele-specific PCRs and oligonucleotide ligation assays because NGS read lengths offer the 
benefit of mutation linkage study. In addition, NGS offers potential cost savings, accessible through 
the use of molecular identifiers (MIDs) and sample pooling. The high template coverage due to 
massive parallel sequencing on an NGS platform permits the detection of minority, drug-resistant virus 
populations. When detected in therapy-naïve patients, these drug-resistant minority variants may 
increase the risk of antiretroviral therapy failure of non-nucleoside reverse transcriptase inhibitor 
(NNRTI)-based combination antiretroviral therapy (cART) failure (Li et al. 2011). 
The primary aim for chapters two and three was to detect minority, drug-resistant viral populations in 
clinical settings for which there is limited published data on these viral variants. In chapter two, we 
included first-line, NNRTI-regimen-experienced patients, at the stage of failing a second-line, lopinavir 
(LPV) boosted with low dose ritonavir (LPV/r)-based cART, with HIV RNA loads >500 copies per 
millilitre of blood. Most of these patients had poor drug exposure (likely poor adherence) as evident 
from low plasma and hair LPV concentrations (van Zyl et al. 2011). In this cohort, the prevalence of 
major protease inhibitor (PI) resistance mutations, as detected by bulk sequencing, was 7% (Fisher et 
al. 2012), similar to that observed by other researchers investigating cohorts failing PI-based regimens 
(Wallis et al. 2010; El-Khatib et al. 2010). However, we did not know if minority, drug resistance 
mutations (DRMs) associated with the first-line, or the current PI regimen, would be detectable.   
Overlapping amplicons were generated from the products of a low fidelity, two-step reverse 
transcription-pre-nested PCR, sampling viral RNA isolated after second-line therapy failure. These 
pre-nested products were also used for bulk sequencing, while the fusion primer amplicons were 
sequenced on the FLX Titanium NGS platform (454 Life Sciences, Connecticut, USA).  
NGS improved DRT by identifying minority, drug-resistant viral populations in five of the seven 
patients included in this study. In addition, minority populations with first-line cART DRMs were 
detected, although no major PI-resistant viral populations were identified. We observed discordance in 
the prevalence of certain DRMs when comparing the DRM quantities (as determined by NGS) to 
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DRMs identified by in-house DRT, when using an expected bulk sequencing threshold of 20% (Palmer 
et al. 2005). This disagreement is possibly due to biased priming of specific templates, followed by 
PCR resampling. Also, K65R was identified at low frequencies in all patients. This finding may have 
been PCR-induced since our pre-nested PCR used low fidelity and reverse transcriptase codon 65 is 
found in a homopolymer run. 
Our study of PI resistance had several limitations:  
 We did not make use of a high fidelity PCR system for the first round of amplification, which 
could have contributed to PCR-induced error.  
 Our target sequences did not include recently described domains in gag and envelope which 
may be associated with PI-failure (Rabi et al. 2013; Sutherland et al. 2015).   
 Due to cost considerations and limited sample availability, we did not perform NGS at the time 
of first-line failure in these patients.  
The lack of detectable majority variant drug resistance in this cohort may be attributed to the rapid 
waning of PI-resistant variants in the absence of sustained drug pressure (in patients with poor or 
intermittent adherence). Under reduced selection pressure, PI-resistant variants wane due to the high 
fitness price of PI resistance mutations (Rosenbloom et al. 2012).  
The 15 infants sampled in chapter three were exposed to the prevention of mother-to-child HIV 
transmission (PMTCT) regimen but otherwise treatment-naïve. Initial drug resistance in infants (a 
combination of transmitted and PMTCT induced resistance) is challenging to identify in PMTCT 
failures since some DRMs may wane below the sensitivity threshold of bulk sequencing, at the time of 
testing (Rowley et al. 2010). However, minority, drug-resistant populations present at baseline (before 
therapy initiation) may affect therapy response (Metzner et al. 2009; Jourdain et al. 2010; Paredes et 
al. 2010; Li et al. 2012; Li et al. 2013).  
Infant samples included in this study had previously been assayed with bulk sequencing and the 
residual plasma samples were used for NGS. To include all cDNA and reduce random enrichment 
error, viral protease and reverse transcriptase were enriched through 14 parallel pre-nested and seven 
parallel nested PCRs. Quantified cDNA assisted in determining the limit of minor variant detection 
while clonal sequencing (cloning and Sanger sequencing) validated the NGS results.  
Both the Ion Torrent Personal Genome Machine™ (PGM) (Life Technologies, California, USA) and the 
Solexa/Illumina MiSeq (California, USA) improved the DRM detection in all patients, below the 
sampling thresholds of bulk sequencing and clonal sequencing. Bulk sequencing was validated by 
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both NGS platforms but there was better agreement between the MiSeq and the clonal sequencing. 
This finding was probably due to homopolymer reading error on the PGM, which resulted in spurious 
insertions or deletions and contributed to the loss of coverage at homopolymer sites.  
Considering the study findings, the Solexa/Illumina MiSeq (California, USA) may be ideal for minor 
variant detection in PMTCT-exposed infants, who were initiated onto cART. In addition to the longer 
read lengths attainable with bidirectional sequencing (2x 300 bp), the superior homopolymer 
sequencing makes the MiSeq (Illumina, California, USA) a suitable candidate for HIV DRT. Moreover, 
the MiSeq (Illumina, California, USA) generates up to 15 gigabases of sequence data which can allow 
for the pooled testing of a large number of samples in one sequencing run. To our knowledge, this 
was the first study to perform and validate comparative NGS of PMTCT failures and the only the third 
study to sequence HIV using the PGM (Life Technologies, California, USA). 
In chapter four we attempt to quantify and overcome PCR resampling and the primer-induced 
selection bias brought about by fusion primers. An amplicon sequencing approach, using fusion 
primers, focuses NGS coverage on the region of interest and is thus most efficient for deep 
sequencing to detect rare variants. Moreover, this approach obviates the need to ligate sequencing 
adaptors as they are included in the fusion primers. As the commercial ligation kits are expensive, this 
can bring about substantial cost reduction. When amplicons are generated for the 454 GS Junior (454 
Life Sciences, Connecticut, USA), the MID fusion primers may be longer than 60 bases and introduce 
a strong primer-induced selection bias. An alternative approach to next generation deep sequencing to 
detect rare variants is the use of limiting dilution PCR (LD-PCR). This method prevents PCR selection 
bias as individual species are amplified separately and sequenced separately. A more elegant solution 
to LD-PCR could be to reduce biased enrichment prior to NGS by partitioning templates in droplets, 
through emulsion PCR (em-PCR).  
We compared two enrichment approaches for amplicon sequencing: A standard or “open PCR” and a 
PCR where the reagents were partitioned in small droplets by a water-oil emulsion. Both the emulsion 
(em-PCR) and open PCRs were with the same high fidelity enzyme mastermix and fusion primers 
containing sequencing adaptors for 454 amplicon sequencing. When we kept the mastermix 
emulsified for the full duration of the PCR reaction, there were no visible PCR products. This was 
probably because the picoliter droplets reached PCR plateau early, which reduced processivity. We 
therefore opted for seven emulsified cycles, to allow partitioned PCR in the first critical priming steps. 
This was followed by emulsion breaking (by centrifugation) and the completion of the remaining 43 
PCR cycles.  
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We investigated the enrichment of mixtures of three different plasmids: one plasmid sequence had no 
mismatches with the fusion primers template-specific regions, while the other two plasmids had 
deliberate mismatches with the primers. In each mixture, one of the three plasmid species constituted 
90%, while the other two, either 9% or 1% of the total. Experiments were performed in triplicate for 
each of three different plasmid mixtures using the same set of nine fusion primers for the open and 
em-PCRs. After PCR enrichment the amplicons were sequenced on the 454 platform to investigate 
any random error or biased enrichment.  
There was extremely uneven representation in NGS reads of the different variants depending on the 
number of fusion primer-template mismatches: our findings showed that a majority poorly matched 
variant represented less than 1% after enrichment, even when present at 90% in the original sample. 
The plasmid template with the most mismatches appeared as a minor variant relative to the perfectly-
matched variant, even when it was at a 10-fold higher concentration in the sampled plasmid mixture. 
Seven cycles of emulsified PCR could not overcome the biased enrichment but resulted in a 
significantly increased representation of the plasmid with fewer mismatches, and a marginal effect on 
the one with the most mismatches. These findings emphasise the strong biased enrichment when 
using fusion primers, as seen by others (Berry et al. 2011).  
Data from quantitative PCR (qPCR) is informative in understanding this phenomenon. Primer template 
mismatches often result in a cycle threshold (Ct) delay with qPCR or, too many mismatches could 
result in no detectable amplification (Pang et al. 2011). The Ct delay is thought to be due to the poor 
efficiency of a mismatched PCR during the first rounds of amplification when the imperfectly matched 
primer and templates lack stability essential for polymerase extension. However, once the primers are 
incorporated, the proportion of perfectly matched template (primer derived), compared to the original 
mismatched template, would exponentially increase with each cycle. Thus, the efficiency of 
amplification would improve.  
Partitioning templates may enhance PCR efficiency by preventing competition of imperfectly matched 
templates with the primer-derived, perfect match. Nevertheless, the poor initial efficiency would still 
result in an initial delay and may explain the limited benefit of using only seven emulsified cycles. 
However, with too many emulsified cycles we found a poor PCR yield, apparently as the minute 
droplets reach early PCR plateau. Although, with an optimal cycle number, PCR plateau may be used 
to an advantage as when in an emulsion, a perfectly efficient droplet PCR would reach plateau earlier 
than a droplet with a lot of primer-template mismatches. This may handicap the perfectly matched 
reactions, compared to the mismatched ones and reduce enrichment bias. Finding the optimal number 
of cycles may require extensive validation and many more NGS experiments which fall outside the 
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scope of this thesis. Our approach was nevertheless the first attempt to overcome fusion primer 
resampling error using an em-PCR approach, which allows droplet-partitioned PCR without expensive 
microfluidics and which did not require magnetic beads to facilitate amplicon recovery. 
Furthermore, we have learned the importance of appropriate controls for NGS experiments. Reaction 
contaminants that can be amplified using the reaction primers or fusion primers could be perceived as 
minor variant populations. Bearing this in mind, we recommend similar control measures as are used 
for single-copy detection assays. As larger fragment PCRs are relatively inefficient, the no-template 
controls may not yield visible bands on gel electrophoresis, even when low-level contamination is 
present. Therefore nested PCR or qPCR could be used to screen no-template controls and reaction 
preparation areas despite being labour intensive.  
Our investigations had the following limitations: In the first study, investigating minor variant resistance 
in patients failing a second-line PI regimen, we did not have samples available at the first-line failure 
episode and therefore could perform deep sequencing at both failure time points. It was therefore not 
known if there were any pre-existing minor drug-resistant variants before PI therapy. In this 
experiment we also did not quantify the cDNA before enrichment. Our assumptions with reference to 
minor variant thresholds were therefore based on the patient viral load and expected extraction and 
reverse transcription efficiencies.  
In the second study investigating minor variant resistance in PMTCT-exposed infants we addressed 
this limitation and quantified the pre-enrichment cDNA. Thus we were able to report the average times 
a template was enriched based on the read coverage and original template quantity. We detected 
additional mutations with deep sequencing in these patients but were not able to assess the effect 
minor variant, NNRTI resistance mutations as these patients were initiated on a high genetic barrier, 
PI-based regimen. Whether these minor variant mutations would affect therapy response should 
NNRTIs be re-introduced in subsequent regimens, is unknown.  
Our last experiment attempted to detect and improve fusion primer associated resampling error. The 
key limitation was that we did not know the optimal number of emulsified cycles (before breaking the 
emulsion by centrifugation), as too many emulsified cycles resulted in very low amplicon yield. This 
poor processivity was probably due to early PCR plateau in small droplets. Seven emulsified cycles, 
although able to reduced resampling error, were too few to overcome it, in the case of multiple 
template primer mismatches.  
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We have used NGS to characterise minor variants with HIV drug resistance in unique patient 
populations: infants exposed to a dual PMTCT regimen of zidovudine and nevirapine and adults who 
were failing a second-line protease inhibitor regimen without major PI resistance mutations detectable 
by bulk sequencing. Despite the potential of NGS for the detection of minor, drug-resistant variants, 
practical and technological challenges would need to be overcome before it could achieve wider 
implementation.  
These challenges include pre-analytical, analytical and post-analytical aspects. Pre-analytically, the 
detection of very rare events requires adequate sample collection, especially in patients with low viral 
loads. Failing an adequate sample, rare variants would not be detected despite extensive enrichment 
and very high sequencing coverage. Analytically, PCR enrichment can introduce a particular selection 
bias, described as resampling error (Liu et al. 1996), especially when fusion primers are used (Berry et 
al. 2011). In our study of infant drug resistance after PMTCT exposure, we used parallel PCR 
reactions to reduce sampling error. This approach did not make use of fusion primers and is therefore 
less biased but, due to the high cost of ligating adaptors, this is less cost-efficient.  
An innovative approach to overcome resampling error associated with fusion primers is the tagging of 
cDNA with random tags during reverse transcription. This strategy allows post-analytic correction of 
relative variant copy number by collapsing all reads with the same random tag into one (Jabara et al. 
2011; Boltz et al. 2015; Zhou et al. 2015; Keys et al. 2015). Despite the value of this approach, it has 
been associated with a low recovery of sample diversity due to the insensitivity of the approach (Boltz 
et al. 2015; Zhou et al. 2015; Keys et al. 2015; Brodin et al. 2015). Our approach to reducing bias with 
a simple em-PCR has shown potential but requires further development to optimise its ability to 
overcome PCR resampling error. As the costs of NGS are expected to decrease in future, further 
improvement of sample enrichment is required to make optimal use of this technology. The improved 
and accurate use of targeted enrichment with fusion primers, which obviates expensive adaptor 
ligation, could make this much more affordable than Sanger sequencing, especially on the Ion Torrent 
(Life Technologies, California, USA) and MiSeq (Illumina, California, USA) platforms.  
Post-analytically, the availability of open bioinformatic pipelines such as the UCSD’s (University of 
California, San Diego) Datamonkey (Pond & Frost 2005), would facilitate quality assurance and 
interpretation of sequencing data. Our SANBI (South African National Bioinformatics Institute) 
collaborators have developed a bioinformatic alignment tool (RAMICS) which allows improved 
alignment of multiple sequences and hence the correction of spurious insertions or deletions 
generated through homopolymer read error on the 454 or Ion Torrent sequencing platforms (Wright & 
Travers 2014).    
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With recent advances in NGS technology and accompanied development in bioinformatics, there is a 
need to develop and customise workflows for particular applications such as HIV minor variant 
sequencing, making optimal use of the newer high coverage platforms such as MiSeq (Illumina, 
California, USA) or Ion Torrent (Life Technologies, California, USA). We have performed some of the 
first experiments on these platforms but further development would be required to fully utilise their 
potential, specifically in the clinical sector (Li & Kuritzkes 2013). This may expand the use of NGS to 
the characterization of low frequency variants in patients on long-term therapy, to characterise HIV 
persistence, which is has depended on the use of LD-PCR and single genome Sanger sequencing 
(Kearney et al. 2014). Developing improved workflows for HIV may also have application when 
sequencing other highly diverse biological populations with similar challenges.    
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